

CONVENTION ISSUE

生物科技誌

BIOTECHGAZINE

SEPTEMBER 2024

BIOHK2024

香港國際生物科技論壇暨展覽

SEPTEMBER 九月11-14

HONG KONG CONVENTION AND EXHIBITION CENTRE

香港會議展覽中心

BIOHK2024
主辦單位



AUSVIC
Capital

BayHelix
GROUP



中国生物工程学会
Chinese Society of Biotechnology

生物科技誌 BIOTECHGAZINE

SEPT 2024

編輯委員會

總編輯 Chief Editor

于常海
YU Cheung-Hoi, Albert

副總編輯 Deputy Chief Editor

陳一諮
CHAN Yi-Ngok

編輯 Editors

韓京
HAN Jing

李冠儒
LI Charles Kwun Yu

曾瑞英
TSANG Sue

殷志慧
YIN Yuki

出版社 Publisher

海康生命出版社有限公司 H. K. Life Publishing Limited

電話 Tel: (852) 2111 2123

傳真 Fax: (852) 2111 9762

電郵 Email: editorial@hkbio.org.hk

地址 香港新界沙田石門安耀街3號 匯達大廈1615-18室
Units 15-18, 16/F South Wing Delta House, 3 On Yiu Street, Shatin, N.T. Hong Kong

廣告查詢 Advertising

電郵 Email: editorial@hkbio.org.hk

出版日期 Publishing Date 2024年9月 SEPT 2024

定價 Price HK\$60

ISSN 2959-6971

版權所有，未經本會及作者同意，不得翻印

All reproduction requests are subject to the approval of HKBIO and authors



Contents

About The Convention

• Welcome message from President	02
• BIOHK2024 Governance	04
• BIOHK2024 Organizing Committee	05
• Program Schedule	08
• AI-Powered Interpreters translation Usage Guide	16
• Convention Floor Guide	17
• Exhibitor Guide	18

Speaker Biographies

• Day1 Keynote Speaker Biographies	22
• Day1 Speaker Biographies	28
• Day2 Keynote Speaker Biographies	54
• Day2 Speaker Biographies	60
• Day3 Keynote Speaker Biographies	89
• Day3 Speaker Biographies	92
• Day4 Keynote Speaker Biographies	117
• Day4 Speaker Biographies	119

Resources

• Speaker Index	127
• Acknowledgements	129
• Supporting Organizations	130
• Exhibitor & Sponsor Advertisement	133

Welcome Message

Dear Biotechnology Enthusiasts,

In September 2023, the second chapter of the BIOHK was held at the Hong Kong Convention and Exhibition Center. With the support of Hong Kong government departments including the Innovation and Technology Commission, InvestHK and Intellectual Property Department, BIOHK2023 International Convention was a great success. Over 200 speakers gave talks and participated in discussions, and the event attracted visitors from 25 countries. The event had exhibitors from all sectors of biotech and it had start-ups pitching to investors and potential collaborators.

We are delighted to announce that the third chapter BIOHK2024 will be held on 11 to 14 September 2024 at the Hong Kong Convention and Exhibition Center. We will endeavor to provide an even bigger and better international biotech experience. As a city with a rich history in industrial development and innovation, and one that is branded “Asia’s World City”, there is no better place to bring together biotech companies from East and West. We look forward to catching up with you about the latest innovations and trends across the international biotechnology industry.

In a recent speech by Mr. John Lee, Chief Executive of the Hong Kong Special Administrative Region, he described Hong Kong as not only **the super connector** between China and the rest of the world, but also as a **‘Super Value Adder’**, as its world-class financial and professional services provide an excellent environment for businesses based in Hong Kong.

Hong Kong has an international business environment, with 9,000 international and mainland companies based here. Supported by the Chinese Government’s intention to establish Hong Kong as an international innovation and technology hub, the Hong Kong Government has devoted much effort to promote biotech. It has recently established the Top Talent Pass Scheme and the Office for Attracting Strategic Enterprises (OASES) to attract international talent and companies. Furthermore, the scale of **biotech fundraising in Hong Kong is the biggest in Asia and the second largest in the world**. This was in part due to the Chapter 18A listing rule implemented in 2018, which allows pre-revenue biotech companies to list on the Hong Kong Stock Exchange. 112 biotech and healthcare companies have listed on the Hong Kong Stock Exchange since 2018.

Hong Kong is considered ‘the gateway to China’ due to its status as a special administrative region. Thus, Hong Kong offers a rich source of opportunities for overseas investors looking to capitalize on the growth of China, and for Chinese companies looking to expand abroad. The Greater Bay Area (GBA) scheme is an

initiative by the Chinese government to link Hong Kong, Macau and 9 cities along the Pearl River Estuary to form an international technology and innovation zone rivalling Silicon Valley. The objective of the GBA initiative is to promote cooperation and integration, and leverage the advantages of Hong Kong, Macau and the Pearl River Estuary. One of the cooperation ventures is the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. A key goal is to have policies in place to enable better integration of Hong Kong and Shenzhen in terms of talent flow, data flow and resource flow. This will allow companies in Hong Kong to tap on the resources in the area.

Owing to its strategic location, the presence of world-class universities, and its reputation as one of the freest economies, Hong Kong is an optimal center for international investors to capitalize on Asia's biotech revolution. Our goal is to establish BIOHK on the annual biotech convention calendar, and foster the GBA as a vibrant biotech research and innovation epicenter in Asia.

COVID-19 accelerated the growth and development of the biotechnology industry. Biotech's essential role in solving humanity's health problems and combating future threats became evident during the COVID-19 pandemic. From AI-assisted drug developments to mRNA vaccines to emerging state-of-the-art biotechnologies, enormous advances have been made in recent years. It is our mission to harness these advancements to foster collaboration at BIOHK2024.

BIOHK aims to bring to you a world-class biotech convention. Our executives are from diverse disciplines across biotech with expertise in areas ranging from academia to venture capital. Business opportunities are best made face-to-face and BIOHK2024 will continue to offer extensive networking opportunities in September 2024.

I hope you will join us at BIOHK2024. Whether you want to expand your international network, explore new markets, attract government and/or private funding or invest in the next biotech unicorn, BIOHK2024 is an ideal place to fulfill all these intentions.

Enjoy BIOHK2024 and its world-class program we will create for you.

Yours sincerely,

President of BIOHK2024



Professor Albert Cheung-hoi YU, PhD, JP
President, BIOHK2024

BIOHK2024 Governance

President

Albert Cheung-hoi YU

President, BIOHK2024; Hong Kong Biotechnology Organization

Vice Presidents

CHAN Russell

CEO, Hai Kang Life Corporation (HKLife) Senior Consultant, Hong Kong Center for Cerebro-cardiovascular Health Engineering (COCHE)

CHEN Chrank

Partner, Ausvic Capital Limited Investment

CHENG Gordon

Chief Executive Officer, Cameron Pace China Limited

HU Charles

Founder & CEO, Ryoden Medical & Transformation Biotechnology Entrepreneur Neuroscience and Investment

HUANG Yuan

Technology Transfer Director of Hong Kong Quantum AI Lab

LEUNG, Chuen Yan

Co-founder, Silver Dart Capital Partner (Healthcare Investments), Value Partners Group

LI, Benjamin

Chairman & CEO, Zhaoke Ophthalmology Limited Pharmaceuticals

WAN Mu, Maki

Past President, Rotary Club Kowloon Golden Mile Public Relationship and Convention

WONG Alister Yu Ngai

Associate, Philip K.H. Wong, Kennedy Y.H. Wong & Co Legal and Business

Yu Ben

Greater Health and Greater Bay Area

ZHENG Peter

Funding And Managing Partner of CDF Capital Orion Fund and Orion Technology Fund

BIOHK2024

Organizing Committee

Organizing Committee	
BA Su Juan	President and CEO, National Foundation for Cancer Research
CHEN Xin Lorna	Chairman, Pan Asia Venture Development Platform (PAVD)
CHEAH Kathry	Chair Professor of Biochemistry, School of Biomedical Sciences, The University of Hong Kong
CHAU Wilton	Asia Regional Managing Partner and Head of Greater China, Shearman & Sterling
CHOW Yiu Ming	Chief Financial Officer, Lee's Pharmaceutical Holdings Limited
GOH Terence	Chairman, Pan Asia Venture Development Platform
HSIAO Wendy	Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology
JE Simon	Chairman & CEO of Galaxy Treasure Financial Group Holdings
JIANG Claire	CEO, Queens (Shenzhen) Biotechnology Co., Ltd.
JIANG Ru Hong	Chairman, CEO and President of ASC Therapeutics Inc.
LAM Stephen	Honorary Professor, Faculty of Medicine (CUHK)
LAW Philip	Lead Partner, Venture Capital & Private Equity, Deloitte

BIOHK2024

Organizing Committee

Organizing Committee	
LEE Tin Lap	Associate Professor, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
LEUNG Thomas	Lo Ka Chung Charitable Foundation Professor in Pharmaceutical Sciences Professor and DoULS
LIU Andy	President, Healthcare Division, BaseBit Technologies
LU Ming Hua	Founding Partner, eChinaHealth
LYU Ai Ping	Vice-President (Research and Development), Hong Kong Baptist University
NEARING A. Kimberly	Venture Partner, Bvcf Management, Ltd
ORR Kevin	Vice President, Winner Medical Group
QIN Jason	Scientific Director, Beijing ITAI Technology
SHI Victor	CEO, Adicon Clinical Laboratories
TAM Paul	Director, Dr. Li Dak-Sum Research Centre
TANG C. Mark	Managing Director, Good Health Capital (New York)
TSUI Victor	COO, Powder Pharmaceuticals Incorporated

BIOHK2024

Organizing Committee

Organizing Committee	
WANG Ji Guang	Assistant Professor, Division of Life Science, The Hong Kong University of Science and Technology
WONG Bing Lou	Adjunct Professor, Department of Biochemistry, Chinese University of Hong Kong
WONG Vivian	Hon Professor, School of Chinese Medicine, The University of Hong Kong
WU George	Corporate partner, DLA Piper Hong Kong
XIE Jia Sheng	Director & Executive President, Guangdong Medical Valley (GDMV)
YANG Hai Ding	Executive Director and Founding Team Leader, Healthcare sector of Cathay Capital
YANG Ray	Partner, Marathon Venture Partners
YUNG Ken	Professor and Associate Head, Department of Biology, Faculty of Science, Hong Kong Baptist University
ZHANG Jimmy	Founding member, Former Chairman of BayHelix Group
ZHENG Peter	Funding And Managing Partner of CDF Capital Orion Fund and Orion Technology Fund
ZHONG Sharon	J.P. Morgan Private Bank – Banker

PROGRAM DAY 1

Wednesday September 11

08:30	EVENT REGISTRATION 注册				
09:00-10:20	Building Hong Kong's Biotech Ecosystem: The Role of the HKIC 建構香港生物科技生态圈: 香港投资管理有限公司的角色 KEYNOTE SESSION - Ms. Clara Chan CEO, Hong Kong Investment Corporation 大会报告 - 陈家齐女士 香港投资管理有限公司行政总裁				
	New Development and Cell-free DNA Diagnostics KEYNOTE SESSION - Prof. Dennis Yuk Ming Lo Associate Dean (Research), Faculty of Medicine, Chinese University of Hong Kong 大会报告 - 卢焯明教授 香港中文大学医学院副院长(研究)				
	Prevention as the best medicine: Combining innovation and data to drive economic growth and improve health outcomes KEYNOTE SESSION - Sir Jonathan Symonds Chair, GSK 大会报告 - Sir Jonathan Symonds 葛兰素史克董事会主席				
	Biotechnology Industry in China 2024 中国生物技术产业2024 KEYNOTE SESSION - Prof. Fu Gao Academician, Institute of Microbiology, Chinese Academy of Science 大会报告 - 高福教授 中国科学院院士, 中国科学院微生物研究所				
	改变手, 治疗脑-细胞-脑功能可塑性" KEYNOTE SESSION - Prof. Wendong Xu 2023 State Scientific and Technology Progress Award First Prize Winner, Fudan University 大会报告 - 徐文东教授 2023年国家科学技术进步奖一等奖获得者, 复旦大学				
10:30-11:25	OPENING CEREMONY 开幕式				
11:25-12:00	Further Deepening Reform Comprehensively* in Science - An Insight into the recent Resolution of the Central Committee of the Communist Party of China and Hong Kong's Contribution 三中全会《决定》在科学领域的进一步全面深化改革-香港的作用 KEYNOTE SESSION - Hon. Chun Ying Leung Vice Chairman, CPPCC 大会报告 - 梁继英主席 中国人民政治协商会议全国委员会副主席				
	To Build Well-educated, Healthy Middle Class by Establishing Technology Industry in Hong Kong KEYNOTE SESSION - Ambassador George Hara Group chairman & CEO, DEFTA Partners 大会报告 - 原丈夫大使 DEFTA Partners 集团主席兼首席执行官				
	MAIN HALL	THEATER 1	THEATER 2	THEATER 3	THEATER 4
12:00-13:00	<p>The Hong Kong Polytechnic University event.</p> <p>Opening 开场曲 Dr. Lawrence Li 李國權醫生 (Deputy Council Chairman, PolyU 香港理工大学校董会副主席)</p> <p>Mr. Ho Sun 何善生 (Chairman, Hong Kong Kowloon Group 香港九龍集團董事局)</p> <p>Strategic Collaboration Agreement Signing Ceremony 战略合作協議簽署</p> <p>Prof. Christopher Chan 陳志強教授 (Vice President (Research & Innovation), PolyU 香港理工大学副校长(研究及創新))</p> <p>Mr. Quang Chien 陳國強先生 (Vice President, Hong Kong Kowloon Group 香港九龍集團副主席)</p> <p>Panel Discussion 小組討論 Moderator 主持 Prof. Christopher Chan 陳志強教授 (Vice President (Research & Innovation), PolyU 香港理工大学副校长(研究及創新))</p> <p>Panelists 小組成員 Prof. Cai Jing 蔡健教授 (Reno, Dean (FHS) & Professor, Department of Health Technology and Information, PolyU 香港理工大学健康及社會科學院院長)</p> <p>Mr. Ivan Fu 傅國強先生 (Chairman of Board of Directors, PanMedBio 聚藥源控股 (深圳)有限公司董事長)</p> <p>Prof. Simon LEE 李國強教授 (Chair Professor of Biomedical Sciences, Department of Food Science and Nutrition, PolyU 香港理工大学食品科學及營養學系講座教授)</p> <p>Prof. Feng Liu 劉福教授 (Honorary Dean, Suzhou Kowloon Hospital 蘇州九龍醫院顧問)</p>	<p>Tapping the potential of HUGRA for clinical trials 挖掘香港及香港大湾区在臨床試驗中的潛力</p> <p>Moderator 主持 Ms. Diana Viola (PharmaBoardroom CEO 首席執行官)</p> <p>Panelists 小組成員 Mr. Mark Loh (Founder and CEO, Ruuska Pharma 史諾諾研創始人及首席執行官)</p> <p>Mr. Henry Yau 游廣賢先生 (HK Clinical Trials Center 香港大學臨床試驗中心執行總監)</p> <p>Dr. Xia Jin 姜傑博士 (Co-Founder & CEO, ImmunoCure Holding 聯合創始人及首席執行官)</p> <p>Prof. Ping Feng 馮萍教授 (West China Hospital 四川大學華西醫院)</p>	<p>Artificial intelligence governance and intellectual property in healthcare 醫學人工智能監管及知識產權</p> <p>Chair 主席 Dr. James Chu 趙孝平醫生 (Medical Faculty, The University of Hong Kong 香港大學醫學院)</p> <p>Opening 开场曲 Prof. Vivian Wong 黃韻慧教授 (Hong Kong University & Hong Kong Metropolitan University 香港大學及香港城市大學)</p> <p>Speakers 演講人 Prof. Gilberto Leung 梁國強教授 (Hong Kong Academy of Medicine 香港醫學科學院) - AI Governance in Healthcare: Towards a Participatory Approach 醫學人工智能的監管</p> <p>Mr. Norman Hui 胡文意大律師 (Faculty of Law, University of Hong Kong 香港大學法律學院) - Intellectual Property and Healthcare Related Issues 知識產權與醫療保健相關問題</p>	<p>International perspectives on Hong Kong as a biotech hub of the world 從國際視角看香港作為世界生物科技中心</p> <p>Moderators 主持 Ms. Josephine Wu (CIO, Alcorica Capital Management) Dr. Charles Yu 馮志強博士 (Managing Director, Ryoden Medical Holdings Ltd / Co-founder, Incubeo Therapeutics)</p> <p>Panelists 小組成員 Sir Jonathan Symonds (Chair, GSK)</p> <p>Dr. Bettina Ermet (Director, Bernina Biotech / Vice President, Swiss Biotech Association)</p> <p>Mr. Tristram Edwards (Co-founder & CEO, Synthex Labs / Co-founder & former CEO, Life Biosciences)</p>	<p>Biotech & biopharma new quality productive forces in Mainland China 中國生物科技建構城新質生產力的培育與形成</p> <p>Speakers 演講人 Mr. Ruben Liang 梁嘉輝先生 (Healthy China Research Center 健康中國研究中心) - Biotech & Biopharma Tendency of Mainland China: Policy & Industry Perspective 中國內地的生物技術與生物醫藥發展趨勢: 政策與產業視角</p> <p>Panel discussion 圓桌會議討論: 因地制宜推動生物科技的創新與產業融合</p> <p>Panelists 小組成員 Mr. Ruben Liang 梁嘉輝先生 (Healthy China Research Center 健康中國研究中心)</p> <p>Ms. Yi Li 李麗女士 (Director of Market Access, InnoGen Pharmaceutical Group 醫諾康藥業市場准入總監)</p> <p>馬志博先生 (中國 (廣東) 省藥研院試驗技術中心管理委員會副主任)</p> <p>馮麗珍女士 (Longly capital 通力創投董事)</p>

LUNCH BREAK 午休

PROGRAM DAY 2

Thursday September 12

08:30	Event Registration 注册				
	MAIN HALL				
09:00-11:35	OPENING REMARKS - Prof. Chung Mau Lo (Secretary for Health, Health Bureau) 开场致辞 - 卢发茂教授 (香港医务卫生局局长)				
	Hong Kong, an ideal ground for life sciences and healthcare industry development KEYNOTE SESSION - Ms. Lilian Cheong (Under Secretary, Innovation, Technology and Industry Bureau) 大会报告 - 张曼莉女士 (香港创新科技及工业局副局长)				
	Strengthen medical and prevention cooperation in the Greater Bay Area to eliminate hepatitis 加强大湾区医疗和预防合作以消除肝炎 KEYNOTE SESSION - Prof. Yu Wang (Chairman, Chinese Foundation for Hepatitis Prevention and Control) 大会报告 - 王宇教授 (中国肝炎防治基金会理事长)				
	The development frontiers and prospects of digital traditional Chinese medicine KEYNOTE SESSION - Prof. Cong Yan (Professor, Beijing University of Chinese Medicine) 大会报告 - 闫聪教授 (北京中医药大学教授)				
	Initiative to reshape the discipline of hepatology in Asian-Pacific region under "One Country, two system" KEYNOTE SESSION - Prof. George Lau (Chairman, Humanity and Health Medical Center) 大会报告 - 廖家保教授 (天下仁心医疗集团主席)				
	In the mood for cell therapy - a better tomorrow has arrived KEYNOTE SESSION - Prof. Han Chong Toh (Deputy CEO, National Cancer Centre Singapore) 大会报告 - 杜汉忠教授 (新加坡国家癌症中心首席执行官)				
	MAIN HALL	THEATER 1	THEATER 2	THEATER 3	THEATER 4
10:15-11:45	The path to Precision Medicine and Digital Medicine (I) 通往精准医学和数字医学之路(I) Opening remarks Dr. Sujuan He (AFCC 亚洲癌症研究基金会) Prof. Michael Yang (City University of Hong Kong 香港城市大学) Chair 主席 Prof. Michael Yang (City University of Hong Kong 香港城市大学) Speakers 演讲人 Prof. Raju Kuchipati (Harvard Medical School 哈佛医学院) - Applications of Precision Medicine Prof. Hai Yan (A-Star, Singapore) - Diagnosis and Targeted Therapy of Gliomas with IDH1 and IDH2 Mutations Prof. Yuhou Jiang (Fudan University Shanghai Cancer Center 复旦大学) - Molecular subtyping and precision treatment of triple-negative breast cancer	Charting a new regulatory pathway in Hong Kong - the CMPE 开辟香港新的监管之路 - CMPE Chair 主席 Dr. Xin Du (Evergreen Therapeutics) Speakers 演讲人 Dr. Rui He (Ramagen) Dr. Ming Li (Amari Biosciences 奕安生物) Dr. Maggie Lo (DASES 引道普药企业办公室) Moderator 主持 Dr. Xin Du (Evergreen Therapeutics) Panelists 小组成员 Dr. Ben Zhen (Hakshang Biotech 皓生生物) Dr. Rui He (Ramagen) Ms. Satorina Chen (Hong Kong Association of the Pharmaceutical Industry 香港制药业协会) Prof. Yuk Lam Lo (HKMA 香港医药管理局) Prof. Ping Fung (West China Hospital)	RNA Medicine to Address Clinical Needs RNA药物及其临床转化 Chair 主席 Dr. Patrick Lu (Sinaomics 赛诺医药) Speakers 演讲人 Dr. Patrick Lu (Sinaomics 赛诺医药) - Advancing RNA Therapeutics for Addressing Unmet Clinical Needs Prof. Eric Westhof (University of Strasbourg) - RNA as a drug Target Dr. Jinchong Lin (复旦大学) - Pioneering mRNA Vaccine Platforms in China: Strategic Innovations for Global Infectious Disease Control Dr. Lihua Zhou (MPVEX 迈普) - Making RNA based cancer early detection blood tests accessible to all	Company Pitching 公司路演	Black Technology 黑科技 (closed door 闭门会议) Chair 主席 Speakers 演讲人 Prof. Akihiko Kondo (Kobe University 神户大学) - Engineering biology and bioindustry for smart cell-based breeding to produce biofuels, chemicals and materials Dr. Anze Zhang (Bei Kang Life Corporation 倍康生物科技) - BioRider Platform: A point-of-care molecular diagnostics game-changer to save lives Prof. Wenzong Su (Fudan University 复旦大学) - Revolution of stroke rehabilitation: Where basic extracellular matrix surgical breakthroughs and neural modulation Prof. Shouyan Wang (Fudan University 复旦大学) - Intelligent deep brain stimulation for precise modulation of the brain activities Prof. Bin Jin (Shandong University 山东大学) - 微创骨科手术机器人系统
11:45-12:45					

PROGRAM DAY 2

Thursday September 12

LUNCH BREAK 午休时段

14:00-15:00

The path to Precision Medicine and Digital Medicine (I)
通往精准医学和数字医学之路 (I)

Chair 主席
Dr. Charles Hu 阮正忠博士 (Hydrex Medical Holdings Ltd 聚电医疗控股有限公司)

Speakers 演讲人
Prof. Daniel Johnson (University of California, San Francisco 加利福尼亚大学旧金山分校) - Precision medicine for Pancreatic Anemia-Associated Head and Neck Cancer

Prof. Wen Li 李敏教授 (The University of Oklahoma Health Sciences Center 俄克拉荷马大学健康科学中心) - Pancreatic Cancer Precision Medicine

Prof. Jiguang Wang 王吉光教授 (Hong Kong University of Science & Technology 香港科技大学) - Study of cancer evolution for precision medicine in glioma

Prof. Leslie Lainevala (University of Colorado 科罗拉多大学) - From bench to bedside: the role of basic science in treating a deadly heart disease

Chair 主席
Dr. Sujana K. Chakrabarti (APCC 亚洲癌症研究学会)

Speakers 演讲人
Prof. Richard Shinko (Baylor College of Medicine 贝勒医学院) - Leveraging a Learning Health System for Disease Gene Discovery

Prof. Jian-Guo Fan 范建刚教授 (Anchorage 安克雷奇) - Early diagnosis of lung cancer: LDCT, nodules, liquid biopsies

Prof. Zongli Zheng 郑宗利教授 (City University of Hong Kong 香港城市大学) - Circulating DNA Derived Tumor Content for Early Detection of Lung Cancer 循环DNA衍生肿瘤DNA含量用于肺癌的早期检测

Prof. Wei Luo 罗文教授 (Geneva Biopharma) - Transforming Drug Development with Innovative Precision Medicine Strategy - Application in Oncology and CNS

HK Government Policies for Biotech Growth
香港政府促进生物科技发展的政策

Moderator 主持
Dr. Brian Wang 黄树强博士 (University of Hong Kong 香港大学)

Panelists 小组成员
Dr. Maggie Le 卢敏珊博士 (CASES 创新重点发展办公室)

Mr. Kwong Shui 洪志伟先生 (Cur Hong Kong Foundation 恒裕香港基金)

Dr. Alex Kwong 何伟权博士 (Hong Kong Shenzhen Innovation & Technology Park 深港创新及科技园)

Prof. Bernard Cheung 郑文涛教授 (Innovation & Technology Commission 创新科技委员会)

Hong Kong: The Super Connector for Mainland China and Global Biotech
香港-中国内地与全球生物科技超级连接点

Moderator 主持
Ms. Donglei Mao 毛重霞女士 (PharmUI 首席主席)

Panelists 小组成员
Mr. Eric Shao 邵文斌先生 (JGM, Greater China, IDVA 大中华医药投融资联盟联席主席)

Dr. Man Cheung Fung 冯文基教授 (MCP Consulting)

Dr. Chuan Yan Lung 梁国耀博士 (Co-founder, Silver Dart)

Mr. Sampson Lau 刘景豪先生 (President, Primeforce Technologies 康成医疗首席执行官)

Mr. Jucyl Ma 马国一先生 (Director of Public Affairs, ZSHK 深港中医药公共事务委员会)

Mainland Perspectives on Clinical Trials and CMPP
中国大陆对临床试验和CMPP的视角

Chair 主席
Dr. Ping Feng 冯萍教授 (West China Hospital, Sichuan University 四川大学华西医院)

Speaker 演讲人
Dr. Ping Feng 冯萍教授 (West China Hospital, Sichuan University 四川大学华西医院) - Chinese Clinical Trial: Practice and challenges

Dr. Lei Song 宋磊博士 (Chiglobe Biotech 奇维生物) - Trends and thoughts on overseas experts of innovative consumer medical devices

Moderator 主持
Mr. Jason Gin 蔡俊基先生 (Rajong IT&I 一参科技)

Panelists 小组成员
Dr. Lei Song 宋磊博士 (Chiglobe Biotech 奇维生物)

Ms. Ann Tam 谭爱娟女士 (AstraZeneca 阿斯利康香港)

Mr. Kwong Shui 洪志伟先生 (Cur Hong Kong Foundation 恒裕香港基金)

Ms. Mary Lai 黎咏莹女士 (Bayer 拜耳香港)

Mr. Da Liu 刘达先生 (CR-CP Life Science Fund 华诺正大生命科学基金)

Ms. Lu Gea 高霞女士 (Gene Capital 基汇资本)

Mr. Andrew Ng 伍国威先生 (VMS Group 维美集团)

Mr. Zhang Yu 张宇 (AWS 亚马逊科技)

Longevity research: East meets West
长寿研究: 东西方交汇

Chair 主席
Dr. Christine Huang 黄国博士 (HK Longevity Medical Center)

Speakers 演讲人
Prof. Kunlin Jin 金泽林教授 (The University of North Texas Health Science Center of HSC-UTH 沃斯堡北德克萨斯大学健康中心) - Phenotype-mediated Mitochondrial Dysfunction in Aging and Age-related Diseases

Dr. Xin Wang 王鑫教授 (Chinese University of Hong Kong 香港中文大学) - Aging acceleration in cancers and its clinical implications

Prof. Abbas Haghighi (Harvard University 哈佛大学) - From Genes and mRNAs to Health: The Convergence of Genomics and AI for a Healthier Future

Prof. Vincenzo Sorrentino (National University of Singapore 新加坡国立大学) - NAD⁺ and its precursors in healthy longevity: opportunities and challenges

Prof. Yu Kuan Lin 吕宇轩教授 (Southern University of Science and Technology 南方科技大学) - Towards safe and efficient anti-aging strategies: geroprotective intervention targeting mTOR

Dr. Wariwat Sangthavong (Bumrungrad Genomic Medicine & VitalLife Scientific Wellness Center) - Longevity medicine and lifestyle medicine landscape in Thailand

Dr. Peter Fadhil (Geri) - Physically-informed foundational models of aging and diseases for drug discovery

Mr. Nicholas Tse 谭国基先生 (史克) - Prevention to change the course of disease

Dr. Anissa Liu (MedLife Biotech) - 医药科技研究的未来道路

Mr. Boris Spodis (199 Biotechnology) - Patient Reprogramming in Cancer & Aging

Dr. Rama Balaji (Glok Proteomics) - Proteomics of human aging & longevity: biological age clocks to disease risk prediction

Mr. Mark Pulowski (Longevity Advocate) - Beyond time - quest for longevity around the world

Moderator 主持
Dr. Christine Huang 黄国博士 (HK Longevity Medical Center)

Panelists 小组成员
Dr. Xiaoying Che 赵晓颖女士 (Global, Collaboration and Strategic Publishing, Science 国际科学合作联盟)

Dr. Wang Li 李敏博士 (ZSHK 深港中心)

Mr. Jack Wang (Asia Longevity Professional's Association ALPA)

Dr. Polak Tsakakoulis (Bumrungrad Genomic Medicine & VitalLife Scientific Wellness Center)

Australia Company Pitching
澳大利亚公司路演

New role for Chinese Medicine: Heredit maintenance
中国的新角色: 治未病

Chair 主席
Prof. Wendy Hsiao 黄文英教授 (澳门科技大学)

Speakers 演讲人
Prof. Zheng Yang 杨正峰教授 (The First Affiliated Hospital of Guangzhou Medical University 广州医科大学附属第一医院) - Explore the CTM against influenza and COPD based on lunggut microbiota regulation

Prof. Chao Bin-San Lau 刘耀明教授 (Department of Pharmacology and Pharmacy & School of Medicine, The University of Hong Kong 香港大学药理学及药理学系) - Research and development of Chinese herbal medicines for healthy aging

Prof. Elaine Leung (School of Chinese Medicine, University of Macau 澳门大学中医药学院) - Modulation of gut microbiota with Chinese Medicines for enhancement of immunotherapy

Prof. Vincent Wong 黄国博士 (School of Chinese Medicine, Macau University of Science & Technology 澳门科技大学中医药学院) - Unraveling the mystery of aging-related diseases - Prevention of rheumatoid arthritis

Prof. Zhixia Lin 林志霞教授 (School of Chinese Medicine, Chinese University of Hong Kong 香港中文大学中医药学院) - An innovative Chinese medicine formula for gout: Efficacy and mechanism

Prof. Ma Li 李敏教授 (School of Chinese Medicine, Hong Kong Baptist University 香港浸会大学中医药学院) - Deciphering the wisdom of Traditional Chinese Medicine for aging-associated neurodegenerative diseases

Prof. Hong-He Zhang 张宏河教授 (School of Chinese Medicine, Hong Kong Baptist University 香港浸会大学中医药学院) - Unleashing the power of plant diversity for innovative drug discovery

Dr. Lin Yie 梁国博士 (TCM Preventive Medical Center, Hospital of Chengdu University of Traditional Chinese Medicine 成都中医药大学附属医院) - Clinical applications of acupuncture in treating pre-diabetes

Dr. Wensu Xia 夏文豪博士 (Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine 成都中医药大学附属医院) - Clinical study on prevention and treatment of diabetes mellitus by traditional Chinese medicine

Company Pitching
公司路演

PROGRAM DAY 3

Friday September 13

08:30		Event Registration 注册			
		MAIN HALL		THEATER 1	
09:00-10:00	On the Role and Place of AI in the Era of Geopolitics KEYNOTE SESSION - Prof. Brian Wong (University of Hong Kong) 大会报告 - 黄裕辉教授 (香港大学)				
	Inheritance and innovation: Bushen Huoxue Fa for the Treatment of Diabetic Nephropathy 传承与创新: 补肾活血法治疗糖尿病肾病 KEYNOTE SESSION - Prof. Mianzhi Zhang (Beijing University of Chinese Medicine) 大会报告 - 张勉之教授 (北京中医药大学)				
	A New Era for Neurodegenerative Disorders: Opportunities and Challenges KEYNOTE SESSION - Prof. Piu Chan (Hospital of Capital Medical University) 大会报告 - 陈彪教授 (首都医科大学宣武医院)				
		MAIN HALL	THEATER 2	THEATER 3	THEATER 4
10:00-11:00	How will China's innovative biopharma industry change in the next decade? 中国的创新生物制药产业未来十年会有怎样的变化 Moderator 主持 Dr. Peter Pang 郭耀辉博士 (General Manager of Shanghai Innovation Center & VVP of China Biologics 康康生物创新中心总经理&康康生物首席运营官) Panelists 小组成员 Dr. Peter Pang (CEO, Hummingbird) Dr. Tony Wang 黄广福博士 (CTO, Artibe) Dr. Li Ming 李明博士 (CEO, ZSHK 通博中药研发执行官) Dr. Michael Wong (R&D Director, Immunocore)	Targeting the Brain: Precision Neuro-therapeutics 靶向大脑-精准神经治疗 Chair 主持 - Dr. Russell Chan 蔡耀雄博士 (E-SENSE Innovation & Technology) Speakers 演讲人 Prof. Jintai Yu 郁金涛教授 (Huashan Hospital, Fudan University 复旦大学) - Alzheimer's Disease cohort development and precision medicine research Dr. Charles Hu 胡正堂博士 (CEO, Ryden Medical Holdings Ltd 美国医疗控股有限公司) - Alzheimer's Disease cohort development and precision medicine research Prof. Yuelin Fu 傅月琳博士 (International Translational Neuroscience Research Institute, Zhejiang Chinese Medical University 浙江中医药大学国际转化神经科学研究所) - Alzheimer's disease phenotype by regulated exomeplex in health and disease Dr. Gergely Tibi (Cartalis Pharma) - Developing Precision Diagnostics and Genes Modifying Therapies for Parkinson's Disease by Maintaining Cellular Rhythmic and Protein Homeostasis	Bridging Research from Academia to Cancer Entrepreneurship Building Successful Biotech Companies 从学术界到癌症企业家的桥梁研究 Opening 开场 Dr. Euphon Ra 巴恩福博士 (CEO & Founder, AP-CR 亚洲癌症研究基金会创始人及首席执行官) Keynote Speakers 主题演讲- Prof. Raju Kuchelapudi (Harvard Medical School 哈佛医学院) Prof. Leslie Leinweber (University of Colorado 科罗拉多大学)	Blockchain Meets Longevity: Success Stories in Harnessing Decentralized Science 区块链遇见长寿: 去中心化科学的成功故事 Moderator 主持 Ms. Martin Ling 黄梦莹博士 (Founding Partner, MUNG Legal 黄梦莹律师事务所创始合伙人) Panelists 小组成员 Dr. Jennie Hanna (Science & Deal Flow, Athena DAO) Mr. Alexandre Mitsaki (Lead of Longevity & WEIR3, VhoDAO) Mr. Liu De 刘达先生 (CR CP Life Science Fund 华国正大生命科学基金)	Sino-US Biotechnology Investment, Merger & Acquisition Summit Forum (Closed door)
11:00-11:15	Business Opportunities in the Middle East: markets, therapeutics and regulatory perspectives 中东商业发展 Moderator 主持 Ms. Diana Viola (PharmaBoardroom) Panelists 小组成员 Mr. Joe Heroin (President & CEO, NewBridge Pharmaceuticals) Mr. Yasser Ghomim (Director of Clinical Projects, POC CRO)	Obesity and Diabetes: new drugs and interventions 肥胖和糖尿病-新药及干预 Chair 主持 Dr. Mark Tang 唐马强博士 (Good Health Capital) Speakers 演讲人 Dr. Liping Liu 刘利平博士 (Founder, CEO & Chairperson, HighTide Therapeutics 君思泰德 药创始人及首席执行官) - G from nature, multifunctional drug development for diabetes and beyond 大自然的馈赠--为糖尿病及其他疾病开发多功能药物 Prof. Zhongmin Ma 马志勇教授 (CEO, Revival BioPharmaceutical 睿思再生药创始人及CEO) - Novel strategies for the treatment of diabetes with β -cell regeneration therapies β -细胞再生疗法作为治疗糖尿病的新策略 Prof. Tianlin Liu 刘铁良教授 (School of Life Science, Fudan University 复旦大学) - The new knowledge to the old target of metabolic diseases Dr. Mark Tang 唐马强博士 (Good Health Capital) - Alternative Method of Weight Loss and Healing Using Energetic Fasting, or Rigpa (唐马) Mr. Star Zuo 左玉强先生 (CEO, Hangzhou Tang Medical Technology 杭州唐医药科技集团 首席执行官) - Obesity and Other Metabolic Disorder Treatment with Minimum Invasive Gastric Bypass Stent 经内镜介入胃转流术 减重治疗肥胖等代谢疾病	City University of Hong Kong HK Tech 300 Start-ups Pitching 香港城市大学 HK Tech 300 项目初创公司路演	Sponsor: JunHe LLP 赞助: 君合律师事务所 Chinese companies navigating overseas: Case studies 中国企业出海案例分析 Ms. Lihua Du 杜立华女士 (Partner, JunHe LLP 君合 LLP 资深合伙人) - Navigating Overseas: Case Study on Chinese Company "go overseas" 远航出海: 中国公司“出海”案例分析 Mr. Xudong Tao 陶晓东先生 (Partner, JunHe LLP 君合 LLP 资深合伙人) - Navigating Overseas: Case Study on China's Biotech's BD Deals with MNCs in 2023/24 远航出海: 2023/24 中国创新药与跨国药企BD交易经典案例	
11:45-12:00	Business development opportunities: best practices of In/Out Licensing 业务发展机会: 进/出许可的最佳实践 Moderator 主持 Mr. Liu De 刘达先生 (CR CP Life Science Fund 华国正大生命科学基金) Panelists 小组成员 Mr. Simon Hui (Chairman, Biometra) Mr. William Pay (Chief Investment & Strategy Advisor to the Chairman, Hong Kong WellHealth Pharma Group) Mr. Joe Heroin (President & CEO, NewBridge Pharmaceuticals)				
12:00-12:45				Landscape of smart health-centric city development 以健康为中心的智能城市发展展望 Opening 开场 Ms. Zoe Zhou (Rainmaker Ventures) Moderator 主持 - Dr. Lawrence Yu 余浩强博士 (Good City Foundation 好城市基金会) Panelists 小组成员 Mr. Peter Ying (Santitas BioTech 三和生物科技) Ms. Stephanie Cheung 陈婉珊女士 (One Wise Design Studio 一口设计工作室) Ms. Lu Gao 高丽女士 (Gao Capital 高汇资本)	

PROGRAM DAY 3

Friday September 13

LUNCH BREAK 午休时段

	MAIN HALL	THEATER 1	THEATER 2	THEATER 3	THEATER 4
14:00-15:00	Smart Hospitals: Revolutionizing Healthcare Delivery 智慧医院: 医疗健康 服务革新 Chair 主持: Dr. Russell Chan 蔡耀达博士 (E-SENSE Innovation & Technology) Prof. Hong Fung 冯康 教授 (CUHK Medical Center 香港中文大学医院) - Smart Hospital: Revolutionizing Healthcare Delivery 智慧医院: 医疗健康服务革新 Prof. Mei-Hui Hsu 许秋梅教授 (Chief Data Officer, Taipei Medical University 台北医学大学资讯科学研究所) - From Smart Hospitals to Smart Healthcare 从智慧医院到智慧医疗 Prof. Bao Wang 王彪教授 (The First Affiliated Hospital of Fujian Medical University 福建医科大学附属第一医院) - 智慧医院助力国家区域医疗中心建设 医疗实践与探索 Mr. Stephen Lau 黎国康先生 (Hospital Authority)	Primary Healthcare and Digital Health Development Forum (closed door) 基础医疗健康数字化发展论坛 (闭门会议)	Integrating Eastern Wisdom with Western Innovation: Case of Breast Cancer 融合东方智慧与西方创新: 乳腺癌案例 Chair 主席: Dr. Wendy Wong 黄韵珊教授 (Department of Pharmacology and Pharmacy & School of Medicine, The University of Hong Kong 香港大学的药理学系) - Multidisciplinary research approach on Chinese herbal medicines for breast cancer treatment 中药治疗乳腺癌的多学科研究方法 Dr. Cindy Wong Lai San 黄碧珊博士 (The University of Hong Kong 香港大学) - Considerations for Concurrent Use of Traditional Chinese Medicine and Chemotherapy in Breast Cancer Management: An Oncologist's Perspective 肿瘤学家的角度审视中医药治疗中国时症 用中药和化疗的问题 Dr. Wendy Wong 黄韵珊教授 (Director, Yuhai Medical Center 前海康中心总监) - The Role of Evidence-Based TCM Practitioners in Integrative Breast Cancer Care in Hong Kong 循证中医在香港乳腺癌症综合治疗中的作用 Panel Discussion 小组讨论	Company Pitching 公司路演	Synthetic Biology is Shaping our Future 合成生物学塑造未来 Chairs 主持 Prof. Jiansong Huang 黄建东教授 (Faculty of Medicine, University of Hong Kong 香港大学医学院) Mr. Yongjian Cong 丛永健先生 (Shenzhen Synthetic Biology Association 深圳市合成生物学协会) Speakers 演讲人 Mr. Yongjian Cong 丛永健先生 (Shenzhen Synthetic Biology Association 深圳市合成生物学协会) - Synthetic Biology is Shaping Our Future Prof. Akhilesh Kando (Kobe University 神户大学) - Accelerating Biopharmaceutical Development through Bio-Digital Fusion Prof. Yinghui Ma 马应飞教授 (Shenzhen Institute of Advanced Technology, CAS 中国科学院深圳先进技术研究院) - Phage Synthetic Biology and Phage Therapy 噬菌体合成生物学和噬菌体疗法 Prof. Jiansong Huang 黄建东教授 (Faculty of Medicine, University of Hong Kong 香港大学医学院) - Synthetic Biology: Its Development in Hong Kong and Beyond Prof. Zhenbin Yang 杨志彬教授 (Shenzhen Institute of Advanced Technology, CAS 中国科学院深圳先进技术研究院) - Synthetic Biology disrupting agriculture
15:00-15:30	Sponsor: AWS / Cyberport 赞助: 亚马逊科技 / 数码港 How AI application has transformed drug discovery and medtech 人工智能应用如何改变药物研发和医疗技术				
15:30-16:00	Chair 主席 Dr. Mark Tang 谭马杰博士 (Good Health Capital) Speakers 演讲人 Mr. Zhaoren He 贺振人先生 (BioMap 五图生物) - Application of AI in protein design and target discovery Dr. Fan Liu 刘帆博士 (neoX Biotech 汇康星光源生物科技) - Generative AI for Biologics and Multi-specific Drug Design Dr. Frank Pan 潘祥博士 (Invalice Medicine) - Dual-Purpose Target Discovery and Aging Research with PreciousGPT Models Dr. E-Pia Ho 何爱群博士 (DisCarta 德基生物) - AI Powering Personalized Cancer Diagnostics and Treatment in Daily Health Care Management for Cancer Patients Mr. Victor Yin (Cyberport 数码港) - Cyberport - The Digital Tech Hub of Hong Kong Mr. Zhang Yu 余斌 (AWS 亚马逊科技) - GenAI trend analysis and case studies in life sciences	Biomedical imaging: future applications, policy and business 生物医学成像: 未来的应用、政策和商业 Chair 主席 Dr. Russell Chan 蔡耀达博士 (E-SENSE Innovation & Technology) Speakers 演讲人 Prof. Alex Ho 胡敏教授 (United Imaging 联影医疗) - Medical Imaging: A powerful tool for scientific discovery and future medicine Prof. Susumu Mori 森田教授 (Johns Hopkins University - School of Medicine 约翰霍普金斯大学医学院) - Population based management of dementia at the preclinical phase based on annual health checkup using brain MRI Prof. Wei-Ming Lee 李伟明教授 (University of Hong Kong 香港大学) - Ultrafast Cardiovascular Ultrasound Imaging and Its Opportunities with Artificial Neural Networks Prof. Mai Tian 田梅教授 (Human Phenome Institute, Fudan University 复旦大学) - 基于分子影像的精准医疗 Panelists 小组成员 Dr. Cathy Lui 吕雅萍博士 (InvestHK) Mr. Frank Lee 李国权先生 (Marks & Clerk 麦仕登)	Ophthalmology: more than meets the eye 眼科: 不仅仅是看得见 Chair 主席 Dr. Jeffrey Pong 庞毅博博士 (Hong Kong Adventist Hospital 香港康安医院) Prof. Jiaqi Zhong 张嘉清教授 (Institute of Brain Science, Fudan University 复旦大学) - Subretinally-implanted nanowire arrays as artificial photoreceptors - rodents, primates and clinical studies Dr. Lau Li-Fai 赖利发博士 (Zhanks Ophthalmology 眼科眼科) - Business Development in the Asian Pacific Region: Opportunities and Challenges Prof. Subrata Chakrabarti (London Health Sci Center & Western University 西安大略大学伦敦健康科学中心) - Targeting long non-coding RNA to treat diabetic retinopathy Mr. Bing Zhang 张兵先生 (Beijing AirDoc Technology 医维科技) - 医疗AI芯片赋能眼健康		
16:00-17:00					

PROGRAM DAY 4

Saturday September 14

08:30	Event Registration 注册			
	MAIN HALL			
09:00-10:00	<p>中医兴旺：摆脱故步自封 开拓推陈出新</p> <p>KEYNOTE SESSION - Prof. Yonghua Ji (Former Director, Key Laboratory of Neurobiology, Shanghai Institutes for Biological Sciences)</p> <p>大会报告 - 吉永华教授 (河北大学教授, 原中国科学院神经生物学重点实验室主任)</p>			
	<p>From Genome to Phenome: New Frontier of the Life Science</p> <p>KEYNOTE SESSION - Prof. Li Jin (President of Fudan University)</p> <p>大会报告 - 金力院士 (复旦大学校长)</p>			
	MAIN HALL	THEATER 1	THEATER 2	THEATER 3
10:00-11:00	<p>《微生物与疫苗》- 新冠病毒发现者高福院士科普讲座及著作签售活动</p>	<p>Navigating Careers in Biotech 中国的创新生物制药产业未来</p> <p>Chair 主席 Dr. Chuen Yan Leung 梁伟新博士 (Co-founder, Silver Dart Capital)</p> <p>Panelists 小组成员 Mr. Ken Wong 黄耀先生 (Executive Director, Hong Kong Life Sciences Society) Dr. Stephen Chan (Associate Director, Tybourn Capital Management) Dr. Ricky Chiu (Founder & CEO, Phase Scientific) Mr. Jason Ho 何国耀先生 (Vice President & Head of Corporate Development, Phase Scientific) Prof. Owen Kip (Assistant Dean (Research), Department of Medicine and Therapeutics, The Chinese University of Hong Kong)</p>	<p>Hong Kong Association of Women Scientists: Opening and First Inauguration Ceremony 香港女科学家协会开幕典礼暨第一届就职典礼</p>	<p>Smart Living: digital innovations for healthy living</p> <p>Mr. Philip Yeung 曾卓尧先生 (Co-Founder & CEO, Carevia 康得南得 联合创始人及首席执行官) - Digital health innovation trends and legal issues 智慧健康 - 数科创新趋势及合规法律议题</p> <p>Mr. Tam Chik 程志辉先生 (Co-founder & CEO, LHC New Energy Company Limited) - The importance of next generation of EV charging network for healthcare</p>
11:15-11:45	STEAM Education and Biotechnology	<p>Bio Health Partnering Convention 2024 2024 欧亚天然健康产业大会</p> <p>Opening Ceremony 開幕式 Welcome Speech 歡迎辭 Prof. Albert Yu 于家海教授 (Chairman, Hong Kong Biotechnology Organization & BIOHK / Honorary President, EA Bio Health Commerce Association 香港生物科技協會, BIOHK主席 / 欧亚天然健康产业峰会联合创始人)</p> <p>Joey Leung 梁展峰 (Chairman President, EA Bio Health Commerce Association / Founder & CEO, AIFA Tech Limited 欧亚天然健康产业峰会联合创始人 / AIFA Tech Limited 创始人兼行政总裁)</p> <p>Aaron Finley (Director, Deloitte China 德勤中国董事)</p> <p>Lamine LA 劉宏奇 (SHERO Initiative 她惠計畫联合创始人/恒基 (中国) 投资有限公司COO特别助理)</p> <p>Keynote Speech 主题演讲 Aaron Finley (Director, Deloitte China 德勤中国董事) - Biotechnology - Green Finance 生物科技-绿色金融</p> <p>Panel 1: Immunotherapy for Solid Tumors: Opportunities and Challenges 主题 1: 實體腫瘤免疫治療的機會與挑戰 Moderator 主持人 Yueping Li 李宇清 (Researcher & Director, South China Hospital of Shenzhen University 暨南大学附属南方医院)</p> <p>Panelists Dr. Cecilia Zhang 張曉博士 (Co-Founder & CSO, Biocytogen Pte Ltd 百吉生物醫藥聯合創始人兼首席科學家) Prof. Ying Ku 伍麗教授 (Southern University of Science and Technology 南方科技大学) Prof. JingYing Zhou 周京穎教授 (The Chinese University of Hong Kong 香港中文大学) Dr. MingJun Wang 王明军博士 (Researcher & Executive Dean, Shenzhen Innovation Immunotechnology Co. Ltd 深圳创新免疫研究有限公司)</p>		<p>AirDoc Technology: Products showcase and sharing</p>
11:45-12:00				
12:00-12:45				<p>Zhaoko Ophthalmology: Focus on clinical needs of ophthalmology 眼科眼科: 聚焦眼科临床需求</p> <p>Mr. Xiangrong Dai (COO, Zhaoko Ophthalmology) - 眼科眼科: 聚焦眼科临床需求的专家眼科和眼科研究管理</p>

PROGRAM DAY 4

15

Saturday September 14

LUNCH BREAK 午休时段

14:00-15:30

STEAM Education and
Biotechnology

Bio Health Partnering Convention 2024 2024 联庄天然健康产业大会

Panel 2: Empowering Change: Innovations in
Products for Health 主题2: 赋能变革——健康产品的
创新领航

Moderator 主持人

Thalia Kong 江楚婷 (Managing Director, Green
Valley Alliance High Technology Co., Ltd. 绿谷联盟
高科技有限公司 (中国) 执行董事)

Panelists 小组成员

Derek Wu 吴福辉 (Chairman, Beijing Qidai Zhi
Technology Investment Co., Ltd. 北京七代志科技投
资有限公司董事长)

Zhiheng Muk 莫智恒 (Founder, Tongde Xin Medical
Tech Limited 深圳市同得心生物科技有限公司创始人
Chubai Yu, 俞楚博 Technical Support, MDC 康大智
造 技术支持)

Winnie Lin 林慧婷 Academy of Nutrition and
Diabetes, Hong Kong representative 美国营养师协
会(JAAND)香港区代表

Panel 3: Physical and Mental Well-being of
Hurban: In a Sustainable Perspective
主题3: 可持续的人居健康——身心同健康

Moderator 主持人

Wille Liu (Founding Partner, First Star Ventures
First Star Ventures 创始合伙人)

Panelists 小组成员

Mujia Wang 王梅娟 (CEO, Matokowas Biotech)

Jane Chan 陈一琴 (Co-founder & CEO, Olyon Ge
Medical Tech Limited 联云微医疗科技联合创始人兼
CEO)

Andrea Baricco (Managing Partner, Mahway,
Mahway 执行合伙人)

Hana Kell (Co-founder & CEO, Nurture Genomics
Nurture Genomics 联合创始人兼CEO)

Integrative East West approaches to diabetes

Chair 主席

Dr. Chris Kam Wu Chan 陈耀华教授 (Assistant
Professor, Hong Kong Baptist University 香港浸
会大学)

Speakers 演讲人

Dr. Billy Chiu 赵志辉医生 (Chief medical
executive, Adventist medical center) - Evolving
role of Family Doctor on Diabetes Mellitus

Dr. Michele Yuan 袁美然医生 (Specialist in
Endocrinology, Diabetes & Metabolism) -
Diabetes 101 from an Endocrinologist
Perspective

Dr. Chris Kam Wu Chan 陈耀华教授 (Assistant
Professor, Hong Kong Baptist University 香港浸
会大学) - Latest evidence of Chinese medicine
for the management of diabetes

Moderator 主持人

Dr. Chris Kam Wu Chan 陈耀华教授 (Assistant
Professor, Hong Kong Baptist University 香港浸
会大学)

Panelists 小组成员
Dr. Gary Chan (Associate consultant, Queen
Mary Hospital)

Dr. Billy Chiu 赵志辉医生 (Chief medical
executive, Adventist medical center)

Dr. Michele Yuan 袁美然医生 (Specialist in
Endocrinology, Diabetes & Metabolism)

15:30-16:00

Main Hall

Chinese



English



THEATER 1



THEATER 2




THEATER 3



THEATER 4



*Scan the QR code below to use AI Interpreters translation
Please select the corresponding QR code based on the specific lecture hall



Exhibitor List

Booth No.	Exhibitor
T01	BioBAY 苏州生物医药产业园
T02	City University of Hong Kong HK Tech 300 香港城市大學 HK Tech 300
T03	Shanghai Pudong Construction Co.,Ltd. 上海浦东建设股份有限公司
T04	The Hong Kong Polytechnic University 香港理工大學
T05	Fuzhou New Area Pavilion 福州新区展团
T06	Hunan Pharmaceutical Development and Investment Group 湖南医药发展投资集团
T07	Australian Biotech Mission 2024
3D-A03	Guangzhou Zhiyi Biotechnology Co., Ltd. 广州知易生物科技有限公司
3D-A04	Hong Kong Huateng Biomedical Technology Co. Ltd. 香港华腾生物医药科技有限公司
3D-A05	ZSHK Laboratories Limited 滬港中科國際生物科技有限公司
3D-A06	Ready Dietech Co., Ltd. 睿迪生物科技（深圳）有限公司
3D-A07	ROHTO PHARMACEUTICAL Co.,LTD. 乐敦制药株式会社
3D-B01,09	BSP Medical Ltd.
3D-B02	NOVOTECH
3D-B03	Opentrons 合创生物工程（深圳）有限公司
3D-B04	Ming Celer Biotech. 广州明迅生物科技有限责任公司
3D-B05	NAF PHARMA LONGISTICS LIMITED 擎天醫藥冷鏈物流有限公司
3D-B06	INSILICO MEDICINE HONGKONG LIMITED
3D-B10	GUANGDONG HUAWEI TESTING Co., Ltd. 广东省华微检测股份有限公司
3D-B11, B12	ZHAOKE (HK) OPHTHA.PHARMA. LIMITED 兆科（香港）眼科藥物有限公司
3D-B13,B14	LEE'S PHARMACEUTICAL(HK) Ltd. 李氏大藥廠（香港）有限公司
3D-C01	Shenzhen TopBiotech Co., Ltd. 深圳靈賦拓普生物科技有限公司
3D-C02	Beijing Life Biosciences Co., Ltd. 北京靈賦生物科技有限公司

Booth No.	Exhibitor
3D-C03	GYENNO SCIENCE 臻络科学
3D-C06	Hong Kong-Shenzhen Innovation and Technology Park Limited 港深創新及科技園有限公司
3D-C07	KINGWORLD MEDICINE / FAT CHI MEDICINE 金活藥業健康發展有限公司/香港佛慈
3D-C08	MedSci Healthcar 上海梅斯医药科技有限公司
3D-D01	Virogen (Hong Kong) Biopharmaceutical Co., Limited
3D-D02	illumina
3D-D03	Ferring Pharmaceuticals Limited 輝凌製藥有限公司
3D-D05	Royale International
3D-D06	Limu International Decoration Engineering Co., Ltd 力牧國際裝飾工程有限公司
3E-A01	Daan Gene Co., Ltd. 廣州達安基因股份有限公司
3E-A02	Guangzhou Biopharma And Health Industry Investment Co., Ltd. 廣州生物醫藥與健康產業投資有限公司
3E-A03	BIOSYNGEN PTE. LTD. 新加坡百吉生物醫藥
3E-A04	Provectus Therapeutics Limited
3E-A05, A12	AstraZeneca Hong Kong And Macau 阿斯利康香港及澳門
3E-A06, A07	中道養生醫術學會有限公司
3E-A08	美譽創健有限公司 Matthey Supply Company Limited
3E-A09	PINGSHAN BIOMEDICAL INDUSTRY PARK 深圳坪山生物医药产业加速器园区
3E-A10	Hangzhou Ausia Biological Technology Company, Ltd. 杭州澳亚生物技术股份有限公司
3E-A11	Haier Biomedical 海尔生物医疗
3E-A13	Hong Kong New Generation Cultural Association 香港新一代文化協會
3E-A14	TIN HEE TONG MEDICINE FACTORY LIMITED 天喜堂藥廠有限公司
3E-A15	Guangzhou Side Medical Technology Co., Ltd. 廣州思德醫療科技有限公司
3E-A16	Guangzhou SINCHOO Medical Technology Co., Ltd. 廣州信築醫療技術有限公司

Booth No.	Exhibitor
3E-A17	Guangzhou Zhongjian TCM Technology Co., Ltd 廣州中健中醫藥科技有限公司
3E-A18	Yubo Technology Limited 裕柏科技有限公司
3E-B01,B11	Hangzhou Zhongying Biomedical Tec Co.,Ltd. 杭州中贏生物醫療科技有限公司
3E-B02	KCI BIOTECH 凱斯艾生物
3E-B03	ALPALIFEBIO 深圳康體生物醫藥科技有限公司
3E-B04	SAIFU Laboratories CO.,Ltd. 北京賽賦醫藥研究院有限公司
3E-B05	MedChemexpress
3E-B06	Guangzhou Nansha Service Center In HongKong 廣州南沙新區香港服務中心
3E-B07,B15	CHINESE PEPTIDE COMPANY 中肽生化有限公司
3E-B08	Jiangsu CoWin Biotech Co., Ltd. 江蘇康為世紀生物科技股份有限公司
3E-B09	Igenesis (Shanghai) Co.,Ltd. 奧然生物科技(上海)有限公司
3E-B10	Messe Dusseldorf (Shanghai) Co., LTD. 杜賽爾多夫展覽(上海)有限公司
3E-B12	Shanghai InnoStar Bio-tech Co., Ltd. 上海益諾思生物技術股份有限公司
3E-B13	Shanghai BIOCAST Biotechnology Co.,Ltd. 上海子瞻醫藥科技有限公司
3E-B14	Beyond Biotechnology Limited 來然生物科技股份有限公司
3E-B16	neoX Biotech(HK) Limited
3E-C01	樂嘉文製藥科技有限公司
3E-C02	HK Council for Testing and Certification 香港檢測和認證局
3E-C03, 04	Nano and Advanced Materials Institute 納米及先進材料研發院
3E-C05	Rain Biotech Solutions Limited 源博生物科技股份有限公司
3E-C06	Biopharma Industry Promotion Center Shanghai 上海市生物醫藥產業促進中心
3E-C07	AIRDOC TECHNOLOGY (HONG KONG) LIMITED 鷹瞳科技 02251.HK
3E-C08	Weihai Shideyuan Biotechnology Co., Ltd. 威海食德源生物科技有限責任公司

Booth No.	Exhibitor
3E-C09	FORMULATRIX 富默乐国际贸易（上海）有限公司
3E-C10	Shanghai Medicilon Inc.上海美迪西生物医药股份有限公司
3E-C11	Moon Pharmaceutical Equipment (Hangzhqu) Co., Ltd. 穆恩制药设备（杭州）有限公司
3E-C12	INTELLECTUAL PROPERTY DEPARTMENT知識產權署
3E-C13, C14	TROMSO NUTRITION TECHNOLOGIES(H.K.)LIMITED 特勒姆瑟營養科技（香港）有限公司
3E-C15	THE CHINESE UNIVERSITY OF HONG KONG 香港中文大學
3E-C16	Centre for Immunology& Infection (C2i) 免疫與感染研究中心
3E-C17	MGI Ineternational Sales Co.,Limited 华大智造
3E-C18	Geneditbio Limited 正基基因科技有限公司
3E-D01,11	JOINN LABORATORIES 昭衍新药
3E-D02	Global Incubation Network
3E-D12	ADVANTAGE AUSTRIA
3E-D03	Centre for Eye and Vision Researhdh 眼視覺研究中心
3E-D04	Hong Kong Biotechnology Organization (HKBIO) 香港生物科技协会
3E-D09, D19	TMRC of Glycomics by Fudan Z & Sysdiagno 复旦张江研究院 - 先思达糖组转行医学联合研究中心
3E-D10, D20	Hong Kong Cyberport Management Company Limited 香港數碼港管理有限公司
3E-D13	Valfoo Asia Pacific Limited
3E-D14	Hai Kang LifeCorporation Limited 海康生命科技有限公司
3E-E03	BeNa Culture CollectionWeiyel Metrolpgy Group 北纳生物伟业计量集团
3E-E04	PackGene Biotech 派真生物
3E-E05	OPIS
3E-E06	ELLEON BIOTECH LIMITED 愛莉安生物技術有限公司
3E-E07	HITACHI ASIA LTD.日立達東有限公司

BIOHK2024

香港國際生物科技論壇暨展覽

KEYNOTE SPEAKER

DAY ONE

Wednesday September 11

*Surname in Alphabetical Order



Clara Chan 陳家齊

Chief Executive Officer
Hong Kong Investment Corporation Limited

Ms Chan was appointed as the inaugural Chief Executive Officer of the Hong Kong Investment Corporation Limited in October 2023. She is a barrister admitted by the High Court of Hong Kong. She was at the Hong Kong Monetary Authority from 2010 to 2023 with roles including Chief Investment Officer (Private Markets). She was an Administrative Officer in the Hong Kong SAR Government from 2004 to 2010, covering areas including home affairs, transport and financial services.

Ms Chan is the co-chair of the World Economic Forum Global Future Council on Responsible Investing, a Council member of Lingnan University and a Board member of Karen Leung Foundation dedicated to work relating to gynaecological cancers.

Ms Chan received the Asia Industry Leadership Award of the 100 Women in Finance in 2016. She was also on the global list of 40 under 40 named by the Private Equity International.

Ms Chan is an advocate for diversity and ESG awareness in the finance industry, and has been a frequent speaker on relevant topics.



George Fu Gao 高福

Director and Professor
CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University).

Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General), China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).



George Hara

**Group Chairman and CEO
DEFTA Partners**

Mr. George Hara is an archaeologist, tech entrepreneur, and venture capitalist.

In Japan, Ambassador Hara served as Senior Advisor to the Ministry of Finance, the Prime Minister's Special Commissioner on the Government Tax Panel, as an advisor to the Ministry of Internal Affairs and Communications, and as a member of various government committees, including Japan's Industrial Structure Council of the Ministry of Economy, Trade and Industry. In these capacities, Ambassador Hara's efforts are aimed at lowering tax rates while increasing tax revenues in order to enable the Japanese government to establish fiscal discipline.

In the private sector, Mr. Hara founded DEFTA Partners in 1984 and became a Partner at Accel Partners in 1990. He was considered one of the most prominent Silicon Valley venture capitalists in ICT in the 1990s and has led more than twenty companies – including Borland, PictureTel, SCO, Tradex, and Unify – to success. Since 2000, Mr. Hara has served as chairman of the board or helped to manage a number of U.S., Israeli and UK companies including Oplus Technologies (Merged with Intel in 2005), Broadcom (merged with Cisco in 2007), Transitive Tech (merged with IBM in 2008) and Fortinet (NASDAQ IPO in 2009).

DEFTA Partners has long-term relationship with top universities and research institutes worldwide to commercialize the R&D achievements and to create new industry. Mr. Hara founded DEFTA Partners Hong Kong Office, to invest and to foster next generation of entrepreneurs, to promote collaboration between Hong Kong and Japan, and to make Hong Kong China's international innovation and technology hub. His vision is to make the new technologies and treatments accessible to patients, and thus create a thick layer of healthy and well-educated middle class all over the world.

Mr. Hara currently serves as Chairman of the Alliance Forum Foundation (AFF), a 501(c)3 non-profit organisation in Special Consulting Status with the UN Economic and Social Council. AFF is comprised of a number of divisions, notably the Alliance Forum Development Programme (AFDP) and the Public Interest Capitalism Research Institute (AFPIC). AFDP implements the organisation's international development activities focused on (1) eradicating malnutrition, (2) improving education and health care, and (3) promoting economic self-reliance and empowerment in developing nations. AFPIC, on the other hand, works to conduct research and define models for post-financial capitalism to replace the prevailing shareholder-centric model of capitalism which lies at the root of global financial crises. He has also previously served on the boards of the San Francisco Opera, University of San Francisco, Tokyo Foundation, Japan Society and the Hara Research Foundation.

Mr. Hara was born in Osaka, Japan, in 1952. After graduating from Keio University's Faculty of Law, he became involved in archaeological research in Central America until the age of 27. Following this, he enrolled in the Stanford MBA Programme in California and received a Master of Science degree from the Stanford University Graduate School of Engineering after a period serving as a UN Fellow.

He is also the author of numerous articles and publications, including a Japanese best-seller entitled 21 Seiki no Kokufuron (An Inquiry into the Nature and Causes of the Wealth of Nations in the 21st Century), published by Heibonsha in 2007, and Atarashii Shihonshugi (New Capitalism) published by PHP Institute in 2009. He is a Global Agenda Council Member and a Meta Council Member of Inclusive Growth of the World Economic Forum (Davos Forum), and serves on International Advisory Council of SALK Institute.



Chun Ying Leung 梁振英

3rd Chief Executive of Hong Kong
Vice-Chairman National Committee of the Chinese
People's Political Consultative Conference

Mr C Y Leung graduated from King's College, Hong Kong Polytechnic and Bristol Polytechnic. He has been awarded Honorary Doctorate degrees by four universities in the United Kingdom, Hong Kong and Shandong. He was Chairman of the Royal Institution of Chartered Surveyors Hong Kong, President of the Institute of Surveyors in Hong Kong and Asia Pacific Chairman of DTZ. Since late 1970s, Mr Leung had participated in the land and housing reforms in the Mainland. After the constitution was amended in 1988, he assisted Mainland cities in land leasing matters on a voluntary basis. Between 1984 and 1997, Mr Leung was involved in the preparatory work for the establishment of the Hong Kong Special Administrative Region. Between 1997 and 2011, Mr Leung was a member of the Executive Council of Hong Kong and was the Convenor of the non-official members between 1999 and 2011. In March, 2012, Mr Leung was elected the fourth term Chief Executive of the Hong Kong Special Administrative Region. Since March 2017, Mr Leung Served as vice-chairman of the National Committee of the Chinese People's Political Consultative Conference.



Dennis Yuk Ming Lo

盧煜明

Li Ka Shing Professor of Medicine

Faculty of Medicine, The Chinese University of Hong Kong

Professor Dennis Lo is the Li Ka Shing Professor of Medicine of The Chinese University of Hong Kong (CUHK) and the President of the Hong Kong Academy of Sciences. His research interests focus on the biology and diagnostic applications of cell-free nucleic acids in plasma. In particular, he discovered the presence of cell-free fetal DNA in maternal plasma in 1997 and has since then been pioneering non-invasive prenatal diagnosis using this technology. This technology has been adopted globally and has created a paradigm in prenatal medicine. He has also made many innovations using circulating nucleic acids for cancer detection, including the screening of early stage nasopharyngeal cancer.

In recognition of his research, Professor Lo has been elected as Member of the Chinese Academy of Sciences (CAS), Founding Member of the Hong Kong Academy of Sciences, Fellow of the Royal Society and Foreign Associate of the US National Academy of Sciences. Professor Lo has won numerous awards, including the 2014 King Faisal International Prize in Medicine, the 2016 Future Science Prize in Life Science, the 2019 Fudan-Zhongzhi Science Award, the 2021 Breakthrough Prize in Life Sciences, the 2021 Royal Medal, the 2021 ESHG Mendel Award, the 2022 ISPD Pioneer Award, the 2022 Lasker-DeBakey Clinical Medical Research Award, the 2023 inaugural Tengchong Science Prize and the 2024 Jiménez Díaz Lecture Award.



Jonathan Symonds

**Chair
GSK Plc**

Sir Jonathan Symonds has extensive international financial, life sciences and governance experience. In July 2021, Sir Symonds co-chaired with Professor Sir John Bell the preparation of the UK Life Science Vision, which sets out a strategy for UK life sciences in the post-Covid world and seeks to capitalise on many of the UK's scientific successes through the pandemic.

In financial services, Sir Symonds served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc from April 2014 to July 2018 and oversaw the formation of the ring-fence bank HSBC UK plc. He was also a partner and managing director at Goldman Sachs between July 2007 and September 2009.

Sir Symonds was Chief Financial Officer of Novartis AG from September 2009 to January 2014 and Chief Financial Officer of AstraZeneca plc from October 1997 and July 2007, a period which included the negotiation and completion of the merger with Astra. As a CFO, Sir Symonds chaired the 100 Group of Finance Directors, co-chaired the HMRC business tax committee and co-founded the Centre for Business Taxation at the Said Business School.

Prior to joining Zeneca in 1997, Sir Symonds was a Partner at KPMG, specialising in large scale business transformation in the chemicals and pharmaceuticals industries. His additional governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc; Non-Executive Chair of Proteus Digital Health Inc; Non-Executive Director, Rubius Therapeutics Inc.



Wendong Xu 徐文東

**Professor, Senior Consultant
Huashan Hospital, Fudan University**

New Cornerstone Researcher, First Xianghui Scholar, Senior consultant, Professor(T2, four-tier system), PhD Supervisor. Winner of National Science Fund for Outstanding Young Scholars, Chief Scientist of the National Innovation Group. Vice president of Huashan Hospital, Fudan University; President of Jing'an District Central Hospital. President of Chinese Society for Surgery of the Hand (CSSH); President of Hand Function Rehabilitation Professional Committee of Chinese Association of Rehabilitation Medicine (CARM).

BIOHK2024

香港國際生物科技論壇暨展覽

SPEAKER

DAY ONE

Wednesday September 11

*Surname in Alphabetical Order



William Cao 曹衛

Founder & CEO
Gracell

William (Wei) Cao, Ph.D. B.M., founded Gracell Biotechnologies in May, 2017 and has been the Chief Executive Officer (CEO) since its foundation. In Feb, 2024, Gracell was acquired by AstraZeneca (AZ) and became a member of the AZ group, setting a landmark precedent for China biotech industry. Dr. Cao has over 30 years of research and development experience in the biotechnology industry, including founded and co-founded two Nasdaq-listed companies in the field of cell & gene therapies. Dr. Cao has been long dedicated in the research and development of novel cell therapies for the treatment of cancer and degenerative diseases. Before that, Dr. Cao served at senior scientific management positions at Chiron (Novartis and Bayer) and Affymetrix (ThermoFisher). Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. Dr. Cao is the author or co-author of about 50 academic papers published in prestigious international congress/journals; He is also the inventor of 100 issued patents and applications for advanced cell therapies.



Chitty Chen 陳萃英

Director
TMRC of Glycomics by Fudan Zhangjiang Institute

Dr. Chitty Chen is the director of Fudan-Centrum Glycomics Translational Medicine Research Center, and the founder and chairman of Sysdiagno Biotech. Dr. Chen studied Biology at Fudan University and completed her PhD in Bioengineering at Ghent University, Belgium. Dr. Chen has been engaged in biomedical research related to liver disease and aging in Europe for a long time. She was a PhD supervisor at Ghent University, and was the head of the Molecular Biomedicine Laboratory at the Flanders Institute of Biotechnology (VIB) in Belgium, where she pioneered the applied research of glycomics.

Dr. Chen was invited by the Chinese Association for Science and Technology to return to China to found Sysdiagno Biotech, and established the first glycomics detection technology platform Glyface®, which initiated the translation of clinical applications of glycomics. The auxiliary diagnostic product for liver cancer Glyface® Oligosaccharide Chain Assay Kit, was recognized as a national innovative medical device product in April 2024, and it was approved for listing by the National Drug Administration (NMPA).



Forrest Chen 陳霖

CSO

Hangzhou Zhongying Biomedical Technologies LTD.

Doctor of Biophysics, Boston University, USA

Postdoctoral Fellow in Pharmaceutical Oncology, Dana-Farber Institute of Oncology, Harvard University (USA)

Employee of Beijing Institute of Technology, Cell Research Institute of Zhejiang University, and the world's top 500 enterprises including Hailiang Co., Ltd.



Su Chen 陳粟

CEO

Virogen (HongKong) Biopharmaceutical Ltd.

Mr. Chen brings over 30 years of professional expertise and management experience in product development, quality management, clinical research, international collaboration, and GMP facility construction in the biopharmaceutical sectors of China and the U.S. He has held prominent roles, including Senior Process Engineer at Chiron Corporation, Head of Manufacturing Technology at Genentech's world-leading mammalian cell culture facility, General Manager of the Biopharmaceutical Division at Qilu Pharmaceutical, and Vice President of Kanghong Pharmaceutical Group. Throughout his career, he has led the clinical development and commercial production of over 10 innovative biologics and several biosimilars.

Mr. Chen is also a recipient of the 2006 U.S. Presidential Green Chemistry Challenge Award and holds a Master's degree in Biochemical Engineering from the University of Toledo, an MBA from UCLA, and a Master's degree in Computer Science from California State University.



Weiwei Cheng 程薇薇

National senior scholar

Xiyuan Hospital, China Academy of Chinese Medical Sciences

CHENG WEI-WEI is currently an expert in stroke disease and geriatric science in Xiyuan Hospital, China Academy of Chinese Medical Sciences, and has been working in science, education and clinical frontline for 48 years. Stroke Screening and Prevention Engineering Committee of the National Ministry of Health invited stroke disease experts. National Administration of Traditional Chinese Medicine National Geriatric Medical Center first medical graduate and graduate supervisor. Beijing Administration of Traditional Chinese Medicine: the first phase of "Zhongjing Outstanding Inheritor of Chinese Medicine"; Chief expert of the international cooperation team of Beijing International Consultation Center of Integrated Chinese and Western Medicine, Beijing Administration of Traditional Chinese Medicine. Senior member of the Chinese Stroke Society, expert member of the International Association for the Prevention and Treatment of Alzheimer's Disease, Shennei of the Chinese Medical Union Medical College and Peking Union Hospital in the 1990s, learned and mastered 6 stroke related modern instrument detection technologies; The academic team led by Professor Wang Yongjun of Tiantan Hospital affiliated to Capital Medical University hired special experts from the Neurology consultation Center. National Science and technology key research and development plan project, China Academy of Traditional Chinese Medicine Xiyuan Hospital research group leader. Research areas: Hemorrhagic or ischemic encephalopathy after stroke; Common diseases of senile science, complicated diseases and other traditional Chinese and western medicine thinking methods of diagnosis and treatment.



Yuen Yee Cheng 鄭婉儀

Associate Professor
University of Technology Sydney

Associate Professor Cheng is a medicinal chemist and molecular and cell biologist whose research is dedicated to the early detection and improved treatment of cancer. Over the past 12 years, her work has focused on mesothelioma, a rare cancer, leading to the initiation of two clinical trials. She is one of the most successful scientists in securing mesothelioma research funding in Australia, with the majority of research grants awarded to her program.

Her innovative research into miRNA has pioneered a new field in mesothelioma detection and treatment. She leads a multidisciplinary team of postdoctoral scientists, oncologists, and pathologists in conducting clinical trials that utilize novel nanocarrier she designed to enhance the tumor-suppressing effects of miRNA while minimizing side effects.

In addition, A/Prof Cheng addresses critical gaps in anticancer treatment by investigating natural plant extracts and formulations. Her research has led to two significant inventions: one currently filed as a PCT application and the other honored with the HKPC patent award. With her innovative technology, she aims to further explore and refine active ingredients for cancer adjuvant therapy.



Martin Cheung 張知恒

Associate Professor, Associate Director
School of Biomedical Sciences, Li Ka Shing Faculty of
Medicine, The University of Hong Kong

Prof. Martin Chi Hang Cheung obtained his BSc in Biochemistry from the Chinese University of Hong Kong and a Ph.D. in Developmental Genetics from the University of Nottingham in the United Kingdom. He received postdoctoral training at the National Institute for Medical Research (now part of the Francis Crick Institute). Currently, Prof. Cheung holds the position of Associate Professor and Associate Director of Research & Innovation in the School of Biomedical Sciences at the University of Hong Kong (HKU). Prof. Cheung's research interests focus on studying the molecular regulation of neural crest development, investigating the genetic regulation that governs neural crest-derived melanoma progression and drug resistance and understanding the molecular pathogenesis of spinal muscular atrophy to identify new therapeutic targets.

Prof. Cheung has published more than 30 peer-reviewed articles in leading journals, as the first or corresponding author, including *Development*, *Developmental Cell*, *PNAS* x 2, *Developmental Biology*, *Nature Communications*, *Stem Cell Reports*, *Journal of Experimental and Clinical Cancer Research*, *Oncogene*, and *Advanced Science* x 3. His research findings have been frequently featured in press releases at HKU and widely covered by the local and overseas media, highlighting the impact and significance of his scientific contributions.



James Chiu 趙承平

Hon Clinical Assistant Professor
Faculty of Medicine, University of Hong Kong.

Dr. James CHIU, MBBS (HK), FCSHK, FHKAM (Surgery), Specialist in General Surgery, LLB(Hons) Lond, is Hon Clinical Assistant Professor at Medical Faculty, University of Hong Kong (HKU), Senior Research Fellow of Centre for Medical Ethics and Law jointly founded by Medical Faculty and Law Faculty, HKU and co-chairman of Professionalism and Ethics Committee of the Hong Kong Academy of Medicine (HKAM).

Dr. Chiu is an Invited member of the International Network for Law and Apology Researchers. His research areas include medicolegal, expert witnesses, healthcare law, healthcare ethics, apologies, apology legislation, negotiation, mediation, disciplinary and regulatory proceedings. James has published many articles in those areas. He has also co-authored "Apology Ordinance (Cap. 631) Commentary and Annotations" (Sweet & Maxwell, 2018), "Mediation in Hong Kong: Law & Practice" (Wolters Kluwer, 2014 & 2022), and "Best Practice Guidelines for Expert Witnesses" of HKAM (2023). James is a Co-editor and Co-author of "Healthcare Law and Ethics: Principles & Practices" (City University of Hong Kong Press, 2023), and the Principal Author of Vol. 43(2) on Professions and Trades of "Halsbury's Laws of Hong Kong" (LexisNexis, 2023). Dr. Chiu has chaired or spoken in over 100 local and international meetings/conferences for healthcare and legal practitioners.



Zhiguo Ding 丁治國

Director
Office of Development and Planning Committee, Beijing
University of Chinese Medicine (BUCM)

Academic Leader, National Superior Specialty of Chinese Medicine (Endocrinology)
Chief Scientist, Shan'xi Province "Scientists + Engineers" Team;
Chief Expert, Thyropathy Hospital, Sun Simiao Hospital, Beijing University of Chinese Medicine;
Chairman, Thyropathy Professional Committee, Beijing Association of the Integrating of Traditional and Western Medicine;
Chairman, Thyropathy Professional Committee, Shan'xi Academy of Modern Medicine in Traditional Chinese Medicine;
President, Shan'xi Thyropathy Specialty Alliance of Integrated Chinese and Western Medicine;
Editor-in-chief, Special Issue of Chinese Medicine in Medical Reference.



Tristan Edwards

CEO
Entheos Labs

Tristan Edwards is the Co-Founder and CEO of Entheos Labs, a biotech company that is changing the future of mental health treatment by advancing the neuroscience of psychedelic medicines. Entheos Labs is focused on developing innovative treatments that are designed to help those who suffer from mood, anxiety, trauma-based, and substance use disorders.

Tristan is also the co-founding CEO and now serves as President of Life Biosciences which advances scientific research and develops innovative new therapies to improve and extend healthy lives for everyone. The company was formed with the collection of leading scientists and companies who focus on the eight biological causes of aging, and now leads the world in cellular reprogramming. Originally from Australia, Tristan is a dynamic investor and global business leader, who has a multi-disciplinary approach to building companies from the ground up. Prior to Life Biosciences, he founded and served as Chief Investment Officer for Mosaic Asset Management, a Singapore-based investment company focusing on Asian equities. Tristan began his career with the Australian Commonwealth Department of Finance and had investment roles with Goldman Sachs and Brevan Howard Asset Management. He also managed a significant portfolio at Trafalgar Capital.

Tristan currently serves as the co-founder and Chairman of Proto Axiom, Australia's pre-eminent biotechnology incubator.



Bettina Ernst

Director of Bernina Bioinvest, Vice President of Swiss Biotech Association

Dr. Bettina Ernst is a biotech entrepreneur and investor. She has been investing in healthcare companies for the past 10 years. She also serves on the board of several early-stage biotech companies, on the board of the Swiss Biotech Association, and as a member of the advisory board of the Swiss Entrepreneur Fund and of the Innovation Council of Innosuisse. Bettina is a co-founder of two biotech companies. Prior to her investment and entrepreneurial activities, she worked for 10 years in fundamental immunology in the US (Scripps Research Institute, San Diego, CA) and in Europe. Bettina holds a PhD in immunology and an undergraduate degree in natural science from the Federal Institute of Technology (ETH) in Zurich. Bettina resides in Switzerland.



Jing Fan 范靖

**Founder and CEO
Hopstem**

Dr. Jing Fan, Founder and CEO of Hopstem, received her bachelor's degree at Peking University, Ph.D in Neuroscience at UBC, and postdoctoral training at Johns Hopkins University. She has been elected as one of the '30 Global Innovative talents of Chinese entrepreneurs' in 2018, the 2022 Forbes list "TOP50 Women in Science and Technology in China", the outstanding founder in biotechnology industry of 2022 BioCon Award, etc. Dr. Jing Fan has more than 20 years of experience in the fields of pluripotent stem cell and neural differentiation, CNS diseases drug discovery. She has published more than 10 academic papers and book chapters on top journals and led the Maryland Stem Cell Foundation project, and participated in major R&D projects such as NIH, Helix Foundation, etc. Since 2017, she has founded Hopstem in US and China, built the team and established advanced iPSC cell therapy development platform for several products in multiple disease fields. The first-of-its-kind allogeneic cell therapy product hNPC01 is under phase I clinical trial targeting chronic ischemic stroke in China, with recent IND approval from FDA. She has raised more than 70 million USD fund for Hopstem from top VCs including Hillhouse and LAV.



George Fu Gao 高福

**Director and Professor
CAS Key Laboratory of Pathogen Microbiology and
Immunology, Institute of Microbiology, Chinese Academy
of Sciences (CAS), Beijing, China**

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University).

Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General), China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).



Alice Hsu 許榮懷

SVP

Clinical Technology Services and Consulting

Alice Hsu currently serves as the Senior Vice President of Clinical Technology Services and Consulting at AlphaLife Sciences Group. In this role, she leads the Clinical Technology Services team, offering expertise in clinical trial system operations, system development and strategic support. Her efforts focus on enhancing efficiency and delivering high-quality services through the implementation of AlphaPrime's integrated system platform.

Alice brings over 15 years of experience in the CRO industry, having worked in project management and clinical operations at leading organizations such as IQVIA, Fortrea, WuXi Clinical, and PPD.

Throughout her career, she has been based in Taipei, Singapore, and Shanghai, gaining expertise in both technical project execution and leadership across clinical operations and management roles.

Alice holds a Master of Health Science (MHS) from Johns Hopkins University Bloomberg School of Public Health and a Master of Science (M.S.) in Nutritional Sciences and Immunophysiology from the University of Illinois, Urbana-Champaign.



Norman Hui 許文恩

Barrister-at-Law; Principal Lecturer

Faculty of Law, University of Hong Kong

Norman Hui has an established practice in intellectual property, personal injuries, and commercial disputes. Norman appears in courts at all levels, as well as other specialist tribunals, including the Trade Marks Registry and the Copyright Tribunal. Norman acts for local clients such as well-known companies dealing in consumer design, comic art, medicinal products, civil engineering and the Government of Hong Kong. Norman is a member of the Committee on Intellectual Property (CIP), is a recognised personal injuries litigator and also a member of the Committee on Personal Injuries (CPI) of the Hong Kong Bar Association.

Norman is also involved in various legal publications including Professional Conduct of Lawyers in Hong Kong, Commercial Litigation in Hong Kong, Halsbury's Laws of Hong Kong.

Norman is a principal lecturer at the Faculty of Law, University of Hong Kong since 2004 and teaches on the PCLL course.

Norman has sat as a Deputy District Judge in 2012, 2023, 2024.



Masayasu Inoue

**Professor Emeritus
Osaka City University Medical School**

1945 Born in Hiroshima
 1974 Graduated from Postgraduate Course of Okayama Univ. Medical School
 1974 Assistant Professor, Kumamoto University Medical School
 1980 Associated Prof of Medicine, Albert Einstein College of Medicine
 1982 Professor, Tufts University of Medical School
 1992 Professor, Osaka City University Medical School
 2011 Emeritus Professor, Osaka City University
 2011 Vice Dean, Miyagi University
 2013 Dean, Health Science Laboratory, Osaka
 2015 Outside Director, Kirindo Co., Ltd.
 2019 Council Member of the Intestinal Flora Transplant Clinical Research Group, Symbiosis Research Institute & Director of FMT Clinic (until 2020)
 2021 Academic Advisor, Kirindo Holdings Co., Ltd.



Xuweisheng Ji **紀徐維晟**

**Expert in traditional Chinese medicine digital health
platforms, BUCM Research Centre for Inheritance and
Digitization of Traditional Chinese Medicine**

Ji Xuweisheng is from BUCM Research Centre for Inheritance and Digitization of Traditional Chinese Medicine, and he is an expert in traditional Chinese medicine digital health platforms. His research focuses on intelligent manufacturing of TCM, embedded TCM IoT devices, equipment and algorithms for collecting and analyzing TCM biological information, and TCM health data platforms. The intelligent IoT moxibustion box, which was developed in the early stage, won the Excellence Award in the Rehabilitation Equipment Finals of the 5th China Medical Device Innovation and Entrepreneurship Competition.



***Xia Jin* 金俠**

Co-founder, Chief Executive Officer and Executive Director, Immuno Cure Holding (HK) Limited

Dr. Xia JIN MD PhD, was Chief Scientific Officer and Vice President of Serum Bio Technology (STAR Market: SH688163) in Shanghai. Prior to that, he was Professor and Principal Investigator of Shanghai Public Health Clinical Center and the Director of Vaccine and Immunology Research Center of Fudan University. He was also Distinguished Professor of Chinese Academy of Sciences and Principal Investigator and Executive Director of Vaccine Center at Institut Pasteur of Shanghai. He had been a tenure-track Assistant and Associated Professor at Rochester University, New York, USA.

He obtained a Medical Doctor degree after completion of the 8-year Curriculum at Peking Union Medical College and then a PhD degree in Life and Biomolecular Sciences from Open University under the tutelage of Professor Sir Patrick Sissons of Cambridge University Clinical School in UK. His postdoctoral training was completed with Drs. Richard A. Koup and David Da I Ho, respectively at the Aaron Diamond AIDS Research Center in New York.

While working in USA, he has been a Principal Investigator or Co-investigator of over research grants from NIH and the Bill & Melinda Gates Foundation. He has served as a member of numerous NIH study sections and also as international expert reviewer for Netherlands, Hong Kong, Taiwan and Singapore research agencies. He has been the Chair (HVTN-064, HTVN-083) and Co-Chair (HTVN-063, HTVN-094) of HIV vaccines clinical trials conducted by the HVTN of NIH/NIAID in USA. He is an Academic Editor of PLoS ONE and Editorial Board Member of JAIDS. His laboratory work focuses on HIV and dengue virus immunology and vaccine development. He has published over 140 SCI papers in Science, J Exp Med, J Clin Inv, J Immunology, J Virol, J Inf Dis, AIDS, Retrovirology, Vaccine.



Yi Tsun Kao 高一村

Associate Professor

Department of Microbiology, LKS Faculty of Medicine, The University of Hong Kong

Professor Kao is a tenured Associate Professor in the Department of Microbiology at the University of Hong Kong and a member of the State Key Laboratory of Emerging Infectious Diseases at HKU. He earned his Ph.D. in Microbiology from UBC in 1999, under the guidance of Professor Julian Davies, and completed his postdoctoral training at Harvard Medical School from 1999 to 2001. Professor Kao's research centers around the application of chemical genetics in infectious diseases, spanning from SARS-CoV, influenza viruses, pathogenic bacteria, to fungi. Recently, he has extended his chemical genetic studies to explore virulence and antimicrobial resistance in bacteria, demonstrating the potential use of non-antibiotic antivirulence compounds for the treatment of *Staphylococcus aureus* infections, including MRSA. Dr. Kao has published extensively in top microbiology journals, such as *mBio*, *PNAS*, *Nature Communications*, and *Nature Biotechnology*. He has received numerous awards, including the Innovation Academy Award from the International Consortium of Prevention and Control of Infection (ICPIC) in Geneva, Switzerland in 2017, and most recently, the 2019 State Scientific and Technological Progress Award. Professor Kao is a pioneer in non-antibiotic antivirulence therapeutics for bacterial infections and is the Founder, Director and Chief Scientific Officer of Antenovus Biotechnology Limited.



Gilberto Leung 梁嘉傑

President

the Hong Kong Academy of Medicine

Professor Gilberto Leung is a neurosurgeon, Clinical Professor, and holder of the endowed Tsang Wing-Hing Professorship in Clinical Neuroscience at the University of Hong Kong (HKU). He graduated from the University of London with MBBS in 1992. During postgraduate training, he was awarded the Hallett Gold Medal and the J. Douglas Miller Medal in Neurosurgery by the Royal College of Surgeons of England and that of Edinburgh, respectively. He holds a MS, a PhD and a MD from HKU; an Intercalated BSc in Physical Anthropology and an LLB from the University of London; and an LLM in Medical Law and Ethics with Distinction from the University of Edinburgh.

He is currently President of the Hong Kong Academy of Medicine; Associate Dean of his HKU medical faculty; Co-Director of the Centre for Medical Ethics and Law at HKU; Deputy Director of the State Key Laboratory of Brain and Cognitive Sciences at HKU; Member of the Research Council of the Health Bureau; and Honorary Consultant Neurosurgeon at Queen Mary Hospital. His research interests cover endoscopic neurosurgery, neuro-oncology, neuroprotection, medical education, and medical law and ethics.



Shaowei Li 李少偉

Professor
Xiamen University

Professor of Biochemistry and Structural Vaccinology, Xiamen University

Shaowei Li is a tenured Professor of Biochemistry and Structural Vaccinology in the School of Life Sciences with a joint appointment in the School of Public Health, Xiamen University, China.

He is the vaccine group leader in the National Institute of Diagnostics and Vaccine Development in infectious diseases (NIDVD), one of the academic leaders in the State Key Laboratory of Vaccines for Infectious Diseases, deputy director in Fujian provincial Xiang An biomedicine laboratory. Dr. Li has inter-disciplinary research interests focusing on structural vaccinology, resulting in more than 120 peer-reviewed papers. He also has translational experience in vaccine development against infectious diseases—such as Hepatitis E vaccine and HPV vaccine, especially in aspects of immunogen design, process development and antigen characterization.

Dr. Li has won two of China's National Science and Technology Awards and been listed in the Top 20 translational researchers of 2016, ranked by Nature Biotechnology. He has served on the Product Development for Vaccines Advisory Committee (PDVAC), World Health Organization (WHO) since 2022.



Yi Li 李毅

Director of Market Access
Innogen Pharmaceutical Group

Ms. Li Yi, Director of Market Access of Innogen Pharmaceutical, has more than 15 years experience in market access and patient innovation payment programs in the pharmaceutical industry. She has worked in Servier, Takeda, and Roche Pharmaceuticals, and has rich experience in healthcare policy analysis and policy shaping, local medical insurance listing and government affairs, patient support programs and responsible for the integrated access strategies/portfolio strategy for innovative drugs (especially on oncology, neuroscience, and rare diseases areas, etc.) Ms. Li graduated from Peking University with a master's degree in pharmaceutical administration and received her bachelor's degree from West China Medical University, school of pharmacy.



You Li 李遊

**Founder and President, BioInsight;
SVP, Clinical & Regulatory Strategy, Function Oncology**

Dr. You Li has more than 15 years of experience in product development and regulatory strategy for pharmaceuticals and medical devices. He currently serves as Founder and President of BioInsight and Senior Vice President, Head of Clinical and Regulatory Strategy at Function Oncology. Dr. Li is also a board member and the current President of the Chinese Biopharmaceutical Association (CBA).

Previously, Dr. Li held various leadership roles in pharmaceutical and medical device companies, as well as a regulatory agency. These positions include:

- Vice President, Program Executive and Clinical Strategy at EQRx (acquired by NASDAQ: RVMD in 2023)
- Vice President, Head of Regulatory Strategy at Thrive (acquired by NASDAQ: EXAS in 2021)
- Senior Lead Reviewer at the US FDA

Dr. Li received his PhD in Human Genetics from the University of Pittsburgh and dual Bachelor's Degrees in Biology and Computer Science from Zhejiang University.



Roben Liang 梁嘉琳

**Director
Healthy China Research Center**

Roben Liang is the founder of the academic platform "Healthy National Policy 2050", the Director of Healthy China Research Center, the Director of Health Strategy Communication Committee of China Population Society, and the guest professor of School of Continuing Education of Shanghai Jiaotong University School of Medicine.

He has been invited to give lectures for the National Health Education Work Conference, National Health Insurance Publicity Work Conference, Guangxi Autonomous Region/Wuhan Cadre Classes for cadres at or above the division level, Guangdong Province/Hainan Province/Guizhou Province Health Commissions, Shanghai Municipality/Guangxi Autonomous Region Health Insurance Bureaus, Sanming Municipal Party School of the "Sanming Health Care Reform", School of Public Health of Peking University, Institute of Hospital Management of Tsinghua University, etc., for officials at the departmental and bureau level and the governmental think tank. The Institute of Public Health of Peking University, Tsinghua University Hospital Management Research Institute, etc. The total number of lectures given to the cadres of departmental and bureau level and below, the directors of provincial, municipal, county and tertiary hospitals, and the listed/multinational pharmaceutical enterprises is over 300.



Jun Liu 劉軍

**Professor,
National Institute for Viral Disease Control and Prevention,
China CDC**

Prof. Liu graduated from the School of Public Health, Peking University Health Science Center in 2005. He received a Ph.D degree from Institute of Microbiology, Chinese Academy of Sciences in 2010 and had the postdoctoral training at Yale School of Medicine. The main research focus of his group is the epitope-specific T-cell recognition of emerging and re-emerging viruses, i.e. influenza viruses, coronaviruses, etc. He has published more than 190 papers in English journals such as Nature (×2), Immunity, PNAS, Nat Commun, EID, CID, JID, J Virol (×10) and J Immunol (×9), etc. He is the Assistant Secretary of Asia-Pacific Biosafety Association (A-PBA), the deputy Editor-in-Chief of Biosafety and Health. During the 2014-16 Ebola epidemic in West Africa, he worked as one specialist in the first Public Health Team from China to support Africa and also the team leader for the Ebola test in P3 Laboratory in West Africa for nine months. He also worked as the team leader of the first Chinese Public Health Team to the Democratic Republic of the Congo during the Ebola epidemic from June to July, 2018. During the COVID-19 pandemic, he worked onsite in difference outbreaks for the emergency responses.



Yangyang Liu 劉洋洋

**副總經理
廣州知易生物科技有限公司**

知易生物聯合創始人、副總經理、醫學博士。“珠江科技新星”獲得者，廣東省活體生物藥工程技術研究中心副主任，“廣州市創新領軍團隊”核心成員。2013年聯合創辦知易生物，全程主導並完成了SK08活菌散的臨床前研究工作，目前負責公司新藥的早期發現以及臨床研究。主持省級科技課題1項，作為骨幹研究人員參與國家“863”計畫，以及其他省市級科技課題5項。申請專利40多件，PCT14件，已授權19件。發表SCI論文14篇。



Mark Lotter

**Founder and CEO
Nuance Pharma**

Nuance Pharma is an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region.

Mr. Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, has over twenty years' leadership experience in the China healthcare market. As one of the founding executives of AstraZeneca China, Mr. Lotter pioneered the nationwide nebulization strategy that fostered a billion-dollar respiratory market in the past decade. Being a serial entrepreneur, Mr. Lotter has proven experience and commitment to bringing world-leading innovative therapies to patients in the Asia Pacific region.



Hang Lu 陸航

Founder and CEO
NextTranslate Biopharmaceutical Co., Ltd.

Dr. Hang Lu is the founder and CEO of NextTranslate Biopharmaceutical Co., a company focusing on the development and manufacture of mRNA- and advanced technology-based preventive and therapeutics products.

Dr. Lu has over 25 years of experience in biological product development in pharmaceutical and biotechnology industry, including Merck Co. and Emergent BioSolutions (EBSI), a NYSE-listed global life sciences company that seeks to protect and enhance life by providing specialty products including vaccines and therapeutics for civilian and military populations. Dr. Lu held roles of increasing responsibilities at EBSI over the last 20+ years, including director of CDMO Analytical Development or PAD, Principal Scientist of R&D or Nonclinical Development. He was responsible for setting up the Immunotoxicology Lab and GxP Lab and was the core team member of more than ten traditional and new generation vaccines and biologics from the discovery to preclinical and CMC development over the product life-cycle, from IND to BLA submissions leading to regulatory approvals in USA.

Dr. Lu obtained his medical degree at Zhejiang University and practiced there as a pediatric hematologist, and then completed his post-doctoral research training at the University of British Columbia with a sponsorship from the Canadian Institutes of Health Research (CIHR) .

Dr. Lu is an advisory committee member of Vaccine Research Council, China Association for Vaccines and was the President of the Chinese Biopharmaceutical Association (CBA, 2021-2022).



Xiaofeng Meng 孟曉峰

President
The WhiteOak Consulting

Dr. Xiaofeng Meng is currently serving as the President of The WhiteOak Consulting with offices located at Hangzhou, China and Maryland, USA.

Graduated with Ph.D/MBA Degree from Rutgers, the State University of New Jersey and Master Degree from Shanghai Institute of Pharmaceutical Industry, Dr. Meng owns more than 20-year experience in pharmaceutical industry and is well recognized as the expert in global regulatory affair and quality management.

At different positions, Dr. Meng has been working on various IND, NDA, ANDA and MA submission with FDA, EMA and China NMPA, covering oral solid, injectables, inhalation, nasal spray and other dosage forms. At The WhiteOak Consulting, Dr. Meng and his team has supported many US and China major pharmaceutical companies for their global regulatory submission, GMP system establishment and official regulatory inspection.

In addition, Dr. Meng has extensive experience in product launch of OTC, Rx generic and branded product to global market.



Hideyuki Okano **岡野榮之**

Distinguished Professor
Keio University

Hideyuki Okano received his M.D. (1983) and Ph.D. of Medical Science (1988) from Keio University. After a postdoctoral fellowship at Johns Hopkins University, he became a Professor at Tsukuba University (1994), Osaka University (1997), and returned to Keio University in 2001. He served as Dean of Keio University School of Medicine/Graduate School of Medicine (2007-2021) and was appointed Visiting Professor at MIT in 2022. He is currently the Director and Distinguished Professor of Keio University Regenerative Medicine Research Center. He was awarded numerous honors like the Medal with Purple Ribbon (2009), the Erwin von Bälz Prize (2014) and Uehara Prize (2022). Currently, he is the president of the Japanese Society for Regenerative Medicine, and is the President Elect of the ISSCR, focusing on stem cell therapies for spinal cord injuries and iPSCs-based modeling and drug development of neurodegenerative diseases such as ALS and Alzheimer's disease.



Leo Poon 潘烈文

Chair Professor

School of Public Health, The University of Hong Kong

Professor Leo Poon received his doctoral training in the University of Oxford. He currently serves as a Chair Professor in the School of Public Health at HKU. Additionally, he is the co-director of the HKU-Pasteur Research Pole and the managing director of Centre for Immunology & Infection, a research centre under InnoHK. As a world-leading virologist and public health scientist, Professor Poon has published over 300 peer-reviewed articles and has been recognized as a Highly Cited Researcher since 2015. His work has been cited over 4,000 times, and he has an H-index of 100. With over 25 years of experience studying emerging viruses, Professor Poon focuses on both human and animal influenza viruses as well as coronaviruses. His work spans from basic virology to public health virology. In 2003, he played a significant role in the discovery of a novel coronavirus as the etiological cause of SARS and was among the first to decode the initial SARS coronavirus sequence. His work on COVID-19 provided solid scientific findings to inform public health policy. He is an advisor in different task groups for infectious disease control in WHO, FAO and WOA. H.



Howard Shi 史淵源

President

Shenzhen Cell Valley Biopharmaceutical Co., Ltd

Howard Shi PhD, President&CEO, Professor and doctoral supervisor.
Postdoctoral fellow, Department of Pathology, Harvard Medical School .
Ph.D., Biochemical and Molecular Biology, Institute of Biophysics, Chinese Academy of Sciences.
Bachelor, Biochemistry, School of Life Sciences, Xiameng University.
Distinguished professor, doctoral supervisor and postdoctoral supervisor at the Beijing University of Traditional Chinese Medicine. Previous executive dean of the School of Life Sciences, Beijing University of Chinese Medicine and president of the Research Institute of Beijing University of Chinese Medicine in Shenzhen.

Mainly explore changing the molecular structure of CAR, enhance the specificity of antigen recognition and killing, and achieve the accuracy of CAR-T treatment.
With rich experience in business management, as founder Dr. Shi established the School of Life Sciences of Beijing University of Traditional Chinese Medicine, Shenzhen Research Institute of Beijing University of Traditional Chinese Medicine, Biotang Inc.(USA), Junjo Pharmaceuticals Co., LTD., Shenzhen Cell Valley and other companies have been operating.



Nan Song 宋楠

Deputy Director

**Medical Research Centre, Beijing Chaoyang Hospital,
Capital Medical University**

Recipient of Beijing Outstanding Youth Fund (2022)

Outstanding Young Talents of Phoenix Programme of Chaoyang District, Beijing (2023)

Capital Medical Young Innovative Scholar (2024)

He has published more than 10 SCI papers related to respiratory diseases in *Molecular Cell*, *Cell Reports*, *PLOS Pathogens* and other journals as the first/corresponding author, with the highest number of citations exceeding 200. He has been responsible for the National Natural Science Foundation of China (NSFC) youth and surface projects, and has been selected for the 'Green Shoots' programme of the Beijing Municipal Healthcare Management Centre.



Diana Viola

**Chief Executive Officer
PharmaBoardroom**

Diana Viola is CEO and cofounder of PharmaBoardroom.com, a global platform for high-level dialogue between government authorities and regulators, C-level industry executives, financial investors and other key stakeholders, as well as Healthcare and Life Sciences Review, comprehensive digital reports covering various healthcare markets and industry thematic. In total, both platforms reach over 53,000 global industry stakeholders across the entire value chain from R&D, manufacturing, and marketing and sales, to supply chain distribution, logistics and other services. Over the past 15 years, Diana has been committed to driving global engagement on relevant industry topics, trends and debates, sharing best practices across international markets, and advocating for collaboration and innovation within the healthcare and life sciences industry.



Paloma Wang 王鵬

**Co-head of China Practice, Partner
Skadden, Arps, Slate, Meagher & Flom**

Paloma Wang is partner and co-head of the firm's China practice, focusing on capital markets and other corporate matters. She represents both issuers and underwriters in initial public offerings on the Hong Kong Stock Exchange, advising investors and corporates on private equity investments and listed issuers on compliance and general corporate and regulatory matters.

Ms. Wang has advised on numerous leading biotech IPOs in Hong Kong since the inception of the biotech regime in 2018, as well as counselling Hong Kong-listed biotech companies on ongoing corporate matters. She co-authors Skadden's annual reports on Hong Kong-listed biotech companies, which provide a comprehensive overview of the market and annual developments since 2018. Ms. Wang has been repeatedly named IPO Lawyer of the Year at Law.com International's Asia Legal Awards (including in 2024). She also has been honored by Asian Legal Business as one of its Dealmakers of Asia in the China Dealmakers category, as well as by Asia Pacific Legal 500 as a Leading Individual.



Xiaojun Wang 王曉鈞

**Vice Director, Professor
Harbin Veterinary Research Institute, the Chinese Academy
of Agricultural Sciences**

Prof. Xiaojun Wang is Deputy Director of the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences. He is the chief scientist of the research team for equine infectious diseases and lentiviral diseases of HVRI. He is also the deputy director of the National Key Laboratory for Animal Disease Prevention and Control, director of the National Reference Laboratory for Equine Infectious Anemia, director of the National Reference Laboratory for Glanders, expert of the World Organization for Animal Health (WOAH), director of the WOAH Reference Laboratory for Equine Infectious Anemia, etc. He has long been engaged in the research of equine infectious diseases and lentiviral diseases. His main research interests are the interaction mechanism between pathogens and hosts and the prevention and control strategies for equine infectious diseases. He has successfully developed five equine disease vaccines and more than 50 diagnostic kits for equine infectious diseases. He had published more than 80 peer-reviewed papers and seven books.



Josephine Wu

Chief Investment Officer
Sapere Capital Management

Josephine has over 20 years' experience in global hedge fund, family office and asset management including over 15 years as an investor in listed, pre-IPO and early-stage healthcare companies across Asia. She specialises in strategic partnerships, operations, market positioning and regulatory affairs across the Pan Asia healthcare landscape. She is Chief Investment Officer of Sapere Capital Management, an asset management platform which provides global asset allocation and investment solutions focused on capital appreciation and wealth preservation for families, corporates and entrepreneurs. Previously, she was the Head of Asia Absolute Return and Alternative Strategies at UBP, Managing Partner of Light & Salt Capital Management, Regional Portfolio Manager at Robeco Hong Kong and Yu Ming Investments, and General Partner at LR Global Partners in New York. Josephine is also the founder of Alonious Management Limited, an investment company that provides business development and commercialisation strategies mainly on innovative industries; she is an independent investment committee member at Biocurate, a non-executive director at RAWs-Tech and a former Board member at Mydecine Innovations Group.



Frank Yang 楊鋒

Founding Partner & CEO
Blue Ocean Capital Group

Mr. Frank Yang has over 20 years VC/PE experience with a record of multibillion-dollar investments in the pharmaceutical industry.

Prior to founding Blue Ocean Capital Group, Mr. Yang served as Managing Director at CCBI, responsible for principal investments and China's first institutional healthcare PE fund. Mr. Yang led investments in dozens of pharmaceutical companies including Innorna, Cure Genetics, Koka Lifesciences, InterHill MED, HighTide Therapeutics, Boan Biotech, Ribo Life Sciences and Signet Therapeutics, among some of which he served as a board member.

Mr. Yang sits on the board of HK Bio-Med Innovation Association ("HKBMIA"), Chinese Financial Association in Hong Kong ("HCFA"), PRC Committee of Hong Kong Venture Capital and Private Equity Association ("HKVCA"), and the advisory board of HKUST MBA Business School. Mr. Yang is a PhD candidate of CUHK and holds the MBA degree from HKUST.



Henry Yau 游廣智

Managing Director
Clinical Trials Centre, The University of Hong Kong

Henry Yau is the Chief Executive Officer of The University of Hong Kong Clinical Trials Centre (China) (HKU-CTCC), Managing Director of Clinical Trials Centre, The University of Hong Kong (HKU-CTC), Honorary Assistant Professor of Faculty of Medicine of Macau University of Science and Technology (MUST). He holds a B.Sc. in Biochemistry and a MBA in Finance. Started his career in the pharmaceutical industry in early-1990s, Henry has been specializing in clinical research management for over two decades since 2000. Henry has also been recognized as a High-end Foreign Expert (Clinical Trials Management) under the National High-end Foreign Experts Recruitment Plan of the Chinese Ministry of Science & Technology (MOST) since early-2023, and undertakes roles in many local and international bodies such as Steering Board Member and Past Chairperson of the International Clinical Trial Center Network (ICN), Member of the Working Group on Good Governance Practice for Research Institutions of the Council for International Organizations of Medical Sciences (CIOMS), and Advisor (Asia) of Training and Resources in Research Ethics Evaluation Program (TRREE). Henry is also devoted to consolidating and transferring practical knowledge in international clinical research management and operations and has been invited to participate as speaker, trainer or panelist in 160 conferences/forums/workshops around the world.



Kwok-Yung Yuen 袁國勇

Chair of Infectious Diseases

Department of Microbiology, The University of Hong Kong

Professor Yuen Kwok Yung is the Chair in the Department of Microbiology and Henry Fok Professor of Infectious Diseases at the University of Hong Kong, and the co-director of the State Key Laboratory of Emerging Infectious Diseases since 2005. He is a physician and microbiologist, and holds an MBBS and MD from the University of Hong Kong.

Professor Yuen has discovered over 100 novel species of virus, bacteria, fungi and parasites from patients and animals. Several of these novel animal viruses or their close relatives cause emerging infectious diseases by jumping from animals to human. In 2003, he led his team in the discovery of human SARS coronavirus, and the bat SARS related coronavirus. Professor Yuen has published extensively in the areas of coronaviruses, influenza and other emerging virus infections, and was named by Clarivate, in its list of Highly Cited Researchers, among the top 1% of scholars worldwide, for three consecutive years from 2020 to 2022.

During the COVID-19 outbreak, Professor Yuen was the first in the world to provide evidence that SARS-CoV-2 could be easily transmitted from person-to-person in a family cluster presenting to the hospital, and that patients could be re-infected with the virus. His discoveries and expertise have been referenced by governments and healthcare policy makers internationally as they responded to the spread of the global pandemic.

Professor Yuen is a qualified specialist in clinical microbiology, internal medicine and surgery in the Hong Kong SAR and the United Kingdom. He is also academician of the Chinese Academy of Engineering (Basic Medicine) and the American Academy of Microbiology. He was awarded the Future Science Prize in 2021. The HKSAR government has awarded him a Silver and Gold Bauhinia Star for his work on microbial hunting and emerging infections.



Ge Zhang 張戈

Director

Development Research Center of Chinese Medicine

Zhang Ge is the Director of the Traditional Chinese Medicine Development Research Center at the Guangdong Branch of the China Academy of Chinese Medical Sciences (Guangdong Provincial Hospital of Traditional Chinese Medicine). He served on secondment at the National Development and Reform Commission, the National Administration of Traditional Chinese Medicine, and the Guangdong Provincial Administration of Traditional Chinese Medicine. Currently, he serves as a council member of the Chinese Health Economics Association, a senior member of the China Computer Federation, and a member representative.

Over the past three years, he has been in charge of more than 20 projects at the provincial and ministerial level, including involvement in the drafting of the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" and the "Implementation Plan for Major Projects to Revitalize and Develop Traditional Chinese Medicine," both published by the State Council. He authored the "14th Five-Year Plan for the Development of Traditional Chinese Medicine in Guangdong Province" and other policies, and has been responsible for the evaluation and promotion of national TCM development policies, as well as advancing the construction of the Greater Bay Area as a center of excellence for traditional Chinese medicine.



Ning Zhang 張寧

Professor

PKU Medicine

北京大學教授，國家“萬人計畫”入選者、國家傑出青年科學基金獲得者、科技部中青年科技創新領軍人才、人事部百千萬人才、突出貢獻專家獎。李氏基金會傑出成就獎獲得者。現擔任北京大學第一醫院腫瘤轉化研究中心主任，北大-白藥國際醫學中心副主任，北京大學國際癌症研究院副院長，北京大學健康大數據國家研究院副院長，中國抗癌協會常務理事、副秘書長，中國老年學和老年醫學學會轉化醫學分會主任委員，《Cancer Biology & Medicine》常務副主編，《Medical Review》常務副主編，白藥集團首席科學家。張寧教授長期從事生物醫學研究，文章發表在Nature、Cancer Cell、Nature Biotechnology、Gastroenterology、Nature Communications等國際期刊。



Jie Zhou 周婕

Assistant Professor
The University of Hong Kong

Prof ZHOU Jie. Assistant professor. Department of Microbiology, The University of Hong Kong.

Prof Zhou's research interests focus on developing organoid models and organoid-based virus research. She and her team established the first human respiratory organoid culture system and first bat intestinal organoid in the world, which has opened up new avenues for diverse applications in biomedical research and drug development. Her contribution to organoid technology is attributed to her clinical medical training and clinical pathology works in China, as well as her experience in virus research. She obtained her PhD from the University of Hong Kong in 2007 and finished postdoctoral training at UCSF in 2009. She has published over 100 research papers in prestigious journal including Nature Medicine, PNAS and Science Advances, ranked among the top 1% of cited scholars by Clarivate Analytics in 2021, and highly cited scholars since 2022. She and the team founded a startup company BiomOrgan Limited to commercialize the proprietary respiratory organoid technology since 2021.



Jiajie Zou 鄒家傑

Director of Toxicology,
JOINN Laboratories

Mr. Zou graduated from China Agricultural University, he is a young member of the Professional Committee of Drug Toxicology and Safety Evaluation of the Chinese Society of Toxicology. He gained the qualification certification of Chinese toxicologists, and has been engaged in preclinical safety evaluation of medicines for more than 15 years. He is mainly engaged in the safety evaluation of new medicines, familiar with domestic and international regulations and guidelines, and has been subject to on-site inspections by USFDA and CFDA for many times. As a project leader, he has been responsible for the safety evaluation of more than 300 medicines and more than 600 projects. Several projects have been successfully submitted to domestic and foreign countries and entered into clinical trials. He has evaluated many novel medicines, including small molecules (mainly chemical 1.1) and large molecules (novel biologics, bispecific antibodies, ADCs, oligonucleotides), etc. He has published more than 10 professional papers.

BIOHK2024

香港國際生物科技論壇暨展覽

KEYNOTE SPEAKER

DAY TWO

Thursday September 12

*Surname in Alphabetical Order



Lillian Cheong 張曼莉

Under Secretary

**Innovation, Technology and Industry of the Hong Kong
Special Administrative Region**

Ms. Cheong joined the Government in 2017 as Political Assistant to the Secretary for Innovation and Technology and was appointed as Under Secretary for Innovation, Technology and Industry in July, 2022.

Before joining the Government, Ms. Cheong served as Assistant to Executive Director and Joint General Manager at a listed company, and had experience in operation and management of real estate development, cross-boundary retail, technology investment, business development and restructuring, digital transformation, investor relations, etc. In addition to profound knowledge in the business sector, Ms. Cheong has extensive public service experience including serving as a co-opted member of the Community Building Committee of the Wan Chai District Council, adviser to a think tank, etc.



George Lau 廖家傑

**Chair Professor and Senior Consultant in Clinical Hepatology,
Zhongshan Hospital, Fudan University, Shanghai**

Professor George Lau graduated from The Faculty of Medicine, The University of Hong Kong in 1987. In 1992, he was awarded Hong Kong-Stanford scholarship for his further training in Gastroenterology and Hepatology at the Stanford University, USA. In 1998, he was recommended by Professor Roger Williams to be further trained in translational Hepatology at the Institute of Hepatology, University College of London (supported by the Royal Society Award). In 2002, he was promoted to Senior Lecturer and Consultant in Gastroenterology and Hepatology at Queen Mary Hospital, Hong Kong. In 2006, he was promoted to full Clinical Professor and assistant Dean, Faculty of Medicine, The University of Hong Kong. He was also well respected by his peer in academic Hepatology and was elected as 19th President of The Asian Pacific Association for the Study of the Liver (APASL) in 2008. In 2009, he founded and become Chairman and Consultant in Gastroenterology and Hepatology, Humanity and Health Medical Group, Hong Kong.

Concurrently, he was appointed as the Co-director and Chair Professor at Liver disease and Transplant Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, Chair Professor at Zhongshan Hospital, Fudan University, Shanghai, China, Distinguished Professor at Shulan International Medical College, Hangzhou, Zhejiang Province, China, Visiting Professor at Qingdao University, Shandong Province, China and Chief Scientist of Lishui Municipal Central Hospital, Zhejiang Province, China. Prof. Lau's research interest is immunotherapy in liver diseases.

Throughout his 3 decades of research, he has published over >300 original articles (including NEJM, Lancet, J Hepatol, Hepatology and Hepatology International) with a citation of 45,000+ and a H-index of 96. Notably, Dr Lau is the lead author for the phase 3 pegylated interferon for CHB in 2005 and HIMALAYA study for HCC in 2022. Prof. Lau has received many awards and honors, including Ten Most Outstanding Young Persons 2002 (HKSAR), HKU Medical Faculty Outstanding Research Output Award, National Science and Technology Progress Award (State Science and Technology Prizes) - Technological advancement in Chronic hepatitis B infection management, Hong Kong SAR Chief Executive's Commendation for government service, and APASL Okuda-Omata Distinguished Award.

Currently, he is the senior member of steering committee of APASL, chairman of APASL Viral Elimination Task Force, and Co-Chairman of APASL Oncology Guideline, Program Director of APASL Hepatology Webinar, Faculty Member of APASL School of Hepatology, Convenor of "Highlight of Hepatology International" Webinar, and executive governance board member of The Asian-Pacific Digestive Disease Federation (APDWF).



Chung-mau Lo

**Secretary for Health,
HKSAR**

Professor Chung-mau Lo was appointed Secretary for Health on 1 July 2022. Before joining the Government, he was Hospital Chief Executive at The University of Hong Kong-Shenzhen Hospital, Chair of Hepatobiliary & Pancreatic Surgery at The University of Hong Kong and Director of Liver Transplantation Centre at Queen Mary Hospital.

Professor Lo has devoted himself to clinical work, teaching and scientific research in the field of hepatobiliary surgery for more than three decades. He is internationally renowned for his expertise in hepatobiliary surgery and liver transplantation. He has published over 600 original articles in refereed international journals and his H-index is 94. His pioneering work in adult right lobe living donor liver transplantation has revolutionised the practice of liver transplant world-wide and has put Hong Kong on the world map of liver transplant. He and his team were awarded China's top national honour of First-class State Scientific and Technological Progress Award in 2005.

He was the President of the International Liver Transplantation Society and the International Society for Digestive Surgery. He has served in the editorial board of many prestigious journals, including the American Journal of Transplantation, Liver Transplantation, Surgery and the Annals of Surgery. He has been elected as an Honorary Fellow of the American Surgical Association and Royal College of Surgeons in Ireland as well as an Honorary Member of the European Surgical Association.



Han Chong Toh 杜漢忠

Deputy CEO (Strategic Partnerships) , National Cancer Centre Singapore
Professor , Duke NUS Medical School

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. Dr Toh obtained his BSc (Intercalated) from the University of London in 'Infection and Immunity' and his medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. Dr Toh is recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018. He led the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunology) grant and is recipient of the NMRC STaR Award 2022. He is European Society for Medical Oncology (ESMO) Scientific Faculty and on the ESMO Annual Congress 2024 Scientific Committee. He is co-lead of the ESMO Asia 2024 Immunotherapy Educational Session. He is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit. He has published over 155 peer review journal papers.



Yu Wang 王宇

Chairman
Chinese Foundation for Hepatitis Prevention and Control

Wang Yu is the chairman of the China Foundation for Hepatitis Prevention and Control.

He received his M.D. from Beijing Medical University and Ph.D. from Japan Jichi Medical University. He has a professional background in viral molecular biology and immunology and has been engaged in research on hepatitis viruses and related diseases. He has successively served as the Director of the Hepatology Institute of Beijing Medical University, the Vice President of Beijing Medical University, the Deputy Director of the China National Biotechnology Development Center, and the Deputy Director of the Department of Rural and Social Development of the Ministry of Science and Technology. From 2004 to 2017, he served as the director General of the Chinese Center for Disease Control and Prevention. He is currently an executive director of the Chinese Medical Association, a member of the Expert Advisory Committee of the National Immunization Program, and a member of the World Health Organization's Western Pacific Region Polio Eradication Certification Committee.



Cong Yan 閆聰

Director
the Wei Gao Research Institute, Beijing University of
Chinese Medicine

Prof. Cong Yan is from School of Life Sciences, Beijing University of Chinese Medicine. He is a member of the Academic Committee and serves as the director of the Wei Gao Research Institute and the Center for Traditional Chinese Medicine Inheritance and Digitalization. He is an editorial board member and reviewer for journals such as TMR Modern Traditional Chinese Medicine Journal and Practical Clinical Medicine Journal, as well as serving as an executive council member of the World Federation of Chinese Medicine Societies' Committee on Evaluation and Promotion of Appropriate Techniques in Traditional Chinese Medicine. Currently, Prof. Yan's group is focusing on the construction of mathematical and physical system of the traditional Chinese medicine, as well as the development of intelligent traditional Chinese medicine diagnosis and treatment technology. At the same time, Prof. Yan undertakes the school-enterprise combination and achievement transformation work in the field of traditional Chinese medicine, focusing on the fields of smart Chinese medicine diagnosis and treatment equipment, traditional Chinese medicine digital therapy, digital Chinese medicine services, etc., as well as the industrialization of new clinical technologies, new products of traditional Chinese medicine.

BIOHK2024

香港國際生物科技論壇暨展覽

SPEAKER

DAY TWO

Thursday September 12

*Surname in Alphabetical Order



Renu Balyan

**Scientific Liaison
Asia Pacific, Olink Proteomics**

Dr. Renu Balyan is the Scientific Liaison for Asia-Pacific region at Olink Proteomics and leads collaborations and strategic partnerships aimed at advancing the use of proteomics in basic research and pharmaceutical development. She holds a Ph.D. in immunology from the National Institute of Immunology in India and post-doctoral research experience in cellular aging of the immune system from the National University of Singapore. Prior to joining Olink, she led biomarker discovery for several clinical trials in biotech settings and has worked extensively in the field of biomarker discovery and development of precision medicine.



Xiaoying Chu 初曉英

**Director, International Collaboration & Partner Publishing
Science/AAAS**

Xiaoying Chu is the Director of Global Collaboration & Partner Publishing (Asia), Science/AAAS. In her role, Xiaoying leads the Science/AAAS Asia office, being responsible for developing and executing the strategic plans for collaborations with universities and associations, representing the Science family of journals in the region, working on scientific meetings, workshops, prizes, and publishing projects. Xiaoying played a key role in the establishment of AAAS's Science Partner Journal (SPJ) program in 2017, and launch of the first partner journal in AAAS's history – Research, in collaboration with CAST (China Association for Science and Technology) in 2018. Sixteen SPJ titles have been published by the AAAS by July 2024.



Boris Djordjevic

CEO
199 Biotechnologies

Mr. Boris Djordjevic is the Chief Executive Officer of 199 Biotechnologies, a startup founded in 2023 focused on translating epigenetic reprogramming and gene therapies research into clinical products. Born in Belgium, Boris pivoted from medicine to entrepreneurship after being inspired by the SENS conference. Following a decade in China's biotechnology sector, he established two longevity clinics in London. At 199 Biotechnologies, Boris leads efforts to develop a broad therapeutic pipeline aimed at extending healthspan and lifespan. His work emphasizes epigenetic reprogramming's potential to address the root causes of aging and age-related diseases, potentially transforming patient care and outcomes. Boris is married with two children.



Xin Du 杜新

CEO
Evergreen Therapeutics, Inc

Dr. Xin Du is a regulatory professional with unique combination of FDA and industry regulatory experience as well as international regulation knowledge and experience. He obtained his Ph.D degree from the University of Florida and completed his post-doctoral training at the National Institute of Health (NIH). He worked for US FDA, and pharmaceutical companies of Aventis-Pastuer, Wyeth, Novartis, BMS, NPS, Actinium, Advaxis and Adlai Nortye. Currently, he is the CEO of Evergreen Therapeutics Inc and serves as Director of SAPA Board and Secretary General of FDA Expert Association.



Jianbing Fan 範建兵

Professor, School of Basic Medical Science, Southern Medical University
Founder and CEO, AnchorDx

Jian-Bing Fan, Founder and CEO, AnchorDx - a company that is focusing on the development of NGS-based clinical diagnosis products - has over 30 years of experience in human genome research and microarray/next-gen sequencing technology development. As a Senior Director of Scientific Research, Dr. Fan played important roles in developing the BeadArray technology and a series of genomics products at Illumina for high throughput genotyping, gene expression and methylation analysis. Prior to joining Illumina, Dr. Fan was the Manager of Polymorphism Research at Affymetrix, where he spearheaded the development of high-density oligonucleotide array technology and its application in large-scale SNP identification and genotyping. Dr. Fan received his PhD in Genetics from Columbia University. He has authored 207 original articles and book chapters, published one book, been granted 71 US/world patents, and served/serving on the editorial board of scientific journals Genome Research and Translational Cancer Research, and is currently an executive editor of Genomics, and Editor-in-Chief, Genomics Data, published by Elsevier.



Peter Fedichev

CEO
Gero.ai

Peter Fedichev is an entrepreneur and scientist with over 20 years of experience in academic research and the biotech industry. He co-founded Gero, a leading longevity startup. Peter's scientific background is rooted in theoretical condensed matter physics and the physics of complex systems. Over time, he has applied methods from these fields to aging biology, biophysics, and bioinformatics. He is recognized as a leading scientist in developing analytical models of aging in humans and animals, distinguishing between reversible/dynamic and irreversible/entropic aspects of aging, and exploring the limits of life-extension and age-reversal.

He earned his M.S. in theoretical physics from the Moscow Institute of Physics and Technology while working at the Kurchatov Institute, one of Russia's premier scientific agencies. In 1994, he moved to the University of Amsterdam and FOM AMOLF in the Netherlands, where he earned his Ph.D. (cum laude), co-authored over 100 publications in peer-reviewed journals, including high-impact journals like Science and Nature Communications. He has also co-authored multiple patents.



Richard Gibbs

Founding Director, Baylor College of Medicine Human Genome Sequencing Center

Richard Gibbs came to Baylor College of Medicine in 1986 where he performed key work on the molecular characterization of human genetic disease and provided an early leadership role for the Human Genome Project (HGP). In 1997 he founded the Human Genome Sequencing Center (HGSC), one of five main groups to complete the HGP. He led many genome projects for model species and contributed to other human genomics programs including MGC, HapMap, 1KG and TCGA. In 2006, the group pioneered Personalized Genomics, with the first diploid whole genome sequence and then developed exome capture technologies for genetic diagnoses. The group has made innumerable Mendelian disease gene discoveries and is focused on accelerating clinical translation of genomics in adult care, via cardiovascular disease risk testing and analysis of large participant cohorts.



Alireza Haghighi

Founding Director, Harvard International Center for Genetic Disease

Professor of Medicine, Harvard Medical School

Alireza Haghighi, MD, DPhil, FACMG, is the Founding Director of the International Center for Genetic Diseases (iCGD), dedicated to advancing genomic and precision medicine globally through partnerships with governments, academia, and industry. Dr. Haghighi is internationally recognized for his leadership in international projects that aim to advance genomic and precision medicine across the world. Dr. Haghighi regularly consults for and advises government leaders, as well as academic and industrial organizations.

He is also the Director of GENetics NETwork in the Middle East and Africa (GENE-ME), a large clinical research network for genetic studies in those regions that aims to: (1) identify novel disease-causing mutations and genotype-phenotype correlations, and (2) advance genomic and precision medicine in the Middle East and Africa through capacity building.

Dr. Haghighi has led many international projects for advancing medical science in different countries to improve the health and well-being of people. He is the Founding President of Advancement Initiative for Medicine and Science (AIMS), a global foundation that brings together academics and physicians and is dedicated to advancing medical science and healthcare around the world.

Among the many prestigious awards and honors, he has received for his scientific and international contributions are the International Genetic Disorders Prevention Award (for outstanding contributions to and scientific excellence in genetic research) and the Global Health Pioneer Award (for his pivotal role in enhancing the quality of life through innovative strategies and capacity-building initiatives).

Dr. Haghighi is an American board-certified geneticist. He completed his graduate and clinical training at University of Oxford, and Harvard Medical School.



Ruyi He 何如意

Chief Scientist

SDIC FUND MANAGEMENT CO

Dr. He joined NMPA in July 2016 as the chief scientist, after having worked at the US Food and Drug Administration (FDA) for more than 17 years. Dr. He received his medical degree from China Medical University. He completed his intern and residency training in Internal Medicine at Howard University Hospital in Washington, DC. Dr. He is a licensed, board-certified physician in Internal Medicine in the USA.



YiZhou Jiang 江一舟

Vice President

Fudan University Shanghai Cancer Center

Dr. Yi-Zhou Jiang is committed to the molecular subtyping and precision treatment of triple-negative breast cancer (TNBC). He has classified TNBCs into four molecular subtypes (the FUSCCTNBC subtyping system) to guide individualized treatment. He has established a "bench-to-bedside" research system that successfully translates basic research into novel clinical treatments and increases the objective response rate in patients with refractory metastatic TNBC from 10% to 29.8%. He has been funded by the National Natural Science Foundation Distinguished Youth Fund Project, the National Natural Science Foundation Outstanding Youth Fund Project, and the Project of the National Key R&D Program of China. In recent years, he has published 29 articles in renowned journals such as Cancer Cell, Science Translational Medicine, Cell Research, Nature Cancer, Nature Genetics, Lancet Oncology, Cell Metabolism, and Nature Chemistry as the corresponding author. His publications were cited a total of 6301 times. He has been honored with the First Prize of Shanghai Science and Technology Award, National Youth Post Expert, DAMO Academy Young Fellow, Shanghai Science and Technology Youth Elite Award, and the First Prize of the Shanghai Health System "Silver Snake Award".



Bin Jin 靳斌

Vice-President of the hospital

The Second Hospital of Shandong University

Jin Bin, Chief Physician, Professor
Shandong Province Engineering Research Center for Multidisciplinary Research on Hepatobiliary and Pancreatic Malignant Tumors, Director
Chinese Journal of Advances in Modern General Surgery, Deputy Editor-in-Chief
Hepatobiliary Surgery Research Center of Shandong University, Director



Kunlin Jin 金坤林

Professor

**Department of Pharmacology and Neuroscience
University of North Texas Health Science Center**

Kunlin Jin is a Tenured Professor at the University of North Texas Health Science Center in the United States. He received his M.D. and Ph.D. degrees in China, where he also served as an Assistant Professor in the Institute of Hematology at Beijing University. In 1992, he came to the US and worked as a postdoctoral fellow at the University of California, San Francisco. He then moved to the University of Pittsburgh from 1995 to 1996, where he was promoted to Instructor. In 1999, he accepted an offer to join the Buck Institute as an Assistant Scientist and has since been promoted to Professor.

Dr. Jin has been a leader in several areas of investigation related to stroke, particularly focusing on the roles of adult neurogenesis and endogenous neuroprotective proteins in regulating the brain's response to ischemic injury. More recently, his research has explored the effects of aging on these processes. He was the first to discover that brain injuries, including those caused by stroke and neurodegenerative diseases like Alzheimer's disease, can stimulate stem cells to generate new neurons in rodents and humans. For many years, there has been hope that stem cells may provide a new avenue for the treatment of brain diseases. Dr. Jin's discoveries have turned this hope into a reality.



Daniel Johnson

Professor and Vice Chair for Research

**Department of Otolaryngology – Head and Neck Surgery
University of California San Francisco**

Dr. Daniel E. Johnson is a biochemist and leading researcher in the fields of otolaryngology and cancer biology. Dr. Johnson's research is focused on identifying cellular signaling pathways that contribute to cancer and the acquisition of drug resistance. Using the knowledge he derives from his studies, he develops new therapeutic agents and strategies for the prevention and treatment of cancer. Dr. Johnson places important emphasis on translating findings from his laboratory to the clinic and has facilitated the development of clinical trials in both leukemia and head and neck cancer. While a professor at the University of Pittsburgh (1993-2016), Dr. Johnson served as Scientific Director of the Acute Leukemia Working Group. Since 2016, he has been on faculty at the University of California San Francisco, where he serves as Vice Chair for Research in the Department of Otolaryngology – Head and Neck Surgery. He has published over 140 papers, served as Section Editor for the journal *Leukemia*, is Editor of two books, and has maintained continuous NIH funding for his research since 1995. He has served on multiple NIH and American Cancer Society Study Sections and on the Board of Scientific Counselors for the National Institute on Deafness and Communication Disorders.



Akihiko Kondo

**President, Founder, and Representative Director
Bacchus Bio Innovation Co., Ltd.**

Akihiko Kondo received his Ph.D. from Kyoto University in Chemical Engineering (1988). He has started his faculty career in 1988 in Department of Applied Chemistry at Kyushu Institute of Technology. He was appointed as full professor of Kobe University in Department of Chemical Science and Engineering in 2003 and also appointed as a team leader at RIKEN Center for Sustainable Resource Sciences (CSRS) in 2012. He was appointed a dean of Graduate School of Science, Technology and Innovation at Kobe University in 2016. He became deputy director of RIKEN CSRS in 2020 and Vice President of Kobe University in 2021.

A. Kondo has developed various platform technologies such as cell surface display systems, metabolic pathway design tools, metabolic analysis technologies, genome editing and long chain DNA synthesis technologies. He also has applied these platform technologies for construction of various microbial cell factories for production of biofuels and various chemicals from biomass, and cyanobacteria and microalgae for production of oil and chemicals from CO₂. He is the scientific founder of several companies including BioPalette (genome editing), Synprogen (genome synthesis), AlgaeNexus (microalgae) and Bacchus Bio innovation (Biofundry), he became CEO of Bacchus Bio innovation this year.



Raju Kucherlapati

**Paul C. Cabot Professor of Genetics and Professor of
Medicine
Harvard Medical School, Boston, MA, USA**

Dr. Kucherlapati is a Professor of Genetics and Medicine at Harvard Medical School. He obtained his PhD degree from the University of Illinois, trained at Yale University and was a faculty member at Princeton University, University of Illinois and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine. He joined the Harvard faculty in 2001 and was the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. His research interests are in the areas of human genetics, gene-modification, genomics and cancer genetics and genomics. He is a fellow of the American Association for the Advancement of Science and is a member of the National Academy of Medicine of the US. He was a member of a Presidential Committee during the administration of President Obama. He also founded several successful biotechnology companies.



Sampson Lau 劉彥榮

President
PrimaNova Technologies Limited

Sampson currently serves as President of PrimaNova Technologies Limited, a medical device company developing next generation neurosurgical medical devices, in neuro monitoring, CSF management, and keyhole minimally invasive surgeries.

Previously, Sampson was Director of Investment and Business Development at China Medical System Holdings ("CMS", HKEX: 0867), responsible for global BD transactions, biotech and medtech equity investments, and managing the company's portfolio of life sciences VC fund investments. Prior to CMS, Sampson was Vice President at Delos Capital, a Hong Kong based life sciences VC fund specializing in early-stage biotech and medtech investment in the US and China, with responsibilities ranging from sourcing and execution of investment opportunities, to post-investment management and value creation.

In the early years of Sampson's career, he had extensive transaction experience in global M&A and buyout investment, working in investment banking and private equity.

Sampson graduated from the University of Chicago with a Bachelor of Arts in Economics.



Leslie Leinwand

Distinguished Professor, MCD-Biology
Chief Scientific Officer, BioFrontiers Institute University
of Colorado Boulder

Dr. Leinwand is a Distinguished Professor of Molecular, Cellular, and Developmental Biology (MCDB) and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. Her research laboratory focuses on the genetics and molecular physiology of inherited diseases of the heart and particularly how biological sex affects the heart in health and disease. She co-founded Myogen, Inc. (acquired by Gilead Pharmaceuticals), Hiberna, Inc., and MyoKardia, Inc. (acquired by Bristol Myers Squibb), which develop therapeutics for inherited cardiomyopathies. She is a Fellow of the AAAS, a former MERIT Awardee of the NIH, an Established Investigator of the American Heart Association, and an elected member of the American Academy of Arts and Sciences and the National Academy for Inventors.



Min Li 李敏

Lynn Cross Research Professor
The University of Oklahoma Health Sciences Center

Dr. Min Li is George Lynn Cross Research Professor, and Virginia Kerley Cade Endowed Chair in Cancer Treatment at The University of Oklahoma Health Sciences Center (OUHSC). He is the Assistant Dean for International Research Collaboration at College of Medicine, and Associate Director for Global Oncology at the NCI designated Stephenson Cancer Center. He is a leading expert on pancreatic cancer, and has published more than 200 papers on high impact journals with multiple NIH grants. He is the Editor-in-Chief of Cancer Letters, and holds many important administrative positions at OUHSC, and multiple committees internationally. Dr. Li is the President of American Pancreatic Association (APA), the largest professional organization in pancreatology in US. He received many awards such as the Outstanding Achievement Award of International Association of Pancreatology (IAP), and the Provost Research Award at OUHSC.



Ming Li 李明

CEO
ZSHK Laboratories Limited

Dr. Ming LI, CEO of ZSHK Laboratories Limited, has been engaged in preclinical evaluation of drugs for twenty years. He was presided over the construction of China's first GLP laboratory that complies with EU multi-country certification. Dr. Ming LI received his Ph.D. in Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. At the same time, he obtained a double master's degree in EMBA from Antai College of Economics and Management of Shanghai Jiao Tong University and KEDGE Business School in France.



Ning Li 李寧

Chairman
Topalliance Biosciences

Ning Li is currently Chairman of Topalliance Biosciences. Before that he served as the Chief Executive Officer of Junshi Biosciences for 6 years. Prior to joining Junshi Biosciences, Ning had been appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He worked at US Food and Drug Administration for more than 12 years as a regulatory reviewer and held positions with increasing responsibilities. Prior to his US FDA career, he worked at the University of Iowa, Dept of Internal Medicine and Westat /NIH DATRI Clinical trial coordinator center. He is an adjunct faculty member at Johns Hopkins University and Peking University. Dr. Li obtained his medical degree from Shanghai First Medical College (Fudan University) and a doctorate degree from University of Iowa. He has published more than 30 scientific papers in the area of clinical trial methodology.



Jinzhong Lin 林金鐘

Professor
School of Life Sciences, Fudan University

Dr. Jinzhong Lin is a Professor at Fudan University, where he leads the Fudan Center for mRNA Translational Research and the Shanghai Zhangjiang mRNA Innovation and Translation Center. He earned his Ph.D. in biophysics from the Chinese Academy of Sciences and completed postdoctoral training at Yale University under Nobel laureate Thomas Steitz. Since returning to China in 2017, Dr. Lin has made significant contributions to the field of mRNA translation regulation, establishing the country's first mRNA drug development center at Fudan University. His research has driven key advancements in mRNA capping, modification, and delivery technologies. Dr. Lin played a pivotal role in developing China's first mRNA COVID-19 vaccine, which successfully completed Phase III clinical trials and received emergency use authorization. This milestone marks the first university-led mRNA vaccine in China. Dr. Lin has authored over 60 high-impact research articles, contributing significantly to the advancement of mRNA science.



ZhiXiu Lin 林志秀

Professor and Director
School of Chinese Medicine, CUHK

Director, School of Chinese Medicine, and Director, Hong Kong Institute of Integrative Medicine, Faculty of Medicine, The Chinese University of Hong Kong; Registered Chinese Medicine Practitioner (HK)

Professor Zhi-xiu Lin graduated from Guangzhou University of Chinese Medicine in 1987 with a BSc in Chinese Medicine. After graduation, he worked as a Chinese medicine doctor at the Affiliated Hospital of Guangdong Provincial Research Institute of Chinese Medicine. In 1991 he moved to England to study English language, followed by a PhD degree study at the Department of Pharmacy, King College, University of London. He obtained his PhD degree in Pharmacognosy in 1999. From 1998 to 2002, he was employed as a Senior Lecturer and Programme Leader on the Chinese Medicine Programme, Middlesex University in London where he was involved with basic and clinical teachings of Chinese medicine. Professor Lin joined The Chinese University of Hong Kong (CUHK) in 2003, and is now Professor and Director of the School of Chinese Medicine, Faculty of Medicine. He is also the Director of the Hong Kong Institute of Integrative Medicine, CUHK. His main research interests include: (1). Pharmacological studies on Chinese medicines for psoriasis, eczema, pancreatic cancer, prostate cancer and neuroprotection; and (2). Clinical trials on effectiveness and safety of Chinese medicines and acupuncture for some common diseases, such as atopic dermatitis, psoriasis, macular edema, dry eye disease, allergic rhinitis, overactive bladder and long-COVID. Over the years, he has published more than 260 research articles on Chinese medicine, among which about 240 articles are in the SCI journals, with a H-index of 52 (Google scholar).



Anessa Liu

Founder & Managing Director
Medilink Biotech (HK) Ltd.

Dr. Liu Huanming holds a PhD in medicine and an EMBA degree from the Chinese University of Hong Kong. The company he founded, Medilink Biotech (HK) Co., Ltd., won the 2023 Forbes China ESG Innovation Enterprise.

The UBetter series of products developed by Dr. Liu and his team for many years use the most advanced science and technology to enhance human immunity and improve the quality of life. The highlight is the liposome technology that won the Nobel Prize in anti-aging. The perfect combination of NMN and Gand products greatly improves the absorption rate of nutritional products. Experiments have proven that the cell absorption rate reaches more than 90%, achieving many breakthroughs - making health products achieve medical effects.



Da Liu 柳達

Managing Director
CR CP Life Science Fund

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Biospectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.



Maggie Lo 盧靜敏

Vice President (Life and Health Technology)
Life and Health Technology, Office for Attracting
Strategic Enterprises (OASES)

Dr. Maggie Lo is the Vice President of Life and Health Technology, Office for Attracting Strategic Enterprises (OASES). At OASES, Maggie focuses on attracting and supporting mainland and international life sciences and health technology companies to set up and expand in Hong Kong. Maggie obtained PhD in Psychiatry at the University of Liverpool, with extensive clinical research experience in UK, Canada and HK.



Yuk Lam Lo 盧毓琳

President
HK Bio-Med Innotech Association

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service.

Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology. He is also the Honorary Founding Chairman of Hong Kong Biotechnology Organization.

In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China.

Professor Lo was heavily involved in several committees of the HKSAR Government. He had been served as the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR.

In Mainland China, Professor Lo was a member of Chinese People's Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades.



Patrick Lu 陸陽

CEO
Sirnaomics

Patrick Y. Lu, Ph.D, Founder, President and CEO of Sirnaomics, Inc., Dr. Lu started his biopharmaceutical industry career in 1993 as a lab head in Novartis and was the co-founder and Executive VP of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and is an inventor for more than 50 issued and pending patents. He has been an invited speaker in many international conferences throughout the world and received a number of Government grants. Under his leadership, Sirnaomics has raised more than US\$170 million dollars and has developed a series of "first-in-class" siRNA therapeutic candidates at different phases of clinical studies, for treatment of cancer and fibrosis diseases, in both USA and China.



Wen Luo 罗文

CEO
Denovo Biopharma

Dr. Luo has over 20 years of experience in the biomedical industry. Before founding Denovo Biopharma, Dr. Luo worked at Ligand Pharmaceuticals, where he led and participated in the research and development of multiple second-generation nuclear hormone receptor modulating drugs, worked on the molecular mechanism of hormone receptors, tissue and organ selectivity, and establishment of drug screening trials, and was responsible for formulating and implementing biomarker strategies for multiple drugs at different stages of development. While at Corvas, he was responsible for the development of new protease drug targets. At Incyte Genomics, Dr. Luo was involved in the management of at the time the world's largest proteome database LifeProt and worked on the research and development of new drug target genes and their splicing variants. He was engaged in the identification and development of new drug targets in the fields of cancer, immune diseases, and angiogenesis at Sugen. He served as a postdoctoral fellow at Howard Hughes Medical Institute of University of California, San Francisco. Dr. Luo holds a PhD in molecular biology and biochemistry from Indiana University.



Yu Xuan LYU (LU) 呂宇軒

Research Assistant Professor

Institute of Advanced Biotechnology, Southern University of Science and Technology (SUSTech)

Dr Yu-Xuan Lyu (Lu), a Research Assistant Professor at Institute of Advanced Biotechnology, Southern University of Science and Technology (SUSTech), China, and a guest researcher at the Max Planck Institute for the Biology of Ageing in Germany, EMBO/Marie Curie Scholar and European Crucible for Future Research Leader. Dr Lyu's work is focused on biological mechanisms of ageing, sex differences, and pharmacological interventions for healthy ageing.

Dr Lyu has made exceptional contributions to ageing research and drug discovery, particularly in elucidating the critical role of the mTOR-autophagy metabolic pathway in intestinal homeostasis and ageing, and understanding sex differences in responses to interventions such as rapamycin and spermidine. His discovery that brief rapamycin treatment in early life can trigger long-lasting geroprotection was highlighted as "Quick course of anti-ageing drug shows success" in Nature. Moreover, his work, titled "Trilogy of Ageing Mechanisms and Interventions," was recognized in the Max Planck Society's Research Highlight of the Year 2022.

Dr Lyu is the champion of the Longhack International Anti-Ageing Biotech Competition. He also initiated and co-founded a start-up project FlyvoTech, based on his research findings, has received two rounds of funding totalling millions to date.



JunYi Ma 馬駿一

Director of Public Affairs
ZSHK

Mr. Ma currently serves as the Director of Public Affairs at ZSHK, the Liaison Representative in HKSAR of PhIRDA and a member of the Medicinal Policy Specialty Committee of PhIRDA.

He is responsible for government and public affairs at ZSHK. He is dedicated to policy research in China's drug review and approval system, healthcare insurance system and pharmaceutical innovation industry. He has been involved in various research projects commissioned by Chinese government departments and industry organizations.



Donglei Mao 毛冬蕾

Editor-in-Chief
PharmaDJ(研发客)

Chief Editor of 研发客/Reporter of 医策研發達人

Educational background:

Mao Donglei graduated from South China Normal University in 2000, majored in the Economics.

Working experiences:

2000-2007: In 2000, Mao Donglei joined the Southern Medical Economics Institute (南方医药经济研究所) which is affiliated with the former CFDA as an editor of the editorial board of the Medicine Economics News (医药经济报);

2007-2010: Served as the editor of the Chinese Journal of Prescription Drugs (中国处方药杂志) editorial board; in 2007, Donglei participated in the survey of "the challenges of the opportunities of the clinical trials in China" initiated by RDPAC (China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee).

2010-2014: Donglei was an editor of the editorial board of the Medicine Economics News (医药经济报).

2010-2014: Donglei was a member of China Advisory Committee of the Drug Information Association (DIA).

In 2015, Mr. Dai Jialing, the Co-founder and Publisher of PharmaDJ and I co-founded a startup company named WesternTide with some other senior pharmaceutical editors in China. We are building up two platforms- PharmaDJ & 研发客- for pharmaceutical R&D community.

研发客 is a Chinese online portal for pharmaceutical R&D executives and researchers. We are trying to establish a communication platform for innovative entrepreneurs and scientist and regulators, where they can find essential intelligence for regulatory updates in China, find the right partners and discuss hot topics with peers. We also provide the deepest and the most insightful analysis on the most important topics for pharmaceutical R&D industry.



Marek Piotrowski

**Longevity Advocate,
Creator 'Beyond Time' movie**

Marek Piotrowski, Longevity Advocate and producer of "Beyond Time" movie - showing a Father-Son Quest for Longevity Around the World.

Former CEO of successful ad agencies working for top global brands, has decided to use all his knowledge and experience to promote the realm of longevity. With a robust background as a CMO in robotics, he's now dedicated to inspiring millions around the World with the top breakthroughs in the field of longevity, offering practical advice and protocols to empower individuals to embrace longer, healthier, and more active lives.

Marek's mission is to bridge the gap between cutting-edge research and the public. He wants to help people understand longevity, fall in love with it and support it - so that the research can draw more investment and attention from scientists and administration - to fuel its growth. Alongside his son Alex (18yo), Marek initiated the "Beyond Time" project, embarking on a year-long global journey engaging with industry luminaries: scientists, clinicians but also "everyday biohackers" like nutritionists, yoga masters, sleep specialists or even blue zone inhabitants and spiritual leaders.

The movie is planned to be published on top media platforms in the first half of 2025.



Wanviput Sanphasitvong

**Business Development Director , Vitallife
Founding Member , ALPA (Asia Longevity Professionals
Association)**

Dr. Wanviput Sanphasitvong graduated from faculty of medicine, Chulalongkorn university with honor in 2006. She has passion in healthy aging and anti-aging field since her graduation. She got her board certification in Preventive medicine, public health and lifestyle medicine. Currently she works at Vitallife scientific wellness center as Business Development Director and Bumrungrad international hospital. Apart from her practice, she serves as a member of KALM Executive committee under department of health, MOPH. (Knowledge management and Academic development center for Lifestyle Medicine) and she is one of the founding members of ALPA (Asia Longevity Professionals Association) It is her Passion and Mission to connect and grow healthy longevity medicine ecosystem in Asia.



Eric Shao 邵文斌

VP, GM

IQVIA Commercial Solutions, Greater China

Eric Shao, VP GM of IQVIA GC Commercial Sols, oversees the development, transformation, and integration of services for healthcare clients in China and the APAC region. With over 20 years of management consulting experience, he specializes in business growth, organizational transformation, strategic product development, R&D planning, BD&L, pricing, reimbursement strategy, and commercial and distribution optimization. Shao also boasts expertise in the MedTech industry, having collaborated with leading companies on strategic planning, policy initiatives, and innovations. He holds an MBA from Fudan University and Norwegian Business School, as well as an EMBA from Washington University in St. Louis.



Vincenzo Sorrentino

Assistant Professor

**Healthy Longevity Translational Research Program, and
Dept of Biochemistry, NUS Singapore**

Vincenzo Sorrentino is an Italian-born scientist in the fields of aging, mitochondrial biology and neuromuscular degeneration. After his PhD with honors obtained at the University of Amsterdam in Medical Biochemistry, he carried his postdoctoral research in Prof. Johan Auwerx's lab at the EPFL in Switzerland. From 2019 till 2022, he took a role as Group Leader at the Nestlé Institute of Health Sciences in Switzerland, to lead research focused on integrating basic discoveries on natural bioactives that modulate NAD⁺, mitochondria and protein homeostasis with their possible translation into clinical applications. Currently, he is Assistant Professor at the NUS with the Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, and is an Adjunct Assistant Professor at the University of Amsterdam. His work on mitochondria and NAD⁺ metabolism in Alzheimer's disease and muscle aging has resulted in his discoveries appearing in *Nature* (2017), *Cell Reports* (2021) and just recently with the discovery of trigonelline as a novel NAD⁺ precursor, in *Nature Metabolism* (2024).



Polakit Teekakirikul

Professor

**Bumrungrad Genomic Medicine & VitalLife Scientific
Wellness Center**

Prof. Polakit Teekakirikul is the Chief Scientific Officer of Bumrungrad International Hospital and practices at the Bumrungrad Genomic Medicine Center, where he focuses on advancing genomics and precision medicine. He earned his MD from Chulalongkorn University. After completing his internship and residency in internal medicine and a fellowship in clinical molecular genetics at Harvard-affiliated Hospitals and Harvard Medical School, he specialized in cardiovascular medicine at the University of Pittsburgh Medical Center (UPMC), focusing on genetic cardiomyopathy and cardiac MRI. Before his current role, Dr. Polakit was an Assistant Professor in the Division of Cardiology at Prince of Wales Hospital and Hong Kong Children's Hospital, under the Chinese University of Hong Kong.



Nicholas Teo

General Manager

GSK Hong Kong & Macau.

Nicholas Teo is the General Manager of GSK Hong Kong & Macau. With almost 20 years of pharmaceutical experience and a proven track record in multiple countries, he has been instrumental in driving the company's growth and the access of innovative medicines to patients in various countries.

Nicholas started out as a medical sales representative in Singapore and has progressed to various key leadership positions throughout his career. This includes Business Unit Director roles in Singapore & Taiwan, where he led the local business to growth in Respiratory, Oncology and established portfolios and also above country roles such as Global Marketing Director & Global Market Access Director, based in the London HQ where he was responsible for brand and pricing strategies for various assets.

He is known for his strategic vision, strong leadership skills, and dedication to fostering a collaborative and innovative work environment. His notable achievements include the successful launch of the global respiratory brand "Trelegy" and also asthma disease awareness campaign "Act Don't React".



***Jiguang Wang* 王吉光**

**Padma Harilela Associate Professor of Life Science
Hong Kong University of Science and Technology**

Prof. WANG received his Ph.D. in Applied Mathematics from Academy of Mathematics and Systems Science, Chinese Academy of Sciences (CAS), and won the Special Prize of President Scholarship and Excellent PhD thesis Award of CAS. Between 2011 and 2015, he was a Postdoctoral Research Scientist at Columbia University. From 2015, he was named as the Precision Medicine Fellow and promoted to an Associate Research Scientist. He established the Wang Genomics Laboratory @HKUST in 2016, focusing on the application of data science in biology and medicine. He won the Excellent Young Scientist Award of NSFC (2019), School of Engineering Young Investigator Research Award (2019), School of Science Research Award (2021), and the Zhong Nanshan Youth Science and Technology Innovation Award (2021).



***Shouyan Wang* 王守岩**

**Deputy Dean, Institute of Science and Technology for Brain-
inspired Intelligence,
Director, Neuromodulation and Brain-machine-interface
Centre, Fudan University**

Professor Shouyan Wang is the Vice Dean Institute of Science and Technology for Brain-Inspired Intelligence, Director of Neuromodulation and Brain-machine-interface Centre, Fudan University. He is the Chairman of Neuromodulation Branch of Chinese Neuroscience Society. Vice Board Chairman of Brain Computer Interface Alliance of China. He had conducted research on neural information decoding and brain stimulation at University of Oxford (2002-2007), University of Southampton (2007-2012) and Chinese Academic of Sciences (2012-2017) before he joined Fudan University. He has developed research platform for neuromodulation, which include research facilities for invasive neuromodulation, non-invasive neuromodulation, advanced technology development of intelligent neuromodulation and neuroimaging as well. His research interests are intelligent neuromodulation, digital healthcare and translational research into clinical applications.



Xin Wang 王鑫

Associate Professor

Department of Surgery, The Chinese University of Hong Kong

Prof. Xin Wang obtained his PhD in 2014 from University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute. From 2013 to 2015, Prof. Wang did his postdoctoral research at the Department of Biomedical Informatics, Harvard Medical School. He is currently an Associate Professor at the Department of Surgery, The Chinese University of Hong Kong, directing the Division of Biomedical Informatics and MPhil-PhD Programme in Translational Genomics. He is currently also leading the Laboratory of Translational Bioinformatics at LI Ka Shing Institute of Health Sciences as a Principal Investigator.

Prof. Wang's group has been focusing on mechanistic and translational research in major human cancers by developing novel methodologies integrating bioinformatics, systems biology, machine learning and artificial intelligence. Prof. Wang published > 90 peer-reviewed papers in leading journals, and his work is currently supported by significant research funds from Hong Kong, Shenzhen City and Guangdong Province in China.



Brian Wong 黃裕舜

**Assistant Professor in Philosophy, University of Hong Kong;
Fellow, Oxford Global Society and Centre on Contemporary
China and the World, University of Hong Kong**

Dr. Brian Wong is an Assistant Professor in Philosophy at the University of Hong Kong. His research examines intersection of geopolitics, political and moral philosophy, and technology, with particular interests in the ethics and dynamics of authoritarian regimes and their foreign policies, responding to historical and colonial injustices, and the impact of automation on labour and human societies. Brian is a Fellow at the newly established Centre on Contemporary China and the World, at the University of Hong Kong. As the Chief Strategy Officer of the HK-ASEAN Foundation, he advises multinational corporations, family offices, and leading think-tanks on geopolitical affairs and macro risks throughout Asia. Having co-founded and served as the inaugural Editor-in-Chief at the Oxford Political Review, a publication aspiring to bridge the theory-practice gap, Brian serves as a columnist at the Hong Kong Economic Journal.



Vincent Wong 黃錦偉

Professor, Executive Director

Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology

Prof. Vincent Kam Wai Wong serves as a full professor at the State Key Laboratory of Quality Research in Chinese Medicine at the Macau University of Science and Technology. Prof. Wong is engaged in critical research on anti-inflammation and anti-cancer therapies. His expertise lies in cancer molecular biology, chemical biology, and the relationship between structure and activity. Recently, he has been focusing on the role of p53 and P-glycoprotein in the drug-resistant phenotype of rheumatoid arthritis. He has made significant contributions to the scientific community with over 180 peer-reviewed publications in Science Citation Index journals. Further, he holds more than 30 patents from the US, Australia, and China. Since 2013, Prof. Wong has been awarded numerous accolades for his research contributions. These include the Bank of China Excellent Research Award, the First-class High Institute Natural Science Award in China, and both Second and First-class Natural Science Awards in Macao. Additionally, in 2022, Stanford University recognized him as one of the top 2% of scientists worldwide.



Wenrui Xia 夏文睿

Resident Doctor

Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine

Medium-grade professional title, Attending physician, PhD candidate. Graduated with a bachelor's degree from Chengdu University of Traditional Chinese Medicine. Took a master's degree in Integrated Clinical Medicine of Chinese and Western Medicine from Macau University of Science and Technology and published more than ten SCI articles under the supervision of Professor W.L. Wendy Hsiao. Accumulated extensive academic experience and acquired relatively comprehensive experimental skills and techniques. Currently pursuing a doctorate at Chengdu University of Traditional Chinese Medicine, focusing on the clinical research of traditional Chinese medicine in the prevention and treatment of endocrine and metabolic diseases. Mentored by Professor Chunguang Xie, president of the Hospital of Chengdu University of Traditional Chinese Medicine. Have a continuous clinical practice under the guidance of Professor Farong Zhang, national famous TCM doctor, a special allowance expert from the State Council. Specializes in the diagnosis and treatment of diabetes and its complications, thyroid-related diseases (e.g. hyperthyroidism, hypothyroidism, thyroiditis), obesity, pruritus, breast nodules, pulmonary nodules, et.al.



Wendong Xu 徐文東

**Professor, Senior Consultant
Huashan Hospital, Fudan University**

New Cornerstone Researcher, First Xianghui Scholar, Senior consultant, Professor(T2, four-tier system), PhD Supervisor. Winner of National Science Fund for Outstanding Young Scholars, Chief Scientist of the National Innovation Group. Vice president of Huashan Hospital, Fudan University; President of Jing'an District Central Hospital. President of Chinese Society for Surgery of the Hand (CSSH); President of Hand Function Rehabilitation Professional Committee of Chinese Association of Rehabilitation Medicine (CARM).



Hai Yan 閻海

**Professor and research professor
Institute of Molecular and Cellular Biology
Agency for Science Technology and Research Singapore**

Dr. Yan's career began with medical training, followed by a Ph.D. at Columbia University and postdoctoral training at Johns Hopkins under Dr. Vogelstein and Dr. Kinzler. At Duke School of Medicine, he held esteemed positions, including a tenured full professorship of Pathology, the Henry S. Friedman Distinguished Professor, and Co-Director of Neuro-Oncology. His research significantly contributes to understanding cancer's molecular mechanisms, advancing diagnosis and drug development. His most notable discoveries include the identification of IDH1 and IDH2 mutations in gliomas. As co-founder of Genetron Health, he served as its chief scientific officer, providing molecular diagnoses for over cancer patients, culminating in a successful public offering on the NASDAQ. At IMCB A*STAR, Dr. Yan leads a neurooncology program. Dr. Yan has received several prestigious awards, including the 2014 AACR Team Science Award and the 2021 International Prize for Translational Neuroscience from the Max Planck Society in Germany.



Michael Yang

Professor
City University of Hong Kong

Professor Michael Yang Mengsu is currently Senior Vice-President (Innovation and Enterprise), Yeung Kin Man Chair Professor in the Department of Biomedical Sciences, and Director of both the Tung Biomedical Sciences Centre and Shenzhen Biotechnology and Health Centre of City University of Hong Kong (CityU). He is responsible for "HK Tech 300", the largest university-based entrepreneurship programme in Asia. He received a Bachelor's Degree of Science from Xiamen University, China, a Doctor of Philosophy (PhD) from the University of Toronto, Canada, and postdoctoral training from The Scripps Research Institute, the United States. Professor Yang serves on the Hong Kong's Research Grants Council, the Health and Medical Research Fund, and the Innovation and Technology Fund. His research interests focus on studying cancer biology and developing biochips and nanotechnology for diagnostics and therapeutic applications.



Zifeng Yang 楊子峰

The First Affiliated Hospital of Guangzhou Medical University

楊子峰現任廣州醫科大學附屬第一醫院廣州呼吸健康研究院副院長、研究員；廣州醫科大學呼吸疾病全國重點實驗室副主任；廣州國家實驗室特聘研究員PI，診斷技術創新研究與轉化中心主任；澳門科技大學特聘教授；澳門大學轉化創新研究院指導委員。

主持科技部重點研發計畫/國自然面上和專項/澳門科學發展基金科研專案逾20項。全球2%科學家（終生學術影響力專家，發表新英格蘭，科學及自然子刊等SCI論文100餘篇；單篇論高被引853，授權專利20餘項。



Lin Yin 殷琳

Resident Doctor

**TCM preventive medical Center, Affiliated hospital of
Chengdu University of Traditional Chinese Medicine**

Lin Yin is a PhD candidate in acupuncture at Chengdu University of Traditional Chinese Medicine, a resident doctor in Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, holds an intermediate professional title in acupuncture; she engages in clinical work and basic research in the prevention and treatment of sleep disorders, emotional disorders and infertility with acupuncture. She has published 5 SCI articles and several Peking University core papers.



Chang Yu 余昶

**Director of Life Science
GCR, AWS**

With extensive experience in the bioinformatics from both industry and academia, Chang Yu have held positions such as bioinformatics scientist and solution architect. Mr. Yu worked at companies like NVIDIA, Intel, and BGI, and served as an adjunct assistant professor at the CUHK, as well as a senior research assistant at the University of Hong Kong's Computer Science Department. Mr. Yu received a master's degree in Biomedical Engineering from Sichuan University and an MBA from HKUST. Currently, Chang Yu am an adjunct supervisor at Sichuan University and the Chinese University of Hong Kong (Shenzhen). Chang have published 29 papers and hold two invention patents. Mr. Yu received the Shenzhen Technological Invention Award in 2011 and was named a "Highly Cited Researcher" globally by Clarivate Analytics in 2019.



Hongjie Zhang 張宏杰

Associate Dean and Professor
School of Chinese Medicine, Hong Kong Baptist University

Professor Zhang is a faculty member of School of Chinese Medicine, Hong Kong Baptist University. From 1991 to 2002, he held faculty positions at the Kunming Institute of Botany, Chinese Academy of Sciences. Subsequently, from 2003 to 2011, he served as a research faculty at the School of Pharmacy, University of Illinois at Chicago, USA. He has more than 30 years of research experience in the isolation, identification, structure elucidation, analysis, synthesis and biological evaluation of small molecules of natural products, leading to the publication of more than 190 peer-reviewed papers and dozens of granted patents. His current research interest is focused on drug discovery and development from natural resources. Specifically, Professor Zhang is interested in finding natural lead compounds from plants found in the Lingnan region of China, and in developing dietary supplements from traditional herbal medicines against different disease targets and pathogens such as cancer, human immunodeficiency virus (HIV), severe acute respiratory syndrome coronaviruses (SARS-CoV), hepatitis C virus (HCV), flu viruses, Ebola/Marburg viruses, dental bacteria, tuberculosis and cancer chemoprevention. His research group has developed a series of cosmetic products on the market based on the research on skin protection and whitening of Dendrobium plants.



Zongli Zheng 鄭宗立

Associate Professor
Department of Biomedical Sciences, City University of Hong Kong

Dr. Zheng focuses on advancing biotechnology to solve clinical problems. Dr. Zheng invented the AMP technology that has been adopted globally for robust molecular diagnosis in both research and clinical settings to guide targeted therapies for cancer patients. Dr. Zheng's pioneering work in precision genome editing includes the CRISPR off-target analysis method GUIDE-seq that is widely used and supported the first FDA-approved therapy utilizing CRISPR Cas9. Dr. Zheng is dedicated to 'liquid biopsy' and 'DNA surgery' research and clinical applications.



Lihan Zhou 周礪寒

Cofounder and CEO
MiRXES

Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered, RNA centric biotechnology company with the mission to improve and save lives through early, actionable, and accessible cancer early detection tests. Lihan oversees MiRXES operations in Singapore, USA, China, and Japan with a team of 300+ staff.

Prior to founding MiRXES in 2014, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform for microRNA biomarker and therapeutic target discovery. Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored more than 30 peer-reviewed publications and several patent applications.

Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35 (2015). He was also awarded the A*STAR Scientist-Entrepreneur Award in 2017, the NUS Outstanding Young Alumni Award, the EY Entrepreneur of The Year™ Singapore awards in 2021, and 2023 Singapore Business Award Young Business Leader of the Year. Under his leadership, MiRXES was named Singapore's Most Promising Start-up in 2016 and Singapore's Fastest Growing Companies in 2018, 2019 and 2020. MiRXES has successfully raised USD \$180 million venture funding since 2016.

BIOHK2024

香港國際生物科技論壇暨展覽

KEYNOTE SPEAKER

DAY THREE

Friday September 13

*Surname in Alphabetical Order



Piu Chan 陳彪

Director

National Center for Geriatric Disorders Xuanwu Hospital of Capital Medical University

Piu Chan, MD, PhD, Professor of Neurology and Geriatrics, is the Chair of the faculty of Geriatrics and the Director of Clinical and Research Center for Parkinson's Disease of Capital Medical University.

He is also the director of National Clinical Research Center for Geriatric Disorders and Parkinson's Disease Center of Beijing Institutes of Brain Disorders, Vice President of the Chinese Association of Geriatrics, the Society of Geriatrics of the China Medical Association, and the President of Society of Geriatrics of Beijing Medical Association. He has been the Vice President of Chinese National Genome Center (Northern) since 2001 and the Vice Director of the Beijing Engineering Center of Drug Development for Neurological Disorders. He is also the council member of the International Association of Gerontology and Geriatrics (IAGG) and the past Secretary of the IAGG Asia-Oceania Region. He has participated in the development of WHO ICOPE project and its implementation in China.

Dr. Chan has participated in the development of clinical diagnostic criteria for Parkinson's disease for China and MDS with more than 400 SCI articles with a Google H-index of 70. Dr Chan has been the Principal Investigator for more than 10 international and domestic multi-center clinical register trials, served as consultant for NMPA-CDE.



Brian Wong 黃裕舜

**Assistant Professor in Philosophy, University of Hong Kong;
Fellow, Oxford Global Society and Centre on Contemporary
China and the World, University of Hong Kong**

Dr. Brian Wong is an Assistant Professor in Philosophy at the University of Hong Kong. His research examines intersection of geopolitics, political and moral philosophy, and technology, with particular interests in the ethics and dynamics of authoritarian regimes and their foreign policies, responding to historical and colonial injustices, and the impact of automation on labour and human societies. Brian is a Fellow at the newly established Centre on Contemporary China and the World, at the University of Hong Kong. As the Chief Strategy Officer of the HK-ASEAN Foundation, he advises multinational corporations, family offices, and leading think-tanks on geopolitical affairs and macro risks throughout Asia. Having co-founded and served as the inaugural Editor-in-Chief at the Oxford Political Review, a publication aspiring to bridge the theory-practice gap, Brian serves as a columnist at the Hong Kong Economic Journal.



Mianzhi Zhang 張勉之

**Vice president
Tianjin Academy of Traditional Chinese Medicine,
Dongfang Hospital, Beijing University of Chinese Medicine**

Professor Zhang Mianzhi, full-time PhD in Nephrology, Postdoctoral Fellow in Traditional Chinese Medicine, Chief Physician, Doctoral Supervisor, Postdoctoral Collaborative Mentor, Vice President of Tianjin Institute of Traditional Chinese Medicine, Vice President of Dongfang Hospital of Beijing University of Chinese Medicine. The First Tianjin Famous Doctors, Tianjin Famous Traditional Chinese Medicine, Leader of the Clinical Key Discipline of Traditional Chinese Medicine Kidney Disease under the National Health Commission, member of the National Committee of the Chinese People's Political Consultative Conference, and member of the Education, Science, Health and Sports Committee.

Hosted 15 national and provincial-level research projects; Won 4 first prizes and 10 second prizes of provincial and ministerial level scientific and technological progress awards; 4 invention patents; Published over 170 professional papers and more than 30 SCI papers in national core journals; Chief editor of over 20 medical treatises.

BIOHK2024

香港國際生物科技論壇暨展覽

SPEAKER

DAY THREE

Friday September 13

*Surname in Alphabetical Order



Subrata Chakrabarti

**Distinguished University Professor,
Pathology and Laboratory Medicine, Western University
Pathologist, LHSC/SJHC**

Subrata Chakrabarti obtained his medical degree from India. Following completion of a Diploma in Ophthalmology, he moved to Canada. He obtained M.Sc and PhD at the University of Manitoba. He then did residency training in anatomical pathology at the University of Manitoba. Following a fellowship at Yale University, he joined University of Western Ontario, Canada. Currently, he is a distinguished University professor and an anatomical Pathologist at London Health Sciences Centre. Dr. Chakrabarti is an active educator. He also served as Chair/Chief of Pathology and Laboratory Medicine at Western University and London Health Sciences Centre from 2111-2021.

Dr. Chakrabarti's research focuses on diabetic retinopathy and other chronic diabetic complications. He has published more than 280 research articles, reviews and book chapters. He has a h-Index of 76. His research is funded by several external agencies. His current research focus is epigenetics and non-coding RNAs in diabetic complications

He developed a technology to treat diabetic retinopathy targeting long non-coding RNA HOTAIR, which can potentially be used as an eye-drop. In parallel he developed a serum-based biomarker panel as a diagnostic and prognostic biomarker for diabetic retinopathy. Recently he started a biotechnology company i-RNA Corp (i-RNA.ca) to commercialize this technology



Yongjian Cong 丛永儉

**Senior Advisor
Shenzhen Institute of Synthetic Biology, Shenzhen Institute
of Advanced Technology, Chinese Academy of Sciences**

Mr. Cong Yongjian has over 20 years of experience in investment and legal practice. Before founding iSynbio Capital, he served in senior roles at JP Morgan, Standard Chartered Bank, and China Development Bank.

Throughout his career, he has directly led the establishment of several USD and RMB funds, with a total fundraising scale exceeding 10 billion USD. As a trained lawyer admitted to practice in mainland China and New York State, he has extensive experience in cross-border M&A, venture capital, private equity, and special situation investments, particularly in transactions with complex legal structures and high risks.

Mr. Cong holds LL.M. from UIBE School of Law and Cornell Law School.



Lihua De 德立華

Partner
JunHe LLP

Ms. De is a senior partner of JunHe LLP. She is a managing partner and a registered foreign lawyer in Hong Kong office.

Ms. De has over 30 years of extensive practice experience in direct investment, M&A and project finance transactions. She has substantial experience in traditional industrial projects, telecommunication projects, real estate projects, transportation projects, nature resources projects and corporate finance projects. Ms. De has served many domestic, Hong Kong and international clients with their inbound and outbound investment, M&A, establishment of Sino-foreign joint venture and wholly foreign owned enterprises, as well as post-formation consultations. Ms. De is also extensively involved in the IPOs and issuance of bonds of companies in Mainland China and Hong Kong.



Hong Fung 馮康

Executive Director and CEO
CUHK Medical Centre (CUHKMC)

Professor Hong Fung is Executive Director and Chief Executive Officer of the CUHK Medical Centre (CUHKMC), and Professor of Practice at the Jockey Club School of Public Health & Primary Care (JCSPHPC), The Chinese University of Hong Kong (CUHK).

Before he joined CUHK in 2014, Dr Fung was Cluster Chief Executive of the New Territories East Cluster and Hospital Chief Executive of the Prince of Wales Hospital at the Hospital Authority (HA) from 2002 to 2013, overseeing the management and operations of 7 public hospitals.

Prior to that, he worked in the HA Head Office and was responsible for the planning and development of the public hospital services and facilities for over a decade. He spearheaded the development of HA's Clinical Management System and electronic patient records.

Professor Fung is also Honorary Clinical Professor at the School of Public Health of LKS Faculty of Medicine, University of Hong Kong. He was President (2014-2018) and Chief Censor (2010-2013) of the Hong Kong College of Community Medicine.

Professor Fung is well recognized for his expertise in medical leadership, health planning, health informatics, and health services management.



Yasser Ghoneim

Director of Clinical Projects
PDC CRO

Yasser Ghoneim is a clinical research professional with over 12 years of experience across diverse therapeutic areas, including Oncology, Hematology, Cardiovascular, Endocrinology/Metabolism, CNS Disorders, Immunology, Rare Diseases, Pulmonology, Psychiatry, and Gastroenterology. He has extensive expertise in managing Phase I, II, III, and IV trials, as well as Real-World Evidence (RWE) studies across the Middle East and Africa.

Yasser began his career as a Clinical Research Associate (CRA) at Sanofi Egypt, followed by roles of CRA II and Senior CRA at MCT CRO and Clinart Dubai. He later advanced to Clinical Project Lead and then Clinical Project Manager at IQVIA Dubai, where he worked for four years. Later he has joined PDC CRO in 2020 as a Clinical Project Manager and has risen in 2022 to the role of Director of Clinical Projects.

Yasser holds a bachelor's degree in Dentistry from Ain Shams University in Cairo, Egypt, and has earned certifications from several international CROs operating in the Middle East. Yasser is committed to contributing to the advancement of clinical research through his work.



Jenna Harris

Science and Dealflow co-Lead
AthenaDAO

Dr. Harris has a decade of research experience in neuroscience, molecular biology, and RNA Biology. She recognized funding as a major bottleneck for discovery during her career and now is a Science and Dealflow co-Lead at AthenaDAO, where she uses decentralized funding mechanisms to fund translation research in women's health. Dr. Harris received her Ph.D. in Molecular and Cell Biology from Brandeis University in Waltham, Massachusetts, USA in 2023. Her dissertation investigated the role of circular RNA in the aging brain. She completed two undergraduate degrees in neuroscience and psychology from Georgia State University in Atlanta, Georgia, USA in 2017. Her undergraduate research led to two publications on nociception in the peripheral nervous system and a thesis on prospective risk of Post-Traumatic Stress Disorder in a civilian population.



Zhaoren He 賀照人

Director of AI Solutions
BioMap

Zhaoren is the Director of AI Solutions at BioMap, with extensive experience in model development and protein design. He holds a Ph.D. from UCSD. He is the key patent inventor of Guardant Shield, the world's first FDA-approved blood test product for solid tumor screening. He has been cited over 1,400 times and has published as the first author in Science Immunology (twice) and Cell Reports. He was also recognized as a high-level overseas talent in Beijing.



Joe Henein

President and Chief Executive Officer
NewBridge Pharmaceuticals

Joe Henein is a senior executive with an accomplished multidisciplinary career of 40 years in the pharmaceutical industry, covering many geographies including USA (Global), Europe, and the Middle East/Africa. Joe holds a Pharm D Degree.

Joe joined as the operational founder of NewBridge as President and CEO- a specialty pharma start-up back in 2010 positioned to be first-in-class regional licensing and commercialization platform for innovative therapeutics. Headquartered in Dubai - UAE, NewBridge offers comprehensive pharmaceutical platform of services and expertise to Global Biopharma and Biotech Companies to bridge the access gap through licensing and commercialization of their U.S. FDA or EMA approved innovative therapeutics that address unmet medical needs of the Middle East and North Africa (MENA) region.

NewBridge is now the largest in its business model category across MENA, reputable and successful company that represents several blue-chip partners and blockbuster products in the region offering new therapeutic advancement to physicians, which helps improving patients' journey.

Prior to that Joe worked in Big Pharma, mostly Wyeth Pharmaceuticals, now part of Pfizer. He assumed many roles of increased dimensions in the industry, most notably Vice President and Global Commercial Chair for number of therapeutic areas in Wyeth World Headquarters, like Infectious Diseases, and Women's Health Care.

Joe also assumed the role of VP & Regional Managing Director for Wyeth in Middle East/Africa prior to joining NewBridge

Joe served on various Wyeth Executive Committees during his tenure as, Global R&D Council, Global Development Strategy Board, and European Operation Council.

On the industry level, he also served as the Vice Chair for the PhRMA MEA Committee and the Chair for the PhRMA MEA Ethics Review Board, under his leadership he chaired the committee that authored and published the first voluntary compliance code book, now in its fourth edition. He also formed and chaired the first Regional Pharma Ethics Review Board in MENA.



Effie HO 何奕輝

**GM,
DiaCarta, APAC**

Effie HO, Ph.D. MBA, Sever as General Manager, DiaCarta in Asia-Pacific
Serving as the Chief Medical and Health Advisor, the United Nations, Organization of Economic Development (OIDE)
Postdoctoral fellow and instructor in Harvard Medical School at Harvard University
NIH Personal Research Award Winner
Director and Co-founder of NxgenClinic, a clinical medical services company in the United States, as well as Founder of Medicur Capital Company
Former President of ZhiDe Biotech Co., Ltd. in Hong Kong; Participated in, led, promoted, nurtured, and facilitated financing activities
Former Vice President of Beijing R&G Technology Co., Ltd.China
Severed as Senior Managers in Clinical Research Development at Pfizer and Johnson & Johnson in the United States
Served as a board member of Oracle Life Sciences Association;
Chairman of Global Clinical Data Organization, China
Holds a PhD in Biochemistry from Rutgers University and MBA from University of Pennsylvania



Min Huei Hsu 許明暉

**Chief Data Officer and Professor
Taipei Medical University**

Min-Huei Marc Hsu is a Professor of the Graduate Institute of Data Science at Taipei Medical University. Dr. Hsu has dedicated himself to the adoption of health information technology. He has been involved deeply in digital health projects in Taiwan. He is one of the essential promoters of Taiwan's EMR exchange program. Dr. Hsu was appointed as Director of Medical Informatics Center at the Ministry of Health and Welfare of Taiwan in March 2011. Before the MOHW appointment, Dr. Hsu served as CIO at Taipei Medical University and also a Consultant Neurosurgeon at Wanfang Hospital (a 746-bed hospital affiliated to Taipei Medical University). Besides, he is author and co-author of more than 100 papers and articles in international conferences and scientific journals, focusing on health data, health information technology, e-health, electronic medical record system, hospital information management, and patient safety.



Alex Peng Hu 胡鵬

**Executive President
United Imaging Research**

Dr. Peng Hu is a Professor with Tenure and Vice Dean of the School of Biomedical Engineering at ShanghaiTech University, and the Executive President of United Imaging Research. Dr. Hu received his B.S. and M.S. degree from Tsinghua University and Ph.D. from the University of Virginia. He finished his post-doctoral training at Harvard Medical School. Dr. Hu was Tenured Full Professor in the Departments of Radiology and Bioengineering at UCLA. He is interested in MRI for cardiovascular disease, MRI-guided cancer radiotherapy, and fast/ real-time MRI. Dr. Peng Hu is a world-renowned scholar in the field of cardiac magnetic resonance. A number of techniques invented by his laboratory have been widely adopted and have become gold standard in clinical practices around the world. Dr. Hu has published more than 130 papers in top journals of the medical imaging field and more than 200 conference abstracts in top conferences.



Simon Hua 華風茂

**Chairman
Biometas Group Limited**

Mr. Hua is the Chairman and CEO of CFS. He joined BOCOMI in 2008 and headed its direct investment and investment banking businesses. He is a member of Investment Committee of BOCOMI funds that he raised and managed. Total capital under his management was USD\$1.5B. Prior to BOCOMI, he was the Managing Director of Investment Banking at CLSA and the Executive Director in China-Euro Securities Limited, an investment bank joint venture by CLSA in China. During his term, CLSA was awarded the best investment bank for medium-size enterprises in Asia. Prior to CLSA, Mr. Hua was General Manager of Corporate Finance of Cazenove Asia, and worked at ICEA, and Bank of America

From 2006 onwards, through his own private equity fund, Shanghai Shengya Investment and BOCOMI's direct investment funds, Mr. Hua made many private equity investments in China, including Guangxi Nanning Water Co. Ltd, Viva Biotech Limited, GCL Silicon Technology Holdings Inc, Bright Smart Securities, Sanjiang Chemical, Boshiwa, Sino Polymer, Topsec Holdings Ltd and Wison, etc.

Mr. Hua advised many China and Hong Kong enterprises, including PetroChina, Sinopec, Chinalco, China Telecom, Lenovo, TCL, China Insurance, Phoenix TV and Ctrip, etc. for their initial listings and refinancings. He also led many financial advisory projects, including the acquisition of Cntorch by Weichai Power and asset restructuring of Guangdong Investment, etc. In the past 18 years, he has completed about 200 listing and project financing projects and about 50 financial advisory projects. The total transaction amount is more than USD \$100B. Mr. Hua holds an MBA from International University of Japan.



Jiandong Huang 黃建東

Professor
The University of Hong Kong

Research Areas

Medical synthetic biology on cancer and infectious disease

Experience

1990-1994 Research Assistant, Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, California, USA

1994-1998 Postdoctoral Research Fellow, ABL-Basic Research Program, National Cancer Institute-FCRDC, NIH, USA, Under the supervision of Drs. Nancy A. Jenkins and Neal G. Copeland

1998-2006 Assistant Professor, Department of Biochemistry, Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR, P.R. China

2006-2014 Associate Professor with Tenure, Department of Biochemistry, Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR, P.R. China

2014- Professor with Tenure, Department of Biochemistry/School of Biomedical Sciences, Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong SAR, P.R. China



Akihiko Kondo

President, Founder, and Representative Director
Bacchus Bio Innovation Co., Ltd.

Akihiko Kondo received his Ph.D. from Kyoto University in Chemical Engineering (1988). He has started his faculty career in 1988 in Department of Applied Chemistry at Kyushu Institute of Technology. He was appointed as full professor of Kobe University in Department of Chemical Science and Engineering in 2003 and also appointed as a team leader at RIKEN Center for Sustainable Resource Sciences (CSRS) in 2012. He was appointed a dean of Graduate School of Science, Technology and Innovation at Kobe University in 2016. He became deputy director of RIKEN CSRS in 2020 and Vice President of Kobe University in 2021.

A. Kondo has developed various platform technologies such as cell surface display systems, metabolic pathway design tools, metabolic analysis technologies, genome editing and long chain DNA synthesis technologies. He also has applied these platform technologies for construction of various microbial cell factories for production of biofuels and various chemicals from biomass, and cyanobacteria and microalgae for production of oil and chemicals from CO₂. He is the scientific founder of several companies including BioPalette (genome editing), Synprogen (genome synthesis), AlgaeNexus (microalgae) and Bacchus Bio innovation (Biofundry), he became CEO of Bacchus Bio innovation this year.



Raju Kucherlapati

Paul C. Cabot Professor of Genetics and Professor of Medicine

Harvard Medical School, Boston, MA, USA

Dr. Kucherlapati is a Professor of Genetics and Medicine at Harvard Medical School. He obtained his PhD degree from the University of Illinois, trained at Yale University and was a faculty member at Princeton University, University of Illinois and Chairman of the Department of Molecular Genetics at the Albert Einstein College of Medicine. He joined the Harvard faculty in 2001 and was the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. His research interests are in the areas of human genetics, gene-modification, genomics and cancer genetics and genomics. He is a fellow of the American Association for the Advancement of Science and is a member of the National Academy of Medicine of the US. He was a member of a Presidential Committee during the administration of President Obama. He also founded several successful biotechnology companies.



Clara LAU 劉碧珊

**Principal Manager (Biotechnology Enterprise)
Invest Hong Kong**

Professor Clara Lau is currently Professor in Phytomedicine at Department of Pharmacology and Pharmacy & School of Chinese Medicine, The University of Hong Kong. She is also currently Adjunct Professor of Institute of Chinese Medicine & School of Chinese Medicine at The Chinese University of Hong Kong. With BPharm and PhD in Pharmacy (Pharmacognosy) from King's College London, University of London, UK, she has a continuous interest in western herbals and traditional Chinese medicines and has almost 30 years of experience in herbal medicines research. Main research areas include anti-cancer natural products and beneficial herb-drug combinations. She has published over 285 refereed journal articles (h-index 49) and 11 book chapters, and has edited 1 book. Currently, she serves as member of ChP-USP Advisory Group on Monographs for Traditional Chinese Medicine Ingredients and Products; President of Good Practice in Traditional Chinese Medicine Research Association; Secretary General of The Consortium for Globalization of Chinese Medicine; Council Member of Modernized Chinese Medicine International Association; Associate Editors of Journal of Ethnopharmacology, Journal of Traditional and Complementary Medicine, Frontiers in Pharmacology; Consulting Editor of Journal Pharmacological Research; Editorial Board member of Phytomedicine, Journal of Natural Products, Journal of Pharmacy and Pharmacology, and Integrative Medicine Research.



Lit Fui Lau 柳烈奎

**President & Chief Scientific Officer
Zhaoke Ophthalmology**

Dr. Lau Lit Fui joined Lee's Pharmaceutical Holdings Ltd. in 2012 and is currently President and Chief Scientific Officer of Zhaoke Ophthalmology. He is primarily responsible for overseeing the overall scientific functions and business development in overseas territories for the company.

Dr. Lau has 26 years of extensive multi-faceted experiences in the drug industry that have made him a fully integrated drug developer. His experience covers early drug discovery, preclinical development, clinical trials, registration, sales and marketing, business development, fund raising, merger and acquisition and IPO.

Prior to his work at Lee's Pharm and Zhaoke Ophthalmology, Dr. Lau spent 14 years at multinational companies including Pfizer Global R&D (USA) and GlaxoSmithKline R&D Center (China). Over the years his outstanding achievements and contributions have been recognized and reflected by the awards that he has received from his employers, business partners and governments.

Dr. Lau obtained both his B.Sc. degree and M.Phil. from The Chinese University of Hong Kong, where he was awarded the Wong Siew Chan Scholarship. He obtained his Ph.D. from the University of Connecticut Health Center and his postdoctoral fellowship at the School of Medicine of John Hopkins University in the United States.



Frank Lee 李易軒

**Chartered (UK) Patent Attorney
Marks & Clerk LLP**

Frank is a chartered (UK) patent attorney at Marks & Clerk LLP.

He is currently based in London. He has over 12 years in handling intellectual property matters, in particular patent and design matters, and has served various IP-related roles in private practice and in-house. He specialises in biomedical, electronics, and digital inventions, in particular medical devices/imaging, semiconductors, telecommunications, software, and AI. His practice covers patent drafting and prosecution, IP portfolio management, IP due diligence, and opinion work.

Frank holds a bachelor (BEng) degree in biomedical engineering and a research master (MPhil) degree in electrical and electronics engineering, both from the University of Hong Kong. His research focused on high field MRI techniques and their applications.

Frank is a frequent speaker and mentor for various business and accelerator programs (e.g., Founder Institute HK and Bridge AI (UK)), and IP training programs. He served as Co-founder and Board of Governor of the HK-GBA Chapter of the International Intellectual Property Commercialisation Council (IIPCC).



Wei Ning Lee 李維寧

**Associate Professor
Department of Electrical and Electronic Engineering, The
University of Hong Kong**

Dr. Wei-Ning Lee received her B.S. and M.S. degrees in electrical engineering from National Taiwan University, Taipei, and her Ph.D. degree in biomedical engineering from Columbia University, New York. She subsequently worked as a postdoctoral fellow at Institut Langevin at ESPCI ParisTech in Paris. She then joined as an assistant professor at the Department of Electrical and Electronic Engineering and Biomedical Engineering Programme at The University of Hong Kong and is now associate professor with tenure. She won a New Investigator Award at the American Institute of Ultrasound in Medicine (AIUM) Annual Convention in 2009 and received an Early Career Award from the Hong Kong Research Grants Council in 2013 and a Healthy Longevity Catalyst Award (Hong Kong) in 2022. Her current research interests focus on developing functional ultrafast ultrasound imaging methods with neural networks to investigate microstructure, mechanics, and hemodynamics of cardiovascular and musculoskeletal tissues. She currently serves on the Editorial Board of Physics in Medicine and Biology and the Advisory Editorial Board of Ultrasound in Medicine and Biology, and the Technical Programme Committee of the IEEE International Ultrasonics Symposium and is an Associate Editor of IEEE Transactions on Medical Imaging.



Da Liu 柳達

Managing Director
CR CP Life Science Fund

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Biospectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.



Fan Liu 劉帆

Co-Founder & CEO
NeoX Biotech

Fan Liu focuses on building models to interpret and predict various functions of proteins through molecular dynamics simulations of protein structures combined with machine learning methods, with applications in immuno-oncology. Dr. Liu was a postdoctoral fellow at Institute of Systems Biology and a principal investigator in computer-aided drug design at BeiGene, where he participated in several basic and translational R&D projects for novel therapeutics. Fan Liu graduated from the science class of Zhu Kezhen College of Zhejiang University with a bachelor's degree and received his Ph.D. in computational chemistry from California Institute of Technology. He has published several highly cited papers in Cell and other academic journals.



***Liping Liu* 劉利平**

**CEO and Chairperson
HighTide Therapeutics Inc.**

Liping Liu is Founder, CEO and Chairperson of HighTide Therapeutics Inc. (HighTide), a publicly listed biotech company (HKSE: 2511) specializing in developing multifunctional, multi-targeted therapies for metabolic and digestive diseases. The rising global incidence of metabolic disorders, including Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), has resulted in diminished life expectancy and productivity. The concurrent occurrence of T2DM and MASH is widespread, heightening the risk of disease progression and mortality. HighTide is discovering and developing novel treatments to meet the needs of patients with diverse comorbid conditions. The company's current focus is advancing its lead compound, berberine ursodeoxycholate (HTD1801), for the treatment of T2DM and MASH. HighTide is currently engaged in a Phase 2b multi-regional clinical trial (CENTRICITY) evaluating HTD1801 in MASH patients with comorbid T2DM or pre-diabetes, and Phase 3 clinical trials in T2DM (SYMPHONY). Prior to establishing HighTide, Liping gained extensive experience in metabolic and digestive diseases through roles in drug discovery and development at US biotech companies, including Stealth BioTherapeutics, ATCC, and MannKind. Liping holds a doctoral degree from Nankai University, completed post-doctoral fellowship training at the University of Toronto and the Hospital for Sick Children, and earned an MBA from the Johns Hopkins Carey Business School.



***Tiemin Liu* 劉鐵民**

**Professor, Head
Department of Physiology and Neurobiology School of Life
Sciences, Fudan University**

Dr. Tiemin Liu obtained his Ph.D. degree from the University of Toronto, and a post-doctoral fellow at the Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, then at the UT Southwestern Medical Center. In 2017, Dr. Liu joined School of Life Sciences, Fudan University as a full professor and has served on the Head of Department of Physiology and Neurobiology since 2019. He was also an adjunct professor in Zhongshan Hospital in Fudan University. His research focuses on the physiology and neurobiology of metabolism. He already published more than 80 papers including Cell, Cell Metabolism, Neuron, Nature Neuroscience, etc.



Cathy Lui 雷雅萍

**Principal Manager (Biotechnology Enterprise)
Invest Hong Kong**

Prior to joining Invest Hong Kong, Dr. Cathy Lui co-founded and served as Chief Executive Officer of OPER Technology Limited. She earned her PhD in neuroscience from Hong Kong Baptist University (HKBU), where she also obtained her biology undergraduate degree. With a prestigious post-doctoral fellowship from the American Parkinson Disease Association, Dr. Lui furthered her nanomaterials research at Northwestern University in the United States. She also held a visiting scholarship at the University of Oxford. Additionally, Dr. Lui received an MBA from Imperial College London. Driven by her dedication to translational research, Dr. Lui has garnered widespread recognition. She was named one of the top ten innovators under 35 in the Asia Pacific region by MIT Technology Review for her scientific achievements. Additionally, Dr. Lui received awards as the Greater Bay Area Outstanding Young Women Entrepreneur and Young Achiever of the Year from the American Chamber of Commerce in Hong Kong, celebrating her success as a serial entrepreneur translating research into solutions.



Yingfei Ma 馬迎飛

**Professor
Shenzhen Institutes of Advanced Technology, CAS**

Dr. Ma Yingfei, PhD, Professor, Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences. At present, his laboratory mainly focuses on the basic and applied research of phages, including: using high-throughput sequencing technology, developing bioinformatics tools to identify phage sequences from environmental and human metagenomic data, and studying the diversity of phages and their functions in the environment and human body; Based on the specific bacteriophage killing characteristics, artificial bacteriophages were designed and synthesized by synthetic biological methods and applied to the treatment of drug-resistant bacterial infections. As of now, his researches have been published in the journals Cell Host Microbe (2023a,b), Nucleic Acids Res (2022,2023), mSystems (2023), Nat Commun (2022), Microbiome (2018), J Virol (2018), etc. as correspondence/first author. As the project leader, he undertook the grants of NSFC, the key research and development subject of the Ministry of Science and Technology, Shenzhen Peacock Team, etc.



Zhongmin Ma 馬忠民

**Founder and Chief Executive Officer
Revivallon Biopharmaceutical Co. Ltd.**

Dr. Zhongmin Ma is the founder and Chief Executive Officer of Revivallon Biopharmaceutical Co. Ltd, a company dedicated to the development of innovative drugs with potential to cure diabetes. He is also an Adjunct Investigator of Zhuhai Fudan Innovation Institute, Fudan University. Dr. Ma has more than 30 years' experience in diabetes research and drug development. Prior to founding Revivallon, he served as the Chief Scientific Officer of Diapin Therapeutics, USA, a company to develop innovative drugs to treat metabolic diseases. Before that, Dr. Ma was a professor at Mount Sinai School of Medicine (MSSM) in New York, where his laboratory made breakthrough discoveries in β -cell regeneration in vivo. This groundbreaking work paved the way for developing novel drugs with potential to cure diabetes. Dr. Ma was one of the founders of Chinese American Diabetes Association (CADA) and served as the President for one term. He got his Ph. D. degree in Biochemistry from St. Louis University School of Medicine and his B.S. degree in Biology from Fudan University, Shanghai, China.



Alex Miloski

**Longevity and Web3 Lead
VitaDAO**

Alex Miloski began his career working at a large hedge fund, where he was first introduced to blockchain technology. His passion for innovation led him to transition into the crypto venture space. Over the past four years, he has spearheaded investment cases in the decentralized science (DeSci) sector, successfully directing the deployment of approximately \$2 million into leading DeSci projects such as Molecule, VitaDAO, and BeakerDAO. Driven by a deep commitment to shaping the future of decentralized science, Alex recently made the decision to dedicate himself full-time to advancing this groundbreaking sector. He was recently appointed as the Web3 Pod Co-Lead and Longevity Pod Interim Lead at VitaDAO. He's also an active contributor to BeakerDAO and BIO.xyz.



Susumu Mori 森進

Professor
Johns Hopkin University

Dr. Susumu Mori is an investigator whose research focuses primarily on developing novel magnetic resonance imaging (MRI) technologies to study brain anatomy. He joined the Johns Hopkins faculty in 1997. He is the Director of the Center for Brain Imaging Science in the Johns Hopkins Medicine Brain Science Institute, he is also affiliated with the Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins Alzheimer's Disease Research Center; the Kennedy Krieger Institute's F.M. Kirby Research Center for Functional Magnetic Resonance Imaging; and the Johns Hopkins Medical Institute's Laboratory of Brain Science Anatomical MRI.

Dr. Mori earned his doctoral degree in biophysics from Johns Hopkins University. He also holds bachelor's and master's degrees from Tokyo University of Fisheries. Dr. Mori is a Fellow of the International Society for Magnetic Resonance in Medicine (ISMRM). He has been awarded the ISMRM gold medal for neuroscience contributions to diffusion imaging (2018).

Dr. Mori focuses on developing an infrastructure for large-scale image analysis platforms. He has been developing a series of image analysis tools that have been widely used throughout the world including MriStudio and MriCloud. He is also developing a platform to analyze clinical data. These platforms provide environments to analyze various types of MR images and perform integrative analyses.



Peter Pang 彭彼得

General Manager
Shanghai Innovation Center & SVP of Chime Biologics

Dr. Pang has over 20 years of broad experience with strong portfolio of success leading the strategic development of drug development and CDMO management in the pharmaceutical and biotechnology industries.

Before joining, Dr. Pang served as SVP of ChemPartner and CEO of ChemPartner Biologics. Dr. Pang has started working in Chime Biologics since 2014 and held the General Manager position between 2018 to 2021. Dr. Pang held several key technical, regulatory and management positions in various pharmaceutical and biotechnology positions in Vancouver and Hong Kong.

Dr. Pang holds a Ph.D. in chemical engineering from the University of British Columbia, Canada. He then joined the Nobel Laureate Michael Smith Laboratories Centre for Blood Research at the University of British Columbia as a Postdoctoral Fellow.



William Pay 裴威廉

**Chief Investment & Strategy Advisor to the Chairman
Hong Kong WinHealth Pharma Group)**

William joined Pappas Capital in 2023 as a Venture Partner. Prior to joining Pappas Capital, he was the Founding Managing Director for Asia at Bryan Garnier & Co., a leading European boutique investment bank headquartered in Paris with over 180 bankers. In this role, he specializes in advising mid-cap, high-growth, and disruptive companies.

William serves as an advisor for many years to EPS Holdings, one of the largest privately held clinical CROs headquartered in Tokyo, Japan. He also holds an advisory position serving the Chairman with Hong Kong WinHealth Pharma Group, a prominent pharmaceutical company focused on commercialization of rare diseases and specialty pharmaceuticals in the Greater China region.

Before transitioning to the investment sector, William's last corporate role was with Bayer Healthcare in the Far East as the Chief of Strategic Sourcing. He led a cross-category strategic sourcing and quality compliance team, managing a volatile supply chain with an annual spend of half a billion euros. Prior to joining Bayer in July 2012, William held various globally-based strategic sourcing and business development/sales marketing positions of increasing responsibility at Takeda (Singapore), Johnson & Johnson (California), and Pfizer (NYC and Madrid) on the buy side, and for PPD (then part of the Carlyle Group and now part of Thermo Fisher) and Quintiles Transnational (now rebranded as IQVIA) on the supply side. His career has spanned over 25 years across Singapore, the US, Europe, and China.

William is a member of the BayHelix Group, a non-profit professional organization of business leaders from the investment and health-tech communities. The group's mission is to shape the growth of the life science industry, foster business collaborations, and share information and career experiences among its members. Educated in both China and the US, William is based in Wuxi near Shanghai. He is fluent in English and Mandarin Chinese. In his free time, William enjoys traveling, reading, and indulging in Japanese/Korean style saunas during the winter, which help him stay balanced and inspired.



Vladimir Parpura

**Distinguished Professor & Director
Zhejiang Chinese Medical University**

Vladimir Parpura, MD, PhD, MAE, holds both a medical degree, awarded from the University of Zagreb, Croatia in 1989, and a doctorate, received in Neuroscience and Zoology from Iowa State University, U.S.A. in 1993. He held faculty appointments in both countries. He is presently a Distinguished Professor and Director of International Translational Neuroscience Research Institute, Zhejiang Chinese Medical University, Hangzhou, China. He has been elected/inducted as a Member of Academia Europaea (MAE) in 2012, a corresponding member of the Slovenian Academy of Sciences and Arts (MSASA) as well as a Fellow of The American Association for the Advancement of Science (FAAAS) both in 2017, and a Fellow of American Physiological Society (FAPS) in 2020. Parpura was President (2017-2019 term) of American Society for Neurochemistry. In 2019, Parpura has been awarded Honorary Professor title at University of Rijeka, Croatia and the journal *Neurochemical Research* had a special issue in 2021 in his honor. In 2013, his laboratory ranked the 3rd in the world in nanotechnology. Since 2021, he has ranked number 2 in the world in astrocyte expertise by experts.com. He discovered astrocyte-neuron glutamate-mediated signaling pathway, i.e. gliotransmission. Parpura has been interfacing neuroscience with nanoscience/nanotechnology, neurochemistry, synthetic biology and biomedical engineering.



Frank Pun 潘穎

**Head
Insilico Hong Kong, Insilico Medicine**

Dr. Frank Pun is the Head of Insilico Hong Kong, where he leads a team of application scientists focused on AI-powered biological target discovery, indication expansion, and drug repurposing. His primary objective is to provide cutting-edge AI technology (Pharma.AI) to scientists and medical professionals worldwide, enabling them to identify actionable therapeutic targets and expedite drug discovery and development.

Frank received his Ph.D. in Biochemistry from the Hong Kong University of Science and Technology in 2010. Following his graduation, he served as a visiting scholar, leading a team dedicated to studying human CNS diseases and cancer for several years. In 2019, he also obtained an MBA from Rutgers Business School in the United States. Throughout his career, Frank has made significant contributions to target discovery, publishing numerous impactful papers in the field.



Mark Tang 唐馬克

Co-founder, 111 Longevity LLC

Partner, Good Health Capital, New York

Mark Tang is the Managing Director of Good Health Capital, a healthcare PEVC firm with offices in New York and Shanghai, and Chairperson of World Biotech Capital LLC, a cross-border venture capital, M&A, licensing, and IPO advisory firm. Mark is also a co-founder of 111 Longevity LLC. Originally from mainland China and educated in the US, Mark is a veteran Chinese biotech investor with over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He served as the biotech director at Rutgers Business School and as a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of "The Essential Biotech Investment Handbook," which is published in both English and Chinese. Mark has co-founded two tech startups that have achieved successful exits and currently sits on the boards of two US biotech companies. He holds degrees from NYU Stern School of Business and the Harvard T.H. Chan School of Public Health.



Xudong Tao 陶旭東

Partner

JunHe LLP

Mr. Tao joined JunHe LLP in 2001. He is a senior partner of JunHe capital market stream and head of life science practice, with focuses on PRC legal services relating to incubation, PE financing, mergers and acquisitions, equity incentive, domestic and overseas listings by various types of biotech and innovative device companies. Mr. Tao plays a leading role in a number of landmark IPO and listing deals involving STAR Market, ChiNext, HKEX, NYSE and NASDAQ and M&A deals involving China and overseas listed companies.



Mei Tian 田梅

Executive Director
The Human Phenome Institute at Fudan University

Prof. Mei Tian is an internationally recognized physician-scientist. She is the Executive Director of the Human Phenome Institute at Fudan University, President of the World Molecular Imaging Society, Vice President of the Chinese Society for Cognitive Science. She has led several major national research projects and published over 200 scientific papers. Dr. Tian serves as the editor-in-chief for two national textbooks on Nuclear Medicine and edited her English monograph on Transpathology. In addition, Dr. Tian is serving as the Associate Editor of two top journals in the field of nuclear medicine and molecular imaging.



Gergely Tóth

CEO and CSO
Cantabio Pharmaceuticals

Gergely Tóth, PhD, MBA is the CEO, CSO and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech. Dr. Tóth previously held various research roles in innovative biotech and global biopharmaceutical companies in the U.S. and was later a Wellcome Trust funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer's, and Parkinson's disease. His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum (Top 10 Emerging Technologies 2019).



Diana Viola

**Chief Executive Officer
PharmaBoardroom**

Diana Viola is CEO and cofounder of PharmaBoardroom.com, a global platform for high-level dialogue between government authorities and regulators, C-level industry executives, financial investors and other key stakeholders, as well as Healthcare and Life Sciences Review, comprehensive digital reports covering various healthcare markets and industry thematic. In total, both platforms reach over 53,000 global industry stakeholders across the entire value chain from R&D, manufacturing, and marketing and sales, to supply chain distribution, logistics and other services. Over the past 15 years, Diana has been committed to driving global engagement on relevant industry topics, trends and debates, sharing best practices across international markets, and advocating for collaboration and innovation within the healthcare and life sciences industry.



***Cindy Wong* 黃麗珊**

**Specialist in Clinical Oncology, Union Oncology Centre,
Honorary Assistant Professor at the School of Public Health,
LKS Faculty of Medicine, The University of Hong Kong.**

Dr. Cindy Lai San Wong, specialist in Clinical Oncologist, is currently practicing at Union Oncology Centre. She is also an Honorary Assistant Professor at the School of Public Health, LKS Faculty of Medicine, The University of Hong Kong.

Since her graduation with M.B.B.S from The University of Hong Kong, she practiced at the Department of Clinical Oncology of Queen Mary Hospital. She is a Fellow of the Royal College of Radiologists (FRCR, UK), Hong Kong College of Radiologists (FHKCR) (Radiology), and Hong Kong Academy of Medicine (FHKAM) (Radiology).

Dr. Wong is devoted to public services. She is a Board Member of the Radiation Board for the Government of HKSAR and an Honorary Associate Consultant for the COVID patients at the Kai Tak Holding Center. During COVID pandemic, she actively provided consultation to infected patients in different holding centers. She also collaborates with NGOs and is advisor to Global Chinese Breast Cancer Organization Alliance, Cancer Information and Forget Thee not. Besides, she is a founding Executive Board Member for Hong Kong Women for Oncology.

In order to share her expertise with the general public, Dr. Wong has published four books on cancer-related topics.



Tony Wong 黃廣輝

**Chief Technology Officer
Arbele Limited**

Dr. Wong received his PhD in surgical oncology from the University of Hong Kong and postdoc in liver cancer at the Cancer Science Institute and National University of Singapore. He has published over 30 original research articles, including Nature Genetics and the New England Journal of Medicine. Prior joining Arbele, he led discovery oncology and immunology research at Roche and Janssen Pharmaceuticals in Shanghai, China. Dr. Wong is responsible for discovery science in bispecific antibodies, ADC, and CAR-NK/T programs from drug discovery to IND enabling.



Wendy Wong 黃韻婷

**Director of Yathei medical center, Adjunct Associate
Professor, Hong Kong Institute of Integrative Medicine,
Chinese University of Hong Kong**

Prof. Wong is a Hong Kong-registered Chinese Medicine Practitioner with extensive experience in primary care evaluation research. She enhances front-line physicians' (Western and Chinese Medicine practitioners) knowledge for effective doctor-patient communication and evaluates care quality using validated patient-reported outcomes. Currently in private practice, she is also an Adjunct Associate Professor at the Chinese University of Hong Kong's Hong Kong Institute of Integrative Medicine (HKIIM). Previously, she was an Assistant Professor at the School of Chinese Medicine and HKIIM, and a post-doctoral fellow at the University of Hong Kong's Department of Family Medicine and Primary Care. Prof. Wong has published her research in various international peer-reviewed journals including the Scientific Reports, PLoS, Family Practice, Quality of Life Research, Complementary Therapies in Medicine and Evidence-based Complementary and Alternative Medicine.



Victor Yim 嚴滌宇

**Head of Fintech
Cyberport**

Victor is head of Fintech at Cyberport supporting 450+ fintech companies in HK. Before joining Cyberport, Victor created the eKYC (electronic know your customer) solutions for TransUnion which are still being used by major retail banks and SVF in HK.

Victor graduated from the University of Hong Kong with first class honour of degree in computer engineering and he is a PhD candidate (Computer Science) at the University of Hong Kong, focuses on Natural Language Processing applications on Regtech and Sustainable Fintech.

Victor has over 20 years of experience in the international tech industry and he has held senior positions with different multinational corporations, including TransUnion, Experian, Nice Actimize, SAS Institute and IBM. He has helped these companies to penetrate the ASEAN and China market focusing on Regtech and Financial Crime Risk Solutions.



Jintai Yu 郁金泰

**Professor
WHO Collaborating Center for Research and Training in
Neurosciences, Fudan University**

Professor Jin-Tai Yu (M.D., Ph.D.) is a Clinical Neurologist, Chief Physician, and Ph.D. Supervisor. He is Chang Jiang Scholar Distinguished Professor of the Ministry of Education of the People's Republic of China, currently serves as the Deputy Director of the Department of Neurology at Huashan Hospital, Executive Deputy Director of the Institute of Neurology at Fudan University, Leader of the National Medical Center for Neurological Disorders in Cognitive Impairment, and Principal Investigator of the National Clinical Medical Research Center for Geriatric Diseases. He also serves as the Deputy Group Leader of the Neuropsychology and Neuropsychiatry Group of the Neurology Branch of the Chinese Medical Association, and Editor-in-Chief of the international journal Brain Disorders. He is in charge of major projects such as the Ministry of Science and Technology of People's Republic of China, and the National Natural Science Foundation's general programs, etc. In recent years, as the corresponding author, he has published more than 100 SCI papers in journals such as Nature Human Behaviour, Lancet Neurology, with a cumulative citation of more than 18,000 times. He has been selected as a "Highly Cited Researcher" for four consecutive years.



Bing Zhang 張兵

Head of Cloud Services
Airdoc

Bing Zhang is currently Head of Cloud Services at Airdoc. He holds a Master's degree in Computer Science and Technology from Tsinghua University. He has rich experience in team management and has built R&D system from scratch. Bing Zhang specialises in technology strategy planning, and is able to plan technology routes based on the company's strategy and build corresponding R&D and technology systems. He has demonstrated strong cross-discipline technology integration capabilities, successfully combining deep learning algorithms with kubernetes, managing AI services through kubernetes, and realising efficient cloud service operation and maintenance. In addition, he excels in learning and communication, and is able to quickly adapt to new environments and work effectively in teams. Bing Zhang was also recognised and rewarded by the company for his innovative work in AI algorithm service management.



Jiayi Zhang 張嘉漪

Principal Investigator, Institutes of Brain Science, Fudan University

Dr. Jiayi Zhang received her B. Sc. Degree from Hong Kong Baptist University and Ph.D. degree from Brown University. She was a Brown-Coxe postdoctoral fellow in Yale University and joined Institutes of Brain Science at Fudan University in 2012. Her recent work focused on the decoding and restoration of vision. Her work was published in journals including Nature Biomedical Engineering, Neuron and Nature Communications (3). She received the State Science and Technology Advancement Award in 2023 and the Young Innovative Woman Award in Shanghai in 2020. She serves as the Vice chairman of the Neurotechnology Panel, Chinese Neuroscience Society (CNS). She is on the editorial board of Progress in Retina and Eye Research. She is currently the vice director of State Key Laboratory for Medical Neurobiology and the vice dean of Institute for Medical and Engineering Innovation at Fudan Affiliated Eye & ENT Hospital.



Yeqing Zhu

CEO

New Horizon health

With over 15 years of experience in various leadership positions, including ebusiness, IT, sourcing, and vendor management, Mr. Zhu have developed a strong expertise in IT and digital strategies. My focus has always been on leveraging technology to drive sales, enhance operational productivity, and streamline processes. As a member of the Committee of Experts for the Ministry of Science & Technology (MOST), Mr. Zhu has actively contributed to the advancement of IT service innovation. Additionally, he hold certifications as an IT advisor for the National Development Bank and the China Banking Regulatory Commission (CBRC), demonstrating my proficiency in advising on IT matters in the financial sector. He is recognized as a distinguished expert for the National Service Outsourcing Human Resources Institute.



Star Yuxing Zuo 左玉星

CEO

Hangzhou Tangji Medical Technology Co., Ltd

Mr. Zuo Yuxing, founder, CEO, and Chairman of Hangzhou Tangji Medical, brings extensive expertise in clinical medicine and commercial sales from both domestic and international enterprises. With 7 years of clinical practice in gastroenterology and 16 years of experience in sales and product management of top-tier international endoscopic medical devices, Mr. Zuo leads Tongee in its mission to revolutionize interventional treatment for metabolic diseases. Tongee, an innovation-driven company focused on doctors and patients, has developed several advanced medical technologies targeting obesity, type 2 diabetes, and nonalcoholic fatty liver disease. Notably, Tongee's Gastric Bypass Stent System, a groundbreaking Class III medical device, has received formal approval for the Chinese market, offering a less invasive solution for patients with metabolic diseases.

BIOHK2024

香港國際生物科技論壇暨展覽

KEYNOTE SPEAKER

DAY FOUR

Saturday September 14

*Surname in Alphabetical Order



***Yonghua Ji* 吉永華**

Professor
Hebei University

Former researcher of Shanghai Institute of Physiology, Chinese Academy of Sciences (CAS), recipient of State Council Special Allowance and National Jieqing Award. He was appointed as a foreign researcher at the Faculty of Medicine of Marseille Nord in 1987 and a special researcher at JSPS of Shizuoka Prefectural University in 1997. He has served as Secretary General and Vice President of the Chinese Society of Neuroscience, Executive Director of the Chinese Society of Biophysics for three terms, member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) for three terms, member of the Executive Committee of the Chinese General Chamber of Commerce (CGCC) for two terms, and Vice Chairman of the Shanghai Municipal People's League for two terms. His interests focus on the neuropharmacology and toxicology of natural toxins, and he has published more than 200 academic papers. He is now a special researcher of Hebei University.



***Li Jin* 金力**

Chinese Academy of Sciences Academician
President of Fudan University
Dean of Shanghai Medical College

Dr. Li Jin, President of Fudan University and Dean of Shanghai Medical College, Director of Human Phenome Institute. He is a member of Chinese Academy of Science and an external member of Max-Planck Society. Dr. JIN's main research areas encompass genetic structure and migrations of human populations, genetics of human complex diseases and computational biology. To date, he has published more than 900 papers in international academic journals including Nature, Science, Cell, NEJM, JAMA etc. and his papers have been cited 50,000 times.

He served as a board member of HUGO, co-founded Genographic Project, Pan-Asian SNP Consortium, and International Human Phenome Consortium (IHPC). He also co-founded National Human Genome Center at Shanghai, CAS-MPG Partner Institute of Computational Biology, Shanghai International Human Phenome Institute.

Dr. Jin has served as editor-in-chief and editorial board member of more than 10 international journals, including Phenomics. He has chaired three national councils including Frontier Biotechnology in the National High-tech R&D Program, National Precision Medicine Research Program, and National Biotechnology and Information Technology Convergence Program.

BIOHK2024

香港國際生物科技論壇暨展覽

SPEAKER

DAY FOUR

Saturday September 14

*Surname in Alphabetical Order



Chris Chan 陳錦華

**Assistant Professor
HK Baptist University**

Chris is the Assistant Professor of the School of Chinese Medicine, HK Baptist University. Chris mainly engaged in integrative clinical services and research of various internal medicine conditions. He is the designer and coordinator of multiple clinical trials and cohorts, which showed that add-on Chinese medicine reduces kidney function decline in diabetes, and was associated with mortality reduction in COVID and acute exacerbated chronic obstructive pulmonary disease. Chris has published over 30 original articles in international peer-reviewed medical journals and has been the investigator of 13 research projects with over HK\$25 million funding support.

Chris received clinical Chinese medicine training from the HKBU (BCM&BSc, MCM), Tung Wah Group of Hospitals (clinical training) and Guangzhou University of Chinese Medicine (MD); clinical epidemiology, personalized medicine and internal medicine training from the London School of Hygiene & Tropical Medicine (MSc Public Health), University Medical Center Groningen (overseas training), Queen Mary Hospital and HKU (PhD), receiving 23 awards. Chris has served for Tung Wah Group of Hospitals, Hospital Authority, World Health Organization and KPMG Advisory on clinical medicine, medical research and health policy previously.

Apart from practice and research, Chris also serves as a board member of the World Federation of Chinese Medicine Societies subcommittees (Clinical Effectiveness Assessment Committee, Special Committee on Classics); Co-chair of Clinical practice guideline group, GP-TCM Research Association; and the council/board member and advisor of various government and NGO panels currently.



Stephen Chan

**Private equity investor
Tybourn Capital**

Stephen Chan is a hedge fund and private equity investor at Tybourn Capital, a multi-billion dollar Tiger Grand Cub hedge fund based in Hong Kong. He oversees healthcare and life science investments at Tybourn. Before joining Tybourn Capital, Stephen was a core member of the CBC Group private equity team, one of the largest healthcare-dedicated private equity funds based in Asia. Throughout his investment career, Stephen has been involved in over 20 transactions across the healthcare value chain, totalling over \$1 billion in investments. He began his career at McKinsey & Co. as a strategy consultant, advising global pharmaceutical companies on corporate and R&D strategy. Stephen holds a PhD in Genetics from the University of Cambridge, where he was also a Croucher Hong Kong Scholar, and a B.Sc. in Biochemistry from Imperial College London.



Tom Chik 植治邦

Co-founder & CEO
LHC New Energy Company Limited

Mr. Tom Chik is the Co-founder & CEO of Linked Charge, Guangdong-Hong Kong-Macao Greater Bay Area e-Mobility super charging network operator .



Billy Chiu 趙志輝

Chief Medical Executive
Adventist medical center

Dr. Billy Chiu is a specialist in Family Medicine and holds a Master of Public Health. He previously served as the Assistant Director of Resident Medical Services at Hong Kong Sanatorium & Hospital. Following his tenure at HKSH, Dr. Chiu transitioned to a medical administration role focusing on clinical operations at the Chinese University of Hong Kong Medical Centre. He later assumed the position of Chief Operating Officer at Gleneagles Hospital Hong Kong. In 2021, he left GHK to join Adventist Medical Centre as Chief Medical Executive, where he is responsible for overseeing overall management, particularly in service quality and the expansion of two centers: Lee Garden and Tai Koo Place Day Procedure Center.

Dr. Chiu is committed to medical education, serving as an Honorary Associate Professor of Family Medicine at both the University of Hong Kong and the Chinese University of Hong Kong. He is also appointed as an Adjunct Associate Professor at the School of Chinese Medicine, CUHK. He actively supports initiatives that integrate Chinese and Western medicine through his roles as Honorary Secretary, Convenor of the Care Model Workgroup, and Member of the Health Committee under the Hong Kong Association for Integration of Chinese-Western Medicine. Additionally, his public service includes positions as Honorary Treasurer and Business Manager of the Hong Kong College of Family Physicians, as well as a Council Member of the Association of Private Medical Specialists of Hong Kong.



Ricky Chiu

Chairman and CEO
PHASE Scientific International Limited

Dr Ricky Chiu is the Founder, Chairman and CEO of PHASE Scientific International Limited, as well as the lead inventor of the Company's core technology. He has been awarded the Ten Outstanding Young Person of the World, the Ten Outstanding of Young Person in Hong Kong, the InnoStars Award, the Young Industrialist of Hong Kong, the Outstanding Leader – Young Entrepreneur and the HKSAR Chief Executive's Commendation for Community Service for his outstanding research achievements in biotechnology innovations and his notable contributions to the fight against COVID-19 pandemic. Dr Chiu is an adjunct associate professor at the School of Biomedical Sciences and the Member of Board of Trustee of the United College of The Chinese University of Hong Kong, as well as the Court Member of The Hong Kong Polytechnic University. He is fully committed to grooming young talents and firmly believes in empowering the next generation to create a positive impact on healthcare globally. Dr Chiu and the PHASE Scientific team are currently engaged in research and product development for the detection of cancer and infectious diseases.



Xiangrong Dai 戴向榮

Chief Operating Officer
Zhaoke Ophthalmology

Mr. Dai joined Zhaoke Ophthalmology in June 2016 and was appointed as an executive director on October 23, 2020, and was appointed as the Chief Operation Officer (COO) on May 20, 2024. He is mainly responsible for the drug research and development and the management of corporate operations.

Prior to joining our Group, Mr. Dai had worked in Lee's Pharm since July 2007, where he served successively as the head of the research and development centre, deputy general manager and COO. He was responsible for multiple new drug development programs, advancing them to the clinical trial stage and successfully obtaining the registration approval for over 20 different drugs. Mr. Dai has over 17 years of extensive experience in drug research and development and corporate operations management.

Mr. Dai obtained his master's degree in biochemistry from Anhui Agricultural University in Anhui Province, China in June 2007.



Aaron Finley

Director
Deloitte China

Aaron is a Director in Deloitte's South China Business Development team based in the Guangzhou office. With a diverse network and broad experience in international business, Aaron helps his clients in developing best practices for international business, accounting, taxation, as well as seek investment and development opportunities. Aaron is also supporting the Deloitte's Greater Bay Area (GBA) Initiative and is leading the development of a hospital collaboration platform so that hospitals around the GBA can better coordinate best practices. Aaron is a licensed CPA in California and has obtained a Masters in Business Taxation from the University of Southern California. Aaron is a Part-Time Lecturer on International Taxation and PhD Student at the Macau University of Science & Technology. Aaron is a member of the Board of Governors of AmCham South China and is a member of the board of the European Chamber of Commerce South China Chapter. He is an Advisor to the Guangdong Investment Promotion Association, an expert of the Guangzhou Capital Market Pool, and a contributor to the Guangzhou City Business Environment Study.



George Fu Gao 高福

Director and Professor
CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University).

Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General), China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).



Angela Yuxin Men 門宇欣

CMO
Haichang Biotech

Dr. Men is the CMO of Haichang Biotech. Prior to joining Haichang, she served as a master reviewer and team leader in the Clinical Pharmacology Office, CDER FDA since 2003 with the responsibility of reviewing IND/NDA/BLA for oncology and neurological new drugs. She has received numerous awards from the FDA, including the Distinguished Service Award, Outstanding Mentor Award, Outstanding Leadership Award and Outstanding Regulatory Science Award, etc. She has actively organized and presented in various workshops and seminars at the national and international conferences. In May 2022, Dr. Men was selected into the IFPMA ICH E21 expert working group. Currently, she serves as President-elect and the board member of the Chinese Biopharmaceutical Association – USA; Ex-Vice President and board member of FDA Chinese Experts Club; Assistant Chair for the Membership and Community Outreach in Federal Asian Pacific American Council (FAPAC) and a member of China Pharmaceutical Innovation and Research Development Association.

Dr. Men received her PhD in pharmaceutical sciences from Virginia Commonwealth University. Before that, she was a clinical neurologist with a medical degree from Tianjin Medical University.



Philip Tsang 曾學銘

Co-Founder & CEO
Caretia

Caretia - Co-Founder & CEO
Cyberport Startup Alumni Association – Vice President (Policy Affairs)
5th Greater Bay Area Outstanding Young Entrepreneur
Stevenson, Wong & Co. – Consultant
Allbright Law Offices (Shenzhen) – GBA Lawyer



Albert Yu

Chairman

Hong Kong Biotechnology Organization (HKBIO)

Professor Albert Yu is a renowned neuroscientist and bio-entrepreneur who has devoted over two decades in neuroscience and infectious disease research and had significant contributions to molecular neurobiology and molecular diagnosis. Professor Yu is the Vice-Director of the Neuroscience Research Institute, Professor of the Department of Neurobiology and also a Professor at the Infectious Disease Center at Peking University. He is also the Chairman & CEO of Hai Kang Life Corporation Limited (HKLife), a Hong Kong-based biotechnology company with operations in Hong Kong and Beijing and is specialized in the R&D and commercialization of clinical and veterinary molecular diagnostics, as well as various cutting-edge food testing technologies and their optimization into user-friendly, cost-effective mobile field units (MFUs). HKLife's core technology, EFADchip, has been recognized as a globally leading technology which will overcome bottlenecks in existing lab-on-a-chip technologies and is expected to revolutionize modern clinical diagnosis. The technology has been awarded the prestigious 2009 Asia Pacific Frost & Sullivan Product Differentiation Excellence Award for In-Vitro Diagnostics.

Under the leadership of Prof. Albert Yu, HKLife has also been fast and accurate in responding to global infectious disease outbreaks such as avian influenza, SARS, and the recent H1N1 influenza outbreak. The technology in avian influenza diagnosis has been awarded the 2004 Hong Kong Award for Industry – Technological Achievement, was recognized as Chinese National Standards, and is being recommended by FAO/OIE in its Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. It is the first and only product being approved by the Japan Ministry of Agriculture, Forestry and Fisheries (JMAFF). In recognition of his expertise, Prof. Yu has been invited by various industrial and academic organizations (e.g. WHO, US Air Force) to introduce the technological advances introduced by HKLife.

Prof. Yu received his BSc, MSc and PhD from the University of Saskatchewan, Canada and spent subsequent years in the Canada, United States, Hong Kong, and China. Prof. Yu's broad cross-cultural experience base and active involvement in both the academic and business environment has led to the strategic vision behind the success of the HKLife team. Also, with a global network and an expanding base of established contacts in China, Prof. Yu has been an important facilitator of dialogue regarding the development of biotechnology in Asia. Over his professional and entrepreneurial career, Prof. Yu has published several books and over 200 peer-reviewed scientific articles and conference papers. He is also the co-inventor of numerous technologies with patents granted in major countries.



Michele Yuen 袁美欣

Specialist in Endocrinology, Diabetes & Metabolism

Dr. Michele Yuen is a specialist in Endocrinology, Diabetes and Metabolism. She is currently in private practice and is an honorary consultant at Gleneagles Hong Kong Hospital and Hong Kong Adventist Hospital. She is also an honorary associate consultant at Queen Mary Hospital and clinical assistant professor at the University of Hong Kong.

Prior to studying medicine, Dr. Yuen obtained a degree in Bachelors of Science in Dietetics from the University of British Columbia, Canada. She then received her medical degree from the University of Hong Kong and specialized as an endocrinologist at Queen Mary Hospital. She further sub-specialized in Obesity Medicine at the Obesity, Metabolism and Nutrition Institute of the Massachusetts General Hospital / Harvard Medical School. She is a member of the Royal College of Physician (United Kingdom) and a fellow of the Hong Kong College of Physician, Hong Kong Academy of Medicine and the Royal College of Physician (Edinburgh).

Dr. Yuen is one of the pioneers of obesity medicine in Hong Kong. She developed the first obesity clinic and joint metabolic and bariatric surgery clinic in Hong Kong in 2016 and founded the Hong Kong Obesity Society to support the development of Obesity Medicine in Hong Kong.

SPEAKER INDEX

*Surname in Alphabetical Order

B

Renu Balyan 61

C

William Cao 29
 Subrata Chakrabarti 93
 Chris Chan 120
 Clara Chan 23
 Piu Chan 90
 Stephen Chan 120
 Chitty Chen 29
 Forrest Chen 30
 Su Chen 30
 Weiwei Cheng 31
 YuenYee Cheng 32
 Lillian CHEONG 55
 Martin Cheung 32
 Tom Chik 121
 Billy Chiu 121
 James Chiu 33
 Ricky Chiu 122
 Xiaoying Chu 61
 Yongjian Cong 93

D

Xiangrong Dai 122
 Lihua De 94
 Zhiguo Ding 33
 Boris Djordjevic 62
 Xin Du 62

E

Tristan Edwards 34
 Bettina Ernst 34

F

Jianbing Fan 63
 Jing Fan 35
 Peter Fedichev 63
 Aaron Finley 123
 Hong Fung 94

G

Fu Gao 23, 35, 123
 Yasser Ghoneim 95
 Richard Gibbs 64

H

Alireza Haghighi 65
 George Hara 24
 Jenna Harris 95
 Ruyi He 65

Zhaoren He 96
 Joe Henein 96
 Effie Ho 97
 Alice Hsu 36
 Min Huei Hsu 97
 Alex Hu 98
 Simon Hua 98
 Jiandong huang 99
 Norman Hui 36

I

Masayasu Inoue 37

J

Xuweisheng Ji 37
 Yonghua Ji 118
 Yi-Zhou Jiang 66
 Bin Jin 66
 Kunlin Jin 67
 Jin Li 118
 Xia Jin 38
 Daniel Johnson 67

K

Yi Tsun Kao 39
 Akihiko Kondo 68, 99
 Raju Kucherlapati 68, 100

L

Clara Lau 100
 George Lau 56
 Lit Fui Lau 101
 Sampson Lau 69
 Frank Lee 102
 Wei Ning Lee 102
 Leslie Leinwand 69
 Chun Ying Leung 25
 Gilberto Leung 39
 Min Li 70
 Ming Li 70
 Ning Li 71
 Shaowei Li 40
 Yi Li 40
 You Li 41
 Roben Liang 41
 Jinzhong Lin 71
 Zhixiu Lin 72
 Anessa Liu 72
 Da Liu 73, 103
 Fan Liu 103

SPEAKER INDEX

*Surname in Alphabetical Order

Jun Liu	42	Philip Tsang	124
Liping Liu	104	V	
Tiemin Liu	104	Diana Viola	47, 112
Yangyang Liu	42	W	
Chung-mau Lo	57	Jiguang Wang	81
Dennis Yuk Ming Lo	25	Paloma Wang	48
Maggie Lo	73	Shouyan Wang	81
Yuk Lam Lo	74	Xiaojun Wang	48
Mark Lotter	43	Xin Wang	82
Hang Lu	44	Yu Wang	58
Patrick Lu	75	Brian Wong	82, 91
Cathy Lui	105	Cindy Wong	112
Wen Luo	75	Tony Wong	113
Yu Xuan Lyu	76	Vincent Wong	83
M		Wendy Wong	113
Junyi Ma	76	Josephine Wu	49
Yingfei Ma	105	X	
Zhongmin Ma	106	Wenrui Xia	83
Donglei Mao	77	Wendong Xu	27, 84
Angela Men	124	Y	
Xiaofeng Meng	45	Cong Yan	59
Alex Miloski	106	Hai Yan	84
Susumu Mori	107	Frank Yang	49
O		Michael Yang	85
Hideyuki Okano	45	Zifeng Yang	85
P		Henry Yau	50
Peter Pang	107	Victor Yim	114
Vladimir Parpura	109	Lin Yin	86
William Pay	108	Albert Yu	125
Marek Piotrowski	78	Chang Yu	86
Leo Poon	46	Jintai Yu	114
Frank Pun	109	Kwok-Yung Yuen	51
S		Michele Yuen	126
Wanviput Sanphasitvong	78	Z	
Eric Shao	79	Bing Zhang	115
Howard Shi	46	Ge Zhang	52
Nan Song	47	Hongjie Zhang	87
Vincenzo Sorrentino	79	Jiayi Zhang	115
Jonathan Symonds	27	Mianzhi Zhang	91
T		Ning Zhang	52
Mark Tang	110	Zongli Zheng	87
Xudong Tao	110	Jie Zhou	53
Polakit Teekakirikul	80	Lihan Zhou	88
Nicholas Teo	80	Yeqing Zhu	116
Mei Tian	111	Jiajie Zou	53
Han Chong Toh	58	Star Zuo	116
Gergely Tóth	111		

Acknowledgements

BIOHK would like to express our sincere gratitude to all the sponsors and supporting organizations listed in the following pages who played a vital role in making the BIOHK2024 convention a resounding success.

We would also like to give special thanks to all session chairs. In particular, those who spent great efforts to organize their sessions.

We would like to thank all the organizations, individuals, and staff members who dedicated their time and efforts to make this convention possible. Special mention is given here to the volunteers from the Hong Kong Polytechnic University.

Lastly, we thank all the participants for attending this conference. Your participation will make the conference even more splendid.

Supporting Organizations

Organizers




Co-organizers



Platinum Sponsors



Gold Sponsors





Supporting Organizations

Special Supporting Organizations



Supporting Organizations



Supporting Organizations

Supporting Organizations



Global Partners



Knowledge Partners



Media Partners





Hong Kong Biotechnology Organization
—— 香港生物科技協會 ——

INTRODUCTION

Hong Kong Biotechnology Organization is an independent nonprofit organization aiming to promote best practice and raise awareness across the biotechnology industry.

WHO ARE WE?

HKBIO was founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business.

OUR GOALS

Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.



HKBIO
Website



HKBIO
WeChat

Contact us!



+852 2799 7688



enquiry@hkbio.org.hk



<https://hkbio.org.hk/>

創科無限・引領未來
Venture Beyond Boundaries

HK TECH 300



HK Tech 300 – a large-scale flagship innovation and entrepreneurship programme with an allocation of HK\$600 million from CityUHK and an additional HK\$1.2 billion investment from co-investors. To date, more than 700 teams have been cultivated, of which over 140 start-ups have been awarded angel fund investment of up to \$1 million each.

HK Tech 300：由香港城市大學撥款6億港元進行的大型旗艦創新創業計劃，聯同共同投資合作夥伴提供超過12億港元額外投資，至今已培育超過700支初創團隊，當中有超過140間初創公司各獲批出最高達港幣100萬元的天使基金投資。

Sponsored Training Programme
資助訓練課程



HK\$100,000
Seed Fund
10萬港元種子基金



HK\$1,000,000
Angel Fund
100萬港元天使基金



HK\$10,000,000
External Funds
1,000萬港元其他外來基金





眼科

人工眼角膜
青光眼引流管



整形美容

胶原蛋白植入剂
含聚乳酸微球胶原蛋白植入剂



口腔

生物矿化复合仿生骨粉
口腔生物膜



泌尿外科

压力性尿失禁填充剂
脱细胞真皮基质中段吊带

生物材料

医疗器械

组织医学工程

INNOVATION LEADS THE FUTURE



股份代码
603127.SH/6127.HK

BIOHK2024 GOLD SPONSOR

AAALAC Accredited
US FDA GLP Inspected
NMPA GLP Certified
OECD GLP Certified
PMDA GLP Inspected
MFDS GLP Inspected
CNAS/ILAC-MRA Certified



昭衍新药 JOINN Laboratories

服务药物创新，专注于药物全生命周期的安全性评价和监测

集团简介

昭衍新药 (股份代码: 603127.SH/6127.HK) 是中国最早从事药物非临床评价的 CRO 企业, 1995 年成立至今, 已拥有近 3000 人的专业技术团队。昭衍新药拥有符合国际规范的质量管理体系 (CNAS/ILAC-MRA 认证), 具备中国 NMPA、美国 FDA、经合组织 OECD、韩国 MFDS、日本 PMDA 的 GLP 资质以及国际 AAALAC (动物福利) 认证资质, 评价资料满足全球药品注册要求。可以向客户提供非临床药理毒理学研究及评价, 特别是非临床安全性评价, 临床试验及药物警戒等一站式服务; 还可以提供兽药、农药及医疗器械评价等服务项目。在北京、苏州、重庆、广州、上海、梧州、南宁、云南以及美国加州、波士顿设有子公司。昭衍秉承“服务药物创新, 专注于药物全生命周期的安全性评价和监测”的宗旨, 保障患者用药安全, 呵护人类健康!

一站式服务能力

CDMO: 北京昭衍生物技术股份有限公司 (昭衍生物)

药物检测: 北京昭衍药物检定研究有限公司 (昭衍药检)

非临床: 北京昭衍新药研究中心股份有限公司 (昭衍新药)

临床检测: 昭衍 (北京) 检测技术有限公司 (昭衍临床检测)

临床 CRO: 昭衍 (北京) 医药科技有限公司 (昭衍医药)

昭衍
JOINN

服务优势

- 20 余年的稳定运营
- 2200+ 生物药 1600+ 化学药物的新药评价经验
- 熟悉 NMPA、US FDA、MFDS、PMDA、OECD 及 ICH 法规, 规范支持全球申报
- “十项全能”的服务能力

联系方式

Wechat: 昭衍 JOINN

Web: www.joinnlabs.com

E-mail: info@joinnlaboratories.com





海康生命科技有限公司

HAI KANG LIFE CORPORATION LIMITED

To save lives from infectious diseases worldwide

BIOHK2024 GOLD SPONSOR

Pneumonia can affect anyone; it claims millions of lives each year.

Let's Set a New Standard for Pneumonia Management

We aim to significantly reduce pneumonia mortality by equipping healthcare professionals with innovative diagnostics for guided treatment.



BioRadar® – Real-time pathogen monitoring in ICUs

Contact Us Today to Save Lives



Scan this code to visit
our official website for
more information!

Contact us!



+852 3902 2906



sue.tsang@haikanglife.com



<https://www.haikanglife.com>



BIOHK2024 SILVER SPONSOR



Digital Tech Hub of Hong Kong

Cyberport is committed to nurturing a vibrant tech ecosystem by cultivating talent, promoting entrepreneurship among youth, supporting start-ups on their growth journey, fostering industry development and integrating new and traditional economies by accelerating digital transformation in the public and private sectors.

- Innovative digital community gathering 2000+ start-ups and technology companies
- Focuses on building key clusters of digital tech:

Application Clusters



FinTech



Smart Living/
Smart City



Digital
Entertainment

Technology Clusters



AI & Big Data



Blockchain



Cybersecurity

Emerging Sphere



Web3Hub
@Cyberport

 **Your Springboard to Success**

www.cyberport.hk

 [cyberport.hk](#)  [cyberport.hongkong](#)  [@Cyberport](#)  [cyberport.hk/linked](#)  [Cyberport Hong Kong](#)  [Cyberport.hk](#)  [Cyberport](#)



數碼港
Cyberport




微信公众号

4000-6655-05




中赢生物简介

国内外不同四家公司NK细胞体外扩增试剂盒扩增效率、纯度及体外杀伤测评报告 (该报告由浙江大学测评出具)




Tube: zhongying2			
Population	#Events	%Parent	%Total
CD3 ⁺ CD56 ⁺	25,000	49.6%	100.0
CD3 ⁺ CD56 ⁻	10,384	20.8	37.6
CD3 ⁻ CD56 ⁺	10,242	20.2	36.5
CD3 ⁻ CD56 ⁻	10,986	21.4	35.9
CD3 ⁺ CD56 ⁺	6,176	12.4	13.4
CD3 ⁺ CD56 ⁻	140	0.3	0.3
CD3 ⁻ CD56 ⁺	100	0.2	0.2
CD3 ⁻ CD56 ⁻	250	0.5	0.5

中赢生物纯度: 94.3%




Tube: SAMPLE2 A1			
Population	#Events	%Parent	%Total
CD3 ⁺ CD56 ⁺	81,000	88.9%	100.0
CD3 ⁺ CD56 ⁻	11,990	13.4	13.4
CD3 ⁻ CD56 ⁺	10,870	12.0	12.0
CD3 ⁻ CD56 ⁻	10,840	12.0	12.0
CD3 ⁺ CD56 ⁺	8,767	9.7	9.7
CD3 ⁺ CD56 ⁻	1,120	1.2	1.2
CD3 ⁻ CD56 ⁺	1,170	1.3	1.3
CD3 ⁻ CD56 ⁻	480	0.5	0.5

A公司纯度: 84.5%



Tube: SAMPLE2 B2			
Population	#Events	%Parent	%Total
CD3 ⁺ CD56 ⁺	81,614	88.9%	100.0
CD3 ⁺ CD56 ⁻	11,905	13.2	13.2
CD3 ⁻ CD56 ⁺	11,510	12.6	12.6
CD3 ⁻ CD56 ⁻	11,300	12.3	12.3
CD3 ⁺ CD56 ⁺	9,208	10.3	10.3
CD3 ⁺ CD56 ⁻	164	0.2	0.2
CD3 ⁻ CD56 ⁺	9,000	10.0	10.0
CD3 ⁻ CD56 ⁻	991	1.1	1.1


B公司纯度: 65.1%



Tube: SAMPLE2 C2			
Population	#Events	%Parent	%Total
CD3 ⁺ CD56 ⁺	61,240	88.9%	100.0
CD3 ⁺ CD56 ⁻	11,906	18.2	18.2
CD3 ⁻ CD56 ⁺	11,230	16.9	16.9
CD3 ⁻ CD56 ⁻	11,107	16.0	16.0
CD3 ⁺ CD56 ⁺	9,680	15.8	15.8
CD3 ⁺ CD56 ⁻	140	0.2	0.2
CD3 ⁻ CD56 ⁺	2,500	3.9	3.9
CD3 ⁻ CD56 ⁻	707	1.1	1.1

C公司纯度: 70.6%

NK细胞体外杀伤实验数据

4种方法扩增的NK细胞杀伤实验,
中赢方法杀伤效率第一

滋养细胞试剂安全性评价

2020年, 国家上海新药安全评价研究中心

对我司提供的高代次与低代次的滋养细胞进行了体外成瘤性试验的验证, 结果显示: 高代次与低代次的滋养细胞均无潜在成瘤性。

中赢生物生产的NK细胞体外扩增试剂盒被试验证实安全有效。

专利技术及荣誉

中赢生物在NK细胞定向扩增激活技术上不断突破进取,

曾获得该领域独家的发明专利: 利用跨膜IL-21定向扩增NK细胞

(专利号ZL201110075736.1, ZL201310173235.6, ZL201310053084.0, 20171049344.7)

成功在体外实现了NK细胞的定向高效扩增与激活,
为NK细胞的临床应用提供了技术支持。2016年, 中赢生物获
CCTV10套《科技之光》报道2020年, 中赢生物成为浙江省2020年的
《国家高新技术企业》
《杭州市区域细胞制备中心》

杭州中赢生物医疗科技有限公司是由浙江骨干企业浙江中赢控股集团有限公司引进, 杭州国家高新区(滨江)重点支持的海外高层次人才团队联合创办的高新技术企业, 总部坐落于杭州市国家高新区(滨江), 是国内较早一家立足于再生医学、专注免疫细胞存储与应用, 集研发、生产、营销为一体的高新技术企业。

公司总部建有杭州市级研发中心, 是杭州市专利示范企业。作为行业领先企业, 主导起草了首个NK细胞制备相关的浙江制造标准——《自然杀伤细胞(NK)扩增试剂》, 并于2023年11月由浙江省质量协会发布实施。

公司研发团队在NK细胞定向扩增激活技术上取得了突破性的进展, 获得了该领域多项发明专利——

利用跨膜IL-21定向扩增NK细胞(专利号ZL 201110075736.1, ZL201310173235.6, ZL201310053084.0, 20171049344.7), 成功在体外实现了NK细胞的定向高效扩增与激活, 为NK细胞的临床应用提供了技术支持。

Lee's Pharmaceutical (HK) Limited

李氏大藥廠（香港）有限公司



ABOUT
LEE'S PHARM

Science, our belief and aspiration

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with 30 years of operation in the pharmaceutical industry in China. The Group is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China. The Company has established extensive partnerships with around 30 international companies and currently markets over 25 proprietary, generic and in-licensed pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan.

—— 守護健康 · 與李同行 ——

VSL#3®
益生菌



• 促進腸道健康 提升免疫力 •

VSL# Woman
Plus 益生菌



• 維持女性陰道微生態平衡 •

Dicoflor
益生菌



• 平衡腸道微生物 減輕過敏反應 •

BUY NOW



Lee's Pharmaceutical Holdings Ltd. (Stock code: 00950.HK)

李氏大藥廠（香港）有限公司 香港沙田香港科學園第三期科技大道東20E大樓1樓



(852) 2314 1282



info@leespharm.com



www.leespharm.com

Vyluma

Atropine Sulfate Ophthalmic Solution

BIOHK2024 SILVER SPONSOR

- 👁️ 24 month Stable, Preservative-free
- 👁️ Global Patented Formula
- 👁️ Largest & Longest Global Registration Trial
- 👁️ Safe and Well-Tolerated for Myopia Control in Children (3-17 years-old)



Product concept photo



VISUS
THERAPEUTICS

Brimochol™ PF Ophthalmic Solution

Carbachol and Brimonidine Tartrate

- 👁️ FDA and EU/UK Primary Endpoints met in Phase III Clinical Trial (BRIO 1)
- 👁️ Preservative-free
- 👁️ Well Tolerated
- 👁️ Once Daily Treatment for Presbyopia




Product concept photo



HEADQUARTERS in Mainland China
No.1 Meide 3rd Road,
Pearl River Industrial Park,
Nansha District,
Guangzhou, Guangdong Province, PRC.

HEADQUARTERS in Hong Kong China
Unit 716, 7/F,
Building 12W, Phase 3,
Hong Kong Science Park,
Shatin, Hong Kong.





君合律师事务所，以北京总部作为依托，在全球拥有十四家办公室和逾千人的专业团队，是国际公认的、卓越的中国大型、综合律师事务所之一。君合致力于在商业与争议解决领域提供一流的法律服务，并将优质的法律服务通过君合平台的国际业务网络有效延伸到客户业务所需的世界每个角落。

君合香港是君合海外最大的办公室，是君合向境内外客户提供跨境法律服务的重要平台。君合香港汇聚了拥有大量香港、中国大陆及国际法律实务经验的律师团队，以该等专业律师团队的文化背景和语言的多样性为客户提供海内外一体化综合的法律服务。

同时，君合拥有一支三十多位经验丰富的合伙人统领的专注于生命健康与医疗服务的专业团队，其成员均为公司与并购、资本市场、私募股权/创业投资、知识产权、合规、争议解决等各团队中长期从事医药医疗业务的法律专业人士，拥有丰富的实战经验。我们能够为客户提供全方位法律服务。

JunHe, headquartered in Beijing, has 14 offices globally and a professional team of over a thousand professionals. It is recognized internationally as one of the excellent large, comprehensive law firms in China. JunHe is dedicated to providing first-class legal services in the fields of business and dispute resolutions, and effectively extending its quality legal services to every corner of the world where its clients' businesses require through its international professional collaboration network platform.

JunHe's Hong Kong office is its largest overseas office and an important platform for providing cross-border legal services to both domestic and overseas clients. The Hong Kong office has assembled a team of lawyers with extensive experience in Hong Kong, mainland China, and international legal practices, providing clients with integrated, comprehensive legal services leveraging the diverse cultural backgrounds and language skills of these professional lawyers.

Meanwhile, JunHe has a professional team focused on the life sciences and healthcare services industry, led by approximately 30 partners. They are well versed in pharmaceutical and healthcare industrial matters coming from teams of corporate and M&A, capital market, private equity and VC, IP, compliance, and dispute resolutions. We are able to provide our clients full rounded and comprehensive legal services.



ZSHK LABORATORIES LIMITED

The GLP One-stop Service CRO



- AnLing Biomed (Suzhou) Co., Ltd.
- Human Experimental Dog Breeding and Research Base
- AnLing Biomed (Shenzhen) Co., Ltd.
- ZSHK (Hongkong) - Hong Kong Science and Technology Park Drug evaluation Laboratory
- Guangxi Non-human Primate Breeding and Research Base

ZSHK Laboratories Limited is a biopharmaceutical pre-clinical research and development service company mainly engaged in pre-clinical research and evaluation services for drugs and medical devices. As a one-stop evaluation and research service platform, it provides services including pharmacology, pharmacodynamics, pharmacokinetics, toxicology and other safety-related studies for pharmaceutical developers and researchers worldwide.

ZSHK has established independent laboratories in Pingshan District of Shenzhen, Guangdong Province, and Suzhou Industrial Park and Suzhou New District, Jiangsu Province. ZSHK also jointly operated the Drug Safety Testing Center in Hong Kong Science Park with Hong Kong Science and Technology Parks Corporation. Paying active efforts in supply chain deploying, ZSHK has established breeding and research bases of experimental dogs and non-human primates in Human and Guangxi.

SERVICES

- A full package of toxicity studies in compliance with NMPA GLP and international GLP requirements**
Covering small molecules, large molecules, CGTs, and other new drugs, with study reports delivered in English/Chinese
Bioanalysis (PK/PD, PK, and TK of small and large molecules)
Animal experiments (various animal species)
Clinical pathology (Conventional and special endpoints)
Histopathology (slide preparation, diagnosis)
Safety pharmacology (conscious animals of various species)
Tissue distribution and immunogenicity testing
Other studies: genotoxicity, reproductive toxicity, carcinogenicity, irritation, anaphylaxis, etc.
- Early toxicity screening ADMET (non-GLP)**
PK/TK, early toxicological screen in liver and kidney cell lines, hERG, mitochondrial viral, etc, al.
- Establishment of animal models and evaluation**
Various animal species, especially primates



EIGHT EXPERIMENTAL PLATFORMS AND FOUR SUPPORT PLATFORMS

Eight Experimental Platforms

- | | | |
|--|---|-------------------------------------|
| Pharmacology and Pharmacodynamics Division | Safety Pharmacology Division | Drug Metabolism Division |
| Drug Safety Evaluation Division | Clinical Pathology and Pathology Division | Large Molecule Bioanalysis Division |
| Small Molecule Bioanalysis Division | Rodents and Non-rodents Surgery Division | |

Four Support Platforms

- | | | |
|----------------------------|------------------------|------------------------------|
| IT and computerized system | File management system | Instrument management system |
| Document management system | | |

COMPANY QUALIFICATIONS

NMPA

Drug safety evaluation
China GLP certification

FDA

Drug safety evaluation
US GLP certification



DRUG SAFETY EVALUATION
OECD GLP COMPLIANCE



Experimental animal welfare
AAALAC International accreditation



QA team
US SQA-RQAP-GLP certification



Validation Capacity of toxicological
pathology examination CNAS accreditation



Bioanalysis and clinical
pathology NIFDC verification



Skadden in China

We are a top-tier international law firm with more than 35 years of experience in China.

Skadden clients include the world's top global pharmaceutical and medical device companies as well as numerous emerging biopharmaceutical and health care businesses.

We have extensive experience advising within the biotech ecosystem and the broader health care landscape. Companies and investors across the industry rely on the sector-specific insights of our attorneys, who work as an integrated team to help clients realize scientific innovations as they navigate an ever-evolving landscape.



#1 in League Tables

Representing issuers in Hong Kong IPOs and listings for the past six years (2018-23)

Representing Chinese companies in U.S. IPOs for 14 consecutive years (2010-23)



Groundbreaking Hong Kong Transactions

Numerous early Chapter 18A (pre-profit biotech) listings

First and second Chapter 8A (WVR) listings



A Leading Firm

Recognized by *Chambers*, *The Legal 500*, *IFLR* and *Benchmark Litigation*, among others

Recognized as a Best International Law Firm for six consecutive years (2019-24),
China Business Law Awards



80,000+ High Purity Small Molecules

- Specific Inhibitors & Agonists
- Natural Products
- Isotope-Labeled Compounds
- Fluorescent Dyes/Probes
- GMP Small Molecules
- Reference Standards
- PROTACs & Molecular Glues
- Click Chemistry
- Biochemical Assay Reagents
- Personalized Customization



60,000+ High Activity Biological Large Molecules

- Recombinant Proteins
- Peptides
- Primary & Secondary Antibodies
- Inhibitory Antibodies
- Oligonucleotides
- Enzymes
- Antibody-drug Conjugates/ADC Related
- Personalized Customization



MCE One-Stop Drug Screening Platform

Compound Libraries

- Ready-to-Use Compound Libraries
- Diversity Compound Libraries
- Fragment Libraries, etc.
- Customized Libraries

Screening Services

- Virtual Screening
- DEL Screening
- SPR Assay Service, etc.
- Lead Compound Optimization



High Efficiency Biological Kits

- Inhibitor Cocktails
- RT/qPCR & PCR Master Mix
- Magnetic Beads & Agarose
- Protein Biology
- 2D/3D Cell Culture
- Cell Analysis



Peer Scientists Recognition –

Cited in 40,000+ Publications
Including CNS Series

Scan and explore more
about our product
brochures!



MCE Profile

- MedChemExpress (MCE) is a leading global brand in the life science industry, providing high-quality bioactive molecules and cutting-edge solutions for scientific research.
- MCE is committed to promoting the progress of human scientific research and pharmaceutical development, making R&D and production more efficient.

R&D Platform

- >8,000 m² R&D Center Square, 1,000+ R&D staff.

Quality Assurance (QA)

- Certified by ISO 9001, CNAS quality management system, strict quality control and verification system.
- Provide various quality inspection reports, including HNMR, LC/MS, HPLC, chiral analysis, elemental analysis, SDS-PAGE, SEC-HPLC, MS, FACS, affinity detection, activity detection, etc.

MedChemExpress USA

Tel: 609-228-6898

E-mail: sales@MedChemExpress.com

Tech Support: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

MedChemExpress Asia Pacific

Tel: 021-58955995

E-mail: sales@MedChemExpress.cn

Address: No.1999, Zhangheng Road, Shanghai, P.R., 201203, China

www.MedChemExpress.com



hLife aims to report and highlight original and high-impact discoveries in the health science field, **linking basic research to transformative medicine** that could improve human health. *hLife* aims to become an authoritative source of original health-related research and a platform for the academic community to promote scientific innovation!

Editors-in-Chief



George F Gao



Chen Dong



Jules A Hoffmann

- Initial issue in 2023
- 12 issues annually
- Golden open access
- Non-Profit & APC free
- Rapid review & Speedy publication
- Format-free submission & Display items refining

Welcome all aspects of medicine-related research

Indexed in **Scopus, DOAJ**





Fast facts



Founded in

1998



Number of employees

~9,250



Annual revenue (2023)¹

\$4.50B USD



Cumulative sequencing
installed base

> 25,000

Headquarters

San Diego, California, USA

Countries served

> 160

Chief Executive Officer

Jacob Thaysen

Sequencing systems

Next-generation sequencing (NGS) is revolutionizing research, enabling experiments that weren't possible before. Illumina offers a range of innovative NGS platforms that deliver exceptional data quality and accuracy, at a massive scale.



**NovaSeq™
X/X Plus**



**NovaSeq™
6000/6000Dx***



**NextSeq™
1000/2000**



**NextSeq™
550/550Dx***



**MiSeq™ and
MiSeqDx***



MiniSeq™ iSeq™ 100

Production-scale systems

Benchtop systems

Applications

- Oncology
- Genetic disease
- Infectious disease
- Multiomics
- Drug discovery
- Microbial genomics
- Reproductive health
- Molecular and cell biology
- Agriculture
- Conservation and sustainability

Customers

- Clinics
- Hospitals
- Research labs
- Health care systems
- Academic institutions
- Government agencies
- Pharmaceutical companies

For Research Use Only. Not for use in diagnostic procedures.
*For in Vivo Diagnostic Use. Not available in all regions and countries.

M-GL-01040 V1.0



On-Board Couriers (OBC)

Through our global foothold, our experts leverage our courier network to offer secure and reliable hand-carry services.



Next Flight Out (NFO)

Our longstanding partnerships with major airlines ensure premium air freight for your biologics & pharma shipments.

Global Foothold

Personalised Solutions

Dedicated Account Managers

Accredited

Data-driven Tools

High-end Monitoring Solutions

Wide Range of Packaging Solutions

Need a quality-driven bio-logistics solution? Discuss with our experts?

关于ATS

ATS 成立于2002年, 隶属于上海多宁集团, 以 **生物制药, 特医食品和复杂制剂** 为核心的**高端装备产品制造研发公司**! ATS 以超高压纳米匀质技术为核心, 拥有20多项相关的专利!


- 2013年ATS 提供的石药集团脂质体生产线申报FDA认证!
- 2016年成为高新技术企业! 使用设备超过2000台, 全面覆盖生物医药行业的核心客户!
- 2018年成为生物医药园区重点培育的瞪羚企业! 产品出口美国FORDOZ 药业, 美国LEAF制药、印度MYLAN 药业、印度太阳制药、Aurobindu药业等等、满足FDA 认证要求!
- 2020年高压均质系统销售量超过400台, 覆盖国内90%的高端制药及纳米材料客户!

ATS复杂制剂纳米化设备研究中心

苏州市科学技术局颁发的 **[ATS复杂制剂纳米化设备研究中心]**

—专为客户提供工艺技术解决方案—

支持客户来样、携样至复杂制剂中心



多种检测设备, 为测试提供数据说明



地址: 苏州工业园区星湖街218号生物医药产业园A4-106
电话: 0512-62761582
网址: www.atshph.com

POCT Molecular Diagnostic Solution

3_{in1}

Extraction + Amplification + Analysis

Sample In Result Out



Intelligent Cassette (iCassette)



Galaxy Lite



Galaxy Nano



Galaxy Pro

- Fully enclosed iCassette
- Preloaded reagent, ready for use
- Minimal hands-on time
- Internal control monitors PCR processes
- No need for freezer storage or transportation
- Comprehensive multiplex panels

Respiratory pathogens

- COVID-19 (ORF1ab / N gene) (2-plexes detection)
- COVID-19 / Flu A / Flu B / RSV (5-plexes detection)
- TB/RF-resistance (6-plexes detection)
- Flu A / Flu B / RSV (3-plexes detection)
- MP/AdV/HHV/HPV (5-plexes detection)
- SP/ KP/ LP/ HI/ BP (5-plexes detection)

Intestinal Pathogens

- CA6/CA10/CA16/EV71 (4-plexes detection)
- CA16/EV71/EV6 (3-plexes detection)

Carbapenem resistance

- KPC/OXA/IMP/VIM/NDM (5-plexes detection)

Sexual Pathogens

- CT/NG/ UU (3-plexes detection)
- HPV 2+16 genotyping (5-plexes detection)
- HPV 16/18 genotyping (2-plexes detection)
- HPV genotyping (20-plexes detection)

Arboviruses pathogens

- DENV/CHIKV/ZIKV (3-plexes detection)
- Dengue Serotyping (4-plexes detection)

Various types of pathogens

- Galaxy CS EXT iCassette (compatible with 3rd party reagents)

Multiplex Respiratory pathogens

- 13 Respiratory pathogens panel*

Antibiotic Resistance

- MRSA (3-plexes detection)*
- VRE (3-plexes detection)*

* Detection kit belongs to Igenex Genomics Microtechnology Co., Ltd.

Making Nucleic Acid Detection

Safer · Faster · Easier · More Accurate



北京赛赋医药研究院有限公司（简称赛赋医药）于2016年成立，致力于成为国际一流一站式医药CRO服务公司，提供国际一流的医药CRO评价服务，并结合技术开发、融资和创新医药产品转化等服务，为企业提供整体创新医药研发规划，加速创新药物的研发进程，帮助企业更快发展。下设医药研发咨询、NMPA/FDA注册申报、抗体药物发现、早期药物筛选及成药性评价、药理药效学评价、药物代谢动力学评价、非临床安全性评价、生物样本检测及伴随诊断产品研发、放射性药物一体化生产研发技术平台等部门，能够为医药研发企业提供专业的一站式医药研发服务。

公司已获得国际AAALAC认证、NMPA十项GLP资质、OECD GLP资质、国家认监委CMA认证、美国CAP认证、美国A2LA ISO-15189认可、美国CAP认证、生物安全二级实验室备案等各类资质或证书，研究报告受中国、美国、欧洲等多个国家广泛认可，支持全球申报。先后获得国家专精特新“小巨人”企业、国家高新技术企业、北京市及河北省企业技术中心、北京市企业科技研究开发机构、北京市中小企业公共服务平台、河北省技术创新中心等荣誉称号并拥有两个博士后科研工作站。

服务范围



赛赋特色

吸入药物一站式服务平台

精神神经药物一站式服务平台

眼科药物一站式服务平台

放射性药物一站式服务平台

全面覆盖创新药研发领域

细胞治疗

- CAR-T细胞
- DC细胞
- TCR-T、TIL
- 间充质干细胞
- IPS细胞
- CAR-NK细胞
- CAPRI细胞
- 血小板
- 造血干细胞
- 外泌体

基因治疗

- 递送方式：电转、病毒、LNP
- 编辑部位：非编辑、体外编辑、体内编辑
- 药理靶点：内源性、外源性

大分子药物

- 单抗/双抗
- ADC
- PDC
- RDC
- 多肽药物
- 融合蛋白

小分子药物

- 氘代药物
- PROTAC药物
- 激酶抑制剂
- 化学多肽
- 放射性药物

小核酸

- 反义寡核苷酸
- shRNA
- siRNA
- miRNA
- saRNA

疫苗

- mRNA疫苗
- 灭活疫苗
- 重组蛋白疫苗
- 新型载体疫苗
- 肿瘤疫苗

天然药物

- 中药
- 民族药
- 天然药物复方
- 天然药物提取物

北京赛赋医药研究院有限公司

北京市北京经济技术开发区科创六街2号院12号楼F7

130-5155-8090 (微信同号)



赛赋医药官方公众号




赛赋医药官方视频号




neoX AI Drug Design



Cyclic Peptide Phage Display



Molecular Glue Target Identification & Screening



Pipeline: "First-in-Class" & "Best-in-Class"

In-house

BCL6 Molecular Glue
BTK PROTAC
Wee1 PROTAC
BCL-XL PROTAC

Anti-CD24 mAb
IL-21 mutein Fc fusion
Anti-TfR nanobody
EGFR-cMET bispecific nanobody

Pipelines

Partnered

Pro-cytokine
Masked cytokine and antibody

ABOUT US 关于我们



北纳生物 (BNCC) 成立于2010年, 是一家专注于实验细胞、微生物菌种、微生物质控品及标准物质领域, 集研发、生产与应用为一体的高新技术企业。

BNCC科研基地建筑面积10000平, 实验区4000平, P2实验室2000平, 设有微生物菌种保藏中心、细胞保藏中心、PCR核酸检测与测序等多个实验室。

引进基因分析仪、PCR仪、全自动核酸提取仪、生物显微镜、超微量分光光度计, 高速冷冻离心机、超低温冰箱、生物安全柜等先进设备百余台, 可对外提供标准菌株、质控菌株、感受态细胞、细胞系、细胞DNA、细胞培养基、质粒、生物标准物质、核酸类质控品、蛋白类质控品、液体室内质控品、检测试剂盒等产品, 满足各类科研人员的需求; 同时也可提供微生物菌种分离、纯化与鉴定、微生物定量检测、微生物生理生化分析、细胞培养、STR鉴定、支原体检测、细胞基因组DNA定制等一站式技术服务。

BNCC潜心钻研, 加大研发力度, 全力打造BNCC品牌, 成为专业权威和最具信赖的细胞、微生物菌种及标准物质供应商, 为广大企业、高校、研究机构等用户提供精确、优质的产品和服务!



基础产品

BNCC保藏各类微生物菌种60000余株, 科研细胞4000余株, 为新品研发提供资源保障; 同时提供配套的培养基、血清等产品。



微生物检测

BNCC微生物检测系列产品涉及食品检测、药品检测、化妆品检测及水质检测等领域, 在微生物实验室能力验证、微生物测量方法评价和仪器校准以及微生物培养基生长率的评价等方面有广泛的用途, 为食品安全、微生物检测领域提供计量溯源保障。品类齐全, 支持定制!



微生物质控品

BNCC微生物质控品包含核酸参考品、液体室内质控品、核酸标准品等, 涵盖市面上所有菌类、病毒的热灭活产品, 品类丰富。采用热灭活技术, 通过数字PCR法进行绝对定值, 可根据客户需求定制热灭活产品。



标准物质

BNCC成功申报菌类平板计数、病毒核酸类国家二级标准物质, 经过国家质量监督总局检验, 量值稳定; 旗下伟业计量独立研制十三大系标准物质, 成功获批国家一级标准物质28种, 国家二级标准物质600多种, 产品涉及食品、环境、化工、临床医学及药品等多个领域。



实验细胞 微生物菌种 微生物质控品 标准物质



热线: +86 18758069589

邮箱: info@bncc.com

网址: www.bncc.com

端到端的基因与细胞治疗CRO&CDMO服务 IIT产品生产到商业化生产

丰富的IIT生产/中美双报IND/临床生产经验

6个

IIT生产项目

13个

中美IND批件
(4个FDA IND)

4个

临床项目

160+批

GMP生产

*以上数据统计截止至2024.5



GMP车间设计和质量体系能够满足中、美、欧相关IND和BLA需求

在临床II期共同申请药品生产许可证，满足BLA申请



IIT产品生产 (A)

(质粒、慢病毒、mRNA及细胞产品等)

博腾生物配合客户进行伦理申报

- 患者入组，临床发送生产需求单
- 预留生产场地
- 入组成功，审核临床样本信息
- 锁定生产产线，启动准备

»
(~7月内)

IIT产品生产 (GMP场地进行)

- 场地预约
- GMP生产及放行
- 成品发运

成熟的IND整包申报服务 (B)

丰富的全流程CMC申报经验



质粒、慢病毒和细胞全流程服务已协助客户获得3个IND默许批件

已执行完成的全流程CMC项目，最快7个月完成工艺开发和GMP生产

创新服务模式：IND药物申报一体化服务



IND药物申报一体化服务已协助客户获得IND临床默许批件





彩科生物
Lychix

Enlighten life
by chips

为生命科学创造先进工具
提高对生命认知的分辨率

关于Lychix彩科生物

彩科(苏州)生物科技有限公司由多位美国海归博士于2018年在苏州生物医药产业园创立,公司以为广大生命科学研究人员提供先进研究工具,挖掘海量高分辨率生命科学数据为目标,以微尺度下多物理场耦合u-MPF(Micro-scaled Multi Physics coupled Force)技术及高端生物芯片设计为核心自主研发生产:高通量单细胞光导系统、单分子免疫分析仪、试剂、芯片等多项高科技产品,在单分子及单细胞水平大大提升了生命科学研究人员对生命认知的分辨率。

公司自成立以来已连续完成A1、A2、B轮融资,得到了国内外顶级生物医药投资机构如IDG、君联资本、弘晖资本、国投招商、国际著名生命科学及诊断公司珀金埃尔默(Perkin-Elmer)旗下产业基金PKI的青睐,多次荣获“2022中国10倍增长潜力医疗企业”“2022未来医疗100强”“中国创新医疗器械榜单Top100”“生命科学工具及服务”价值榜等众多荣誉。



单细胞功能分析分选

LyTARS™

高通量·多组学·单细胞·广筛选

高通量单细胞光导系统

- ✓ 单B细胞抗体发现/细胞治疗/细胞株开发/合成生物学
- ✓ 将抗体药物早期发现时间缩短1-1.5个月
- ✓ 在单张芯片上实现高通量的单细胞同时培养及细胞分泌物活性分析
- ✓ 在保持细胞活力的情况下高效回收单细胞
- ✓ 高效的多轮筛选assay,极大降低后期验证工作量



阿尔茨海默病超敏检测

LyMedivh™ AXL

超敏·精准·开放

单分子免疫分析仪

单分子免疫分析系统,可直接对血清、血浆、脑脊液和细胞裂解液中的生物标志物进行超高灵敏度检测,适用于低丰度标志物的开发和验证,药物研发过程中的生物分析,疾病的早期检测和预后跟踪并可适应更广泛的科研需求



自主研发

芯片&试剂

- ✓ 彩科生物自主研发配套硅基芯片Partition和即抛型微流控盘片
- ✓ 单分子系列试剂盒可检测比传统ELISA方法浓度低1000倍的生物标志物,具有灵敏度高、数字化成像、适用性广等特点,通用型试剂盒,支持用户自主开发感兴趣的生物标志物,满足不同的科研需求
- ✓ 单细胞系列试剂盒,具有稳定性高、实验效果好的优势



400 1186 722

www.Lychix.com

地址:江苏省苏州市工业园区桑田街218号2号楼102单元



2025 医疗器械创新展 Medical Fair China 2025

苏州国际博览中心, 苏州, 中国
Suzhou International Expo Centre, China

2025.08.20-22

www.medicalfair.cn

Member of  **MEDICAlliance** 全球医疗系列展成员

**医疗器械行业创新发展风向标
Compass of Medical Device
Industry Innovation**



官方微信 Official WeChat

 **+86-10-65907101**



主办单位 Host:




杜塞尔多夫展览(上海)有限公司
Messe Düsseldorf (Shanghai) Co., Ltd.

国际支持 Powered by:




NeoLNP™: 1-minute efficient RNA encapsulation




NeoLNP™: Full series RNA transfection reagents from *in vitro* to *in vivo*

NeoLNP™ *in vitro* Transfection Kit -- Efficient LNP transfection of difficult-to-transfect cell lines

● Jurkat cell line




● THP-1 cell line




NeoLNP™ *in vivo* Transfection Kit -- easy RNA evaluation in animal studies

● Tail-vein injection: for targeted and efficient delivery to the liver/spleen




Luc mRNA expression encapsulated by NeoLNP™ in the liver and spleen post-injection (left); the same produced by a microfluidic device (right). Notably, both exhibit negligible differences.

● intratumoural



● i.m. injection



About Us

Scindy Pharmaceuticals, founded in 2021, is a research and development enterprise focused on innovations in the field of nano-carriers. Our primary objective is to drive both the basic research and the clinical application of novel therapies. We place a special emphasis on RNA, leveraging our cutting-edge NeoLNP™ delivery technology. We have harnessed the unique capabilities of our leading i-Core LNP platform to successfully launch innovative gene vector products based on LNPs. These products are specifically tailored for cell and gene therapy, reflecting our commitment to pushing the boundaries in this crucial area of healthcare.

Scindy Pharmaceutical (Suzhou) Co., Ltd.

Address: 6 / F, Block B, Building 4, No. 108 Yuxin Road, Suzhou Industrial Park, Suzhou, Jiangsu, P.R.China

Telephone: 0512-8886 5668

Email: service@scindypharm.com

Website: www.scindypharm.com



Try our products



Add us on WeChat

简化液体处理 面向大众的自动化设备

MANTIS®

高精度纳升级微量分液系统



TEMPEST®

高通量纳升级分液系统



F.A.S.T.™

纳升级固相置换移液系统



FLO i8®

独立8通道移液工作站



更多信息请访问我们的网站

www.formulatrix.com

sales@formulatrix.com | 021-61562961 | 15901821208

生物医药国有检测服务平台

赋能研发、助力申报、一站服务

广东省华微检测股份有限公司（华微检测）为广州市微生物研究所与广东华南新药创制中心的高水平技术团队共建的专门从事生物安全、生物医药及保健品等领域的第三方检测机构。

华微检测实验室严格遵照 ISO/IEC17025、RB/T214 等标准、规范要求运行，并已取得第三方检测机构CMA与CNAS证书与实验动物许可证证书，并遵循GLP管理的规定运行。

华微检测与中山大学、暨南大学等多家高校合作，建有1600m²的动物实验中心（鼠、兔、猪、犬）、广东省药代动力学研究中心、生物制品分析检测综合服务平台；可为客户提供包括药品、医疗器械、保健食品、生物制品等多领域一站式的质量检测、科学研究及专业技术培训等服务。推进生物医药企业自主创新能力提升和成果快速转化，推动粤港澳大湾区乃至全国生物医药产业集群做大做强。



业务范围

华微检测非临床药效学评价

脑血管疾病、心肺血管疾病、神经系统性疾病、代谢综合征疾病、病原微生物感染试验、肿瘤转移模型

广东省药代动力学研究中心

动物造模与科研服务
非临床PK-PD研究
临床生物样本分析服务

生物制品分析测

分子生物学实验、细胞功能研究、细胞库检测、病毒清除工艺验证

注册咨询平台

政府资源支持
丰富的专家库资源
成熟的咨询平台
注册申报服务

医疗器械科研、检测与注册申报服务

医疗器械生物相容性与可沥滤物研究
医疗器械灭菌效果及环氧乙烷残留
医疗器械临床前药效与药代研究
医疗器械注册咨询

保健品检测服务

原料检测、功能学评价、安全毒理学检验与评价、功效或标志性成分检测、卫生学及稳定性试验等



联系我们

手机：潘工 19128207328（微信同号）
林工 19128209928（微信同号）
吴工 19128209916（微信同号）

官网：www.gdhvt.com
地址：广州市黄埔区揽月路3号F栋106



扫码关注

模型定制

快速小鼠模型

- QuickMice™快速人源化纯合小鼠定制
- QuickMice™快速KO纯合小鼠定制
- QuickMice™快速点突变小鼠定制
- QuickMice™快速KI纯合小鼠定制
- QuickMice™快速CKO纯合小鼠定制
- QuickMice™快速纯合小鼠定制

复杂小鼠模型



- QuickMice™多位点基因编辑小鼠定制
- QuickMice™长片段基因编辑小鼠定制

成品小鼠

nuNPG免疫缺陷小鼠模型

Lamin A早衰小鼠模型

定制流程



明迅生物致力于目前世界上先进的新一代动物模型技术（TurboMice™四倍体补偿技术）的开发和应用。TurboMice™技术突破了小鼠造模周期长和复杂模型成功率低的技术难题。可实现几乎任何目标基因位点的编辑，可短至2个月由胚胎干细胞直接制备完整纯合基因编辑小鼠模型，急研究者之所急，为研究者节约时间。

天下武功，唯快不破，新药同行，选我明迅！



广州明迅生物科技有限公司

电话：400-8388-113

邮箱：sales@mingceler.com

网站：www.mingceler.com

技术支持（微信同号）：18126776342

地址：广州市黄埔区开源大道188号



专注于基因治疗, CRO&CTDMO整体解决方案

PackGene CTDMO Platform: Accelerating your gene therapy from discovery to manufacturing

基因治疗CTDMO一站式服务平台

CTDMO One-Stop Service Platform for GMP Manufacturing

技术优势

Technology advantages

- 从载体构建到IND/BLA一站式服务
One-stop service from vector design and cloning to IND/BLA
- 派真独立IP的细胞株PCA、PCSL0-
PackGene independent IP cell lines PCA, PCSL0-
PackGene independent IP cell lines PCA, PCSL0-
- 高产、稳定、可放大的AAV及质粒、mRNA平台工艺
High-yield, stable, and scalable AAV and plasmid, mRNA platform processes
- 自主高产二质粒生产系统、线性化质粒生产系统
Independent high-yield two-plasmid production system and linearized plasmid production system
- 自主新型AAV衣壳
Autonomous novel AAV capsid

合规

Compliance

- 第三方认可的中试及商业化生产基地
Third-party recognized pilot and commercial production base, approved by NMPA
- 中检院AAV标准品制备方法及检测方法转移方
Regulation of AAV standards and transfer of detection methods to the CMAA
Regulation of AAV standards and transfer of detection methods to the CMAA
- All-in-one内部AD及QC平台
All-in-one internal AD and QC platform
- 严格的客户IP保护体系 ISO27001
Strict customer IP protection system ISO27001



项目经验

Project experience

- 国内最多的AAV IND项目经验
The most AAV IND projects experience in China
- 零发补通过FDA/NMPA中美IND申报
Passed FDA/NMPA zero-complaint applications
- 成功交付15+FDA/NMPA IND申报项目
Successfully delivered 15+ FDA/NMPA IND application projects
- 成功交付中试规模AAV批次>200批
Successfully delivered 200 batches of pilot-scale AAV batches
- 成功交付数十个IND项目
Successfully delivered dozens of IND projects
- CMC、毒理、临床方案的FDA/CTD资料审核及递交
Review and submission of FDA/CTD documents for CMC, toxicology, and clinical studies

高效

Highly efficient

- 基于QbD的高效产品开发体系
Efficient product development system based on QbD
- 中试规模AAV批一次成功率>95%
The success rate of pilot-scale AAV batches > 95%
- 稳定可靠的物料供应链体系
Stable and reliable material supply chain system
- 经验丰富的国内外专业团队
Experienced professional team of home and abroad


CRO平台：“载体设计-生产-分析”一站式服务

CRO platform: one-stop service for vector design, production, and analysis



派真服务优势

PackGene service advantages





企业简介

知易生物是一家立足中国、面向全球的处于临床开发阶段的原创新药研发企业，是中国活体生物药（LBPs）的领跑者，拥有完整的从菌株发现到LBP开发的技术与产业化平台，实现了中国首个采用新一代益生菌（NGPs）的LBP药物进入临床与III期、FDA首次批准基于*Bacteroides fragilis*的LBP进入临床、中国首次批准LBP用于肿瘤治疗的注册性临床研究等行业重大里程碑。

公司建有广东省活体生物药工程技术研究中心，获批“广州市创新领军团队”，获广东省“专精特新中小企业”等荣誉。公司已完成了超4亿元融资，投资机构包括深创投、国投创业、清控金信、粤科金融、韩投伙伴KIP、石药基金、广州开发区基金等国内外知名机构。

产品管线

项目	类别	特色	适应症	Discovery	Pre-clinical	IND	Phase I	Phase II	Phase III
SK08	生物制品1类 (NMFA)	LBP	IBS						
			病毒性腹泻						
			UC						
			肿瘤 (PD1联用)						
SK10	未在人体应用过的生物制剂 (FDA)	LBP	CID						
GMO01	生物制品1类 (NMFA)	LBP	IBD						
ZY19	未在人体应用过的生物制剂 (FDA)	LBP	肿瘤/代谢						
GK01	生物制品1类 (NMFA) (合作开发)	LBP	—						
TP2	生物制品1类 (NMFA)	细菌成分	自身免疫病						
FK01	生物制品1类 (NMFA)	LBP	细菌性阴道炎						

微生态CRO服务简介

微生态产品的研发解决方案

微生物菌株分离、纯化、筛选、鉴定

菌株安全性评价

微生态产品相关检测与质量研究

菌株的培养特性与发酵工艺研究

微生态制剂研究

工程菌（细菌载体药物）的研发

微生态中美注册及法规服务

联系电话 020-82258826

地址:广州市黄埔区瑞泰路2号A栋三层
网址:<https://www.zypharm.com.cn/>



提供无菌生产全方位解决方案

承接委托MAH、中试业务

企业服务



西林瓶



预灌封



卡式瓶

企业简介:

杭州澳亚生物技术股份有限公司是一家集产、学、研为一体，以无菌冻干粉针剂为主导产品的现代化制药企业，年产能力接近5亿瓶，是目前国内大型的注射剂委托加工企业。

主要生产剂型包括西林瓶冻干粉针剂、预灌封、卡式瓶和小容量西林瓶注射剂，终端灭菌及非终端灭菌产品均可承接。

本公司为客户提供全方位的无菌生产解决方案，具备无菌生产与保障实力、透明信息化工厂、个性化技术转移和维护客户商业机密等职业CMO服务要素。



联系人：冯 雅 13588724680
徐汉军 13656638733

扫码了解更多



全自動移液工作站

01.

一觸即動 輕鬆易用

搭載智慧屏幕, 讓實驗室

02.

全新升級 無限適配

全新模組+1/8/96通道
+16個板位, 通量選擇更靈活

03.

開源生態 隨心定制


從編程零基礎 到定製化整合
皆為所用

04.

全球驗證 值得信賴

高精準度, 高穩定性
世界百強知名院校合作驗證

- 我們已經幫助全球範圍內數千個實驗室
完成實驗流程的自動化



多元方案 全方位適配

滿足不同生物科研應用領域的自動化液體處理需求

蛋白質純化

質譜前處理

NGS文庫製備

核酸提取

質粒提取

合成生物學

PCR檢測

分子育種



Opentrons Labworks Inc.
合創生物工程(深圳)有限公司

+86 180 9895 2246

www.opentrons.com.cn

marketing.china@opentrons.com

Opentrons Labworks Inc.

湖南春光九汇 现代中药有限公司

Hunan Brilliance & Abundance Scientific
Chinese Herbal Medicine Co.,LTD

湖南春光九汇现代中药有限公司是湖南省属国有企业湖南医药发展投资集团控股，湖南省中医药研究院参股的一家现代化医药企业。

公司成立于 2001 年，以中药研发制造为主业，主营产品有中药配方颗粒、中药超微饮片及药食同源大健康产品。

先后获得 15 项具有国内领先水平的科研成果及大奖，“中药超微粉体关键技术的研究及产业化”项目获国家科学技术进步二等奖。

公司是湖南省“高新技术企业”、战略性新兴产业百强企业、“专精特新”小巨人企业、省级企业技术中心、省级中药配方颗粒智能标杆车间、湖南省新型研发机构。



Hunan Brilliance & Abundance Scientific Chinese Herbal Medicine Co.,LTD., short for B&A Herbal, established in 2001, is a modern pharmaceutical high-tech provincial state-owned enterprise controlled by Hunan Pharmaceutical Development and Investment Group.

The main products include traditional Chinese medicine (TCM) Concentrated herbal granules, Ultramicro herbal granules and health products.

The products are selected from high-quality authentic medicinal herbs, produced and inspected in strict accordance with the National Pharmacopoeia and GMP specifications.

We have over 550 single-flavored herbs, which are complete in variety and easy to take, and can meet the basic prescription requirements of Chinese doctors. Currently, The products have been used in thousands of hospitals, clinics and pharmacies in China, solving health problems for countless patients and won high praise in the market. In the future, we will continue to provide high-quality products and services to protect people's health.



中药配方颗粒 TCM Concentrated herbal granules

◦ 获得生产备案号556个

中药超微饮片 Ultramicro herbal granules

◦ 全成分入药，有效成分充分释放

药食同源超微饮品 Health products

◦ 超微草本茶，致力于大健康养生

超微®



◀ 扫码了解更多

地址：浏阳市经济技术开发区康平路 10 号

电话：0731-84282828

网址：www.hnccgj.com

邮箱：cgjhsc@163.com

湖南南新制药股份有限公司

Hunan Nanxin Pharmaceutical Co., Ltd.

湖南南新制药股份有限公司是一家专注于流行性感冒等抗病毒、传染病防治药品，以及恶性肿瘤、心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、生产与销售的制药企业。

经过多年的发展，公司逐渐建立起创新药和仿制药结合的研发生态体系，原料药和制剂一体的产业链布局，以及覆盖全国30多个省的营销网络。

公司已经形成了以有重大临床需求的创新药为主、以有市场增长潜力的仿制药为辅的有序产品梯队，拥有36个化学药品品种的58个制剂生产批件和6个原料药生产批件；在研新产品20个，其中1-2类创新药项目7个，一致性评价项目1个，仿制药项目12个。

公司是湖南省省级企业技术中心，于2020年3月在上海证券交易所科创板上市，股票代码688189.SH。

Hunan Nanxin Pharmaceutical Co., Ltd. is a pharmaceutical enterprise dedicated to the research, development, production and sales of antiviral and infectious disease prevention and treatment drugs such as influenza, as well as drugs for the treatment of other major diseases such as malignant tumors, cardiovascular and cerebrovascular diseases, and diabetes.

After years of development, the company has gradually established a research and development system combining innovative drugs and generic drugs, an industrial chain layout integrating APIs and preparations, and a marketing network covering more than 30 provinces across the country.

The company has formed an orderly product echelon dominated by innovative drugs with significant clinical needs and supplemented by generic drugs with market growth potential. It has 58 preparation production approvals and 6 API production approvals for 36 chemical drug varieties. There are 20 new products under research, including 7 Class 1-2 innovative drug projects, 1 consistency evaluation project, and 12 generic drug projects.

The company is a provincial enterprise technology center in Hunan Province. It was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in March 2020, with stock code 688189.SH.



核心研发领域：流感

重点研发领域：


心脑血管疾病 | 糖尿病 | 恶性肿瘤





Hua Medicine
华领医药

控制血糖
稳而有道



华领医药 | 患者为先 创新为本 良药为民

华领医药2011年成立于中国上海,经过十余年探索,率先在葡萄糖激酶激活剂类口服降糖药物领域实现了重大突破,开创出一条**中国新药自主研发**的可行路径。

作为**国内首批药品上市许可持有人(MAH)¹**,华领医药成为了推动创新研发成果快速上市的先行者。

公司核心产品华堂宁®于2022年9月30日获中国国家药品监督管理局(NMPA)批准上市, **改善2型糖尿病患者血糖稳态失调²**,是**全新机制**的口服糖尿病药物³,具有重大突破。



华堂宁®(多格列艾汀片)

是异位变构葡萄糖激酶(GK)全激活剂,作用于胰岛、肠道内分泌细胞以及肝脏等葡萄糖储存与输出器官中的葡萄糖激酶靶点,改善2型糖尿病患者受损的葡萄糖刺激的胰岛素和GLP-1分泌,进而**改善β细胞功能,减低胰岛素抵抗,从而改善2型糖尿病患者血糖稳态失调**,具有**重塑血糖平衡生理调节**的作用机制。

1. MAH - Marketing Authorization Holder

2. NMPA, 2022 <https://www.nmpa.gov.cn/directory/web/nmpa/yaopin/yypjgd/20221008173753169.html>

3. Klein, K.R., Buse, J.B. A new class of drug in the diabetes toolbox. Nat Med 28, 901-902 (2022).



400-820-5552



<https://www.huamedicine.com/>

让每一个生命健康有为
Make Every Life Healthy and Promising!

应用

Applications

Infectious Disease

- ☒ COVID 19
- ☒ Influenza A & Influenza B
- ☒ HIV

Oncology

- ☒ Gastric Cancer
- ☒ Colon Cancer
- ☒ Colorectal Research
- ☒ Liquid Biopsy Technologies

Eugenics & Good Parenting

- ☒ PGT
- ☒ NIPT
- ☒ Neonatal

Other

- ☒ Scientific Research
- ☒ Forensic
- ☒ Veterinary

核心产品

Flagship
Products

Cell-Free
DNA Storage
Tube

Single Cell
WGA Kit

Magbead
Free-Circulating
DNA Maxi Kit

专业分子原料及
体外诊断试剂供应商

Professional Supplier of
Molecular Raw Materials and IVD Reagents

PCR Enzymes

Nucleic Acid Extraction Kits

NGS Library Preparation

Sample Collection &
Stabilization Tools



关注微信公众号:
@康为世纪生物

Subscribe to our
WeChat official
account!

Contact Us:

4006-222-360

<https://www.cwbio.com/>

@Jiangsu Cowin Biotech Co.,Ltd

@CoWin Biotech Co.,Ltd



凯斯艾生物科技（苏州）有限公司

KCI Biotech (Suzhou) Inc.



药效学疾病模型

- 心脑血管系统疾病模型
- 中枢神经系统疾病模型
- 呼吸系统疾病模型
- 肝脏、代谢系统疾病模型
- 泌尿系统疾病模型
- 自身免疫、炎症模型
- 肿瘤模型



大动物研究平台

- 心梗、心衰模型
- 脑卒中、帕金森模型
- 呼吸 ARDS、哮喘模型
- NASH、Fibrosis 模型
- 干细胞及基因治疗评价服务
- 关节炎、疼痛模型
- 器械植入评价模型



病理学/影像学服务平台

- 组织病理
- 免疫组化
- 分子病理学
- 智能数字病理
- 病理(云端)阅片
- 组织微阵列(TMA)
- 核磁共振(MRI)
- 断层扫描(CT)
- 超声检测(B超)



药代动力学 / 毒理学平台

- 药代动力学研究
- Non-GLP 毒理学研究
- 毒代动力学研究



ABSL2 (P2) 服务平台

- 小动物 ABSL2 屏障设施
- 大动物 ABSL2 设施
- 疫苗研发服务
- 感染模型服务
- 基因治疗服务



医疗器械服务平台

- 介入性医疗器械疗效评价
- 医疗器械安全性评价
- 医疗器械生物检测分析

企业介绍

COMPANY PROFILE

凯斯艾生物科技（苏州）有限公司及其全资子公司江苏珂玛麒生物科技有限公司是一家新药研发临床前 CRO 服务公司，在苏州和海门两地建立了一家集药效学评价、药代动力学评价、NON-GLP 毒理学评价、医学影像学评价及病理学评价为一体的符合国际标准的综合性技术服务平台。动物实验设施获得了 AAALAC（国际动物评估与认证协会）认证，动物模型种类涵盖大小鼠、兔、豚鼠、非人员长类、犬和猪。

目前，KCI&KMQ 正承载着来自 300+ 合作伙伴的新药研发项目，以技术为先导，以客户为中心，通过高质量和高性价比的研发服务，助力合作伙伴成功开发新药。

凯斯艾生物科技（苏州）有限公司
KCI Biotech (Suzhou) Inc.

江苏珂玛麒生物科技有限公司
Jiangsu KMQ Biotech Inc.

地址：江苏省苏州市工业园区金鸡湖大道 99 号纳米城·西北区 12 栋 501
江苏省南通市海门市临江镇洞庭湖路 100 号 B4 栋

电话：0512-69998806/13524244224

邮箱：BD@kci-biotech.com

网址：<https://www.kci-biotech.com/>



穆恩制药设备（杭州）有限公司

Moon Pharmaceutical Equipment (Hangzhou) Co., Ltd.

公司简介:

穆恩制药设备（杭州）有限公司成立于2016年11月，位于美丽的杭州医药港小镇，是一家专业从事制药装备和服务于制药公司的高新企业。公司积极开展与浙江大学、中国药科大学、华东理工大学等知名院校的交流合作，坚持“以科学理论为基础，以市场需求为目标”的战略，打造出一支高素质的技术团队。致力于以客户为导向，以质量为基本，为解决生物制药研发实验室高端设备及中小试高端分装设备不断创新前行。

Moon Pharmaceutical Equipment (Hangzhou) Co., Ltd., founded in November 2016 and located in the beautiful Hangzhou Medical port town, is a high-tech enterprise specializing in pharmaceutical equipment and services for pharmaceutical companies. The company actively carries out exchanges and cooperation with Zhejiang University, China Pharmaceutical University, East China University of technology and other well-known universities, adheres to the strategy of "taking scientific theory as the basis and market demand as the goal", and creates a high-quality technical team. We are committed to customer-oriented, quality-oriented, and continuous innovation to solve the problems of high-end equipment in biopharmaceutical R & D laboratories and high-end sub packaging equipment in small and medium-sized trials.

地址：浙江省杭州市钱塘区下沙街道福城路501号银海科创中心23幢

Address: Building 23, Yinhai Technology Innovation Center, 501 Fucheng Road, XiaSha Street, Qiantang District, Hangzhou city, Zhejiang Province

电话：0571-86826995

Tel: 0571-86826995

网址：www.hz-moon.com

Website: www.hz-moon.com



Intelligent Protection of Life Science through Digital Services, Products and Solutions

Company Profile

As a Global Innovative Life Science and Medical Digital Service Ecosystem Brand, Haier Biomedical is committed to the intelligent protection of life science and safety by delivering superior products and services.

Our goal is to build the best user ecology experience through scientific and IoT technical innovations and scenario services, creating an ecosystem to provide a panorama of safe and convenient services for all, to make life better through the intelligent protection of Life Science.

Company Advantages



Service

140+
Countries & Regions



Technology

1300+
Intellectual Property Patents



Product

300+
Certified Medical Devices



Qingdao Haier Biomedical Co.,Ltd.

No.280 Feng Yuan Road, High-tech Zone,
Qingdao, 266109, P.R. China

E-mail: inquiry@haierbiomedical.com

Website: www.haiermedical.com



Haier Biomedical
International



Haier Biomedical
International



@haiermedicalint



Haier Biomedical
International



Haier Biomedical
International

通过物流 拥抱健康生活



擎天医药冷链物流是一家获得GDP认证的物流服务供应商，专门为制药、生物技术和生命科学产品提供储存和运输服务。



我们的服务

我们对每一次冷链运输采用风险安全评估方法，以达到行业内最高标准

致力於良好配送规范

我们通过ISO9001:2015、ISO45001:2018、ISO14001:2015和GDP认证



- 质量管理体系
- 经过验证的流程
- 风险管理
- 持续培训和改进
- 标准作业程序 (SOP) 和客户主导作业流程 (COP)



细胞和基因供应链



临床试验物流



制药和原料药



生物和传染性物质



生物制药和医疗器械



仓储和配送

提升實驗動物福利-令生命更有尊嚴

公司簡介 & 主營業務：

ReadyDietech 致力於為實驗動物提供各種新形態的營養補充品和全營養膳食替代物，為研究人員實現的研究目的，並提高實驗動物的總體福利水平。其主要產品包括替代傳統粗飼料嘅純化原料顆粒狀代餐產品Ready Bite, 用于動物疾病預防和治療、術後恢復同運輸過程中補充水分營養嘅啫喱狀代餐產品Ready Jelly, 以及專門為無菌動物研發嘅營養奶粉或人工乳Ready Powder。我們所有產品都是用精煉的原料按照精準的配方經過特殊的工藝做成，批次間營養素誤差不超過0.5%，確保您的實驗的可重複性、可修改性和可報道性。

產品：



實驗動物純化造模飼料Ready Bite® (Lab Animal Purified Diet)

實驗動物功能啫喱Ready Jelly® (Lab Animal Functional Gel)

實驗動物人工乳 Ready Powder® (Lab Animal Artificial Milk)

特点：

1. 優勢在於

· 價格合理 · 供貨穩定 · 物流有保障 · 專業技術 & 服務團隊跟進售前售後

2. 技術先進，自主知識產權。技術團隊來自美國，有自主研發功能凝膠配方和生產工藝，超高脂飼料成粒機器和工藝，人工乳粉配方等。

3. 擁有Ready Bite®, Ready Jelly®, Ready Powder®獨家商標權，分別對應顆粒飼料，功能凝膠和功能人工乳粉三條產品線。

聯繫我們：

Sales Director: Eric Huang

Mobile\WhatsApp: +86 18666627970

E-mail: erich@readydietech.com

Website: <https://www.readydietech.com/en/>

依托卓越医生平台的 医学学术及数字化的高效驱动能力

十余年深耕医学领域，积极拥抱数字化AI时代

梅斯医学隶属于梅斯健康(2415.HK)，依托积累十余年专业的互联网医生平台，应用大数据和人工智能技术链接医生、患者和药械企业，提供数字化解决方案，赋能医疗生态，改善医疗质量。

业务包括医生平台解决方案、RWS解决方案、精准全渠道营销解决方案、APO创新数字化营销解决方案、医院数字化科研平台解决方案以及VITA GLOW皮肤健康精准管理平台，为创新药械企业提供医学、市场、准入和传播一站式数字化解决方案。

600+

员工

150+

硕士及以上
学历团队

450万+

平台注册会员

300万+

注册医生用户

280万+

每月活跃用户

证据产生



临床研究

向医生提供临床研究
辅助服务
提供有针对性的**解决
方案及指导**



真实世界研究

向药械企业提供产品
安全性及有效性的
**真实世界循证研究
(RWS)服务**

300万
注册医生用户



MedSci 梅斯

中国领先的在线
专业医生平台



280万平均每月
活跃用户

证据传播



全渠道营销

精准、高效地向目标
医生群体推送**学术医
疗内容**



医学知识传播

帮助医生学习及分享
医疗市场**最新医学知
识信息及医学证据**



医学决策支持


医学证据经传播后
可广泛支持医学决策
进而**改善医疗质量**



梅斯医学



梅斯智库



美迪西 一站式医药临床前研发服务平台 (CRO)

加速您的新药研究进程!

美迪西成立于2004年，总部设立于上海，是一家专业的生物医药临床前综合研发服务CRO（合同研究组织），致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务，不断推动新药研究的进程。2019年11月5日，美迪西正式登陆科创板，成为科创板首家上市的医药CRO企业（股票代码：688202）。

20⁺年

新药研发经验

2600⁺名

新药研发科学家及研发服务人员

2000⁺家

全球范围内活跃客户

85000⁺m²

研发实验室

服务范围

- 药物化学
- 定制合成
- 放大合成
- 新药开发新技术
- 重组蛋白表达与纯化
- 结构生物学平台
- 计算生物学和分子模型构建
- 体外生物学

- 肿瘤模型
- 消化系统模型
- 炎症模型
- 神经系统模型
- 内分泌代谢模型
- 其他模型
- 体内DMPK研究
 - 吸收/分布/代谢/排泄
 - 组织分布
 - 物料平衡等
- 体外ADME研究
 - P450抑制和诱导
 - 血浆蛋白结合
 - 转运体抑制等
- 一般毒理学
- 毒代动力学
- 安全药理学
- 生殖毒性
- 遗传毒性
- 免疫原性
- 致癌性

药物发现

药学研究

临床前研究

IND申报

- 原料药工艺
- 原料药质量
- 原料药放大生产
- 原料药申报
- 处方前研究
- 处方工艺开发
- 制剂中试放大
- 质量研究及稳定性研究
- 申报资料撰写

- FDA
- NMPA
- EMA
- TGA



美迪西 Medicilon



美迪西 Marketing



美迪西 生物招聘

网址: www.medicilon.com 电话: +86 (21) 5859-1500
邮箱: marketing@medicilon.com.cn

服务热线: 400-780-8018

上海市生物医药产业促进中心

Biopharma Industry Promotion Center Shanghai

上海市生物医药产业促进中心成立于2021年8月，是上海市科学技术委员会直属事业单位，是落实上海市生物医药产业发展领导小组和上海市生物医药产业推进工作专班目标任务办事机构。

中心根据上海市委和市政府关于生物医药产业发展规划和战略部署，以促进上海生物医药产业高质量发展为使命，打造具有全球影响力的生物医药产业高地和产业集群。

创新创业
赛事

审评
审批
服务

临床
试验
加速器

产医
融合

投融资
对接

上海国际
生物医药
产业周

人才
培养
和服务

投资促进
伙伴计划

特殊
物品
通关

产业服务与孵化加速



招商引资与项目落地



国际交流与会务合作



产业分析与课题研究



成果转化与技术转移



Brilliance
追求卓越

Innovation
守正创新

Persistence
务实笃行

Cooperation
合作共赢

《企业成长的
陪伴者

《产业生态的
营造者

《生命健康的
守护者



藥明巨諾

藥明巨諾(港交所代碼: 2126)是一家獨立的、創新型的生物科技公司,專注於研發、生產及商業化細胞免疫治療產品,並致力於以創新為先導,成為細胞免疫治療引領者。創建於2016年,藥明巨諾已成功打造了國際領先的細胞免疫治療的綜合性產品開發平臺,以及涵蓋血液腫瘤、實體腫瘤和自身免疫性疾病的細胞免疫治療產品管線。藥明巨諾致力於以突破性、高品質的細胞免疫治療產品給中國乃至全球患者帶來治癒的希望,引領中國細胞免疫治療產業健康規範發展。

倍諾達®

倍諾達®(瑞基奧倫賽注射液)是藥明巨諾在巨諾醫療(一家百時美施貴寶的公司)的CAR-T細胞工藝平臺的基礎上,自主開發的一款靶向CD19的自體CAR-T細胞免疫治療產品。

源於
國際平臺

忠於
中國患者

優於
製備工藝



本圖僅為示意圖

倍諾達®已被中國國家藥品監督管理局准予三項適應症:

- ▶ 經過二線或以上系統性治療後成人患者的復發或難治性大B細胞淋巴瘤
- ▶ 經過二線或以上系統性治療的成人難治性或24個月內復發的濾泡性淋巴瘤
- ▶ 經過包括布魯頓酪氨酸激酶抑制劑治療在內的二線及以上系統性治療的成人復發或難治性套細胞淋巴瘤



上海益诺思生物技术股份有限公司成立于2010年,是一家专业的提供生物医药非临床研究服务为主的综合研发服务(CRO)企业,秉承“科学引领,质量唯先,诚信敬业,合作共赢”的核心价值观,以创新促发展、以质量求生存、以信誉赢客户、以管理创效益。公司具备行业领先的国际化服务能力,与国际标准接轨,为全球医药企业和科研机构提供全方位的、符合国内及国际申报标准的一站式新药研发服务。

60,000+
现代化设施

1000+
在职员工

上海(总部)
18000+平方米

南通
30000+平方米

美国旧金山

深圳
10000+平方米

黄山
100+亩

NMPA GLP 认证

U.S. FDA GLP 检查

OECD GLP 认证

AAALAC 认证

美国CAP认证

覆盖药物PCC-IND-NDA生命周期



PCC



- 早期成药性评价



IND



- 非临床药效学
- 非临床药代动力学
- 非临床安全性评价



NDA



- 临床生物样本分析
- 生物标志物与转化研究

覆盖与贯穿药物研发全链路的, 专家领衔的个性化研究方案设计服务

770+ 家

已服务
新药研发客户

100+ 个

年均IND package
完成量

30+ 个

年均NDA/BLA package
完成量

2 例

FDA NDA/BLA
获批

20 例

NDA/BLA
获批

数据更新至2023.12

上海益诺思生物技术股份有限公司

上海总部

中国(上海)自由贸易试验区郭守敬路199号

业务咨询

电话: +86-21-60211999

邮箱: services@innostar.cn / marketing@innostar.cn



扫码关注
益诺思视频号




扫码关注
益诺思公众号

- First & Now-only 3D Disease Modeling in China
- One-Stop Complex in vitro Model Solution Provider
- Partnership with FDA / EMA / MNC for Standardizing NAM

BIOCAST's vision is to become the standard of 3D disease modeling company, on the pathway leading from disease biology to breakthrough for therapeutics tomorrow.


We work with biopharmaceutical clients of all sizes, from start-ups to established, global organizations, developing and implementing high-content imaging-based, phenotypic cellular assays for lead optimization, mechanism-of-action studies, and target validation for preclinical models.

State-of-the-Art Facilities and Experts



BOOTH NO.3E-B13

End-to-End in vitro Services for Drug Development





AlpalifeBio™
康体生命

Customized VHH Antibody Discovery

About Us

"7+ Years Full-Service CRO."

"Only naïve camelids will be used for immunization."

Best Services

Alpaca Immunization
Yeast & Phage Display
Antibody Expression
Humanization Maturation



alpalifebio.com

深圳靈賦拓普生物科技有限公司 Shenzhen TopBiotech Co., Ltd.

致力於成為全國實驗動物科研服務領跑品牌
Committed to becoming the leading brand of experimental animal research services in China



深圳靈賦拓普生物科技有限公司(簡稱靈賦拓普)成立於2015年,是一家專注動物科研,服務臨床前研究與評價的創新型CRO企業。公司以動物模型為核心,同時開展細胞、病理、蛋白、分子、生化、行為學等一站式服務,賦能生命科學和生物醫藥研究。

靈賦拓普在深圳南山、光明、坪山及廣州擁有研發基地及實驗動物中心,提供醫療器械評價、大小動物模型開發、藥物篩選與評價、動物飼養等臨床前CRO服務。先後獲得國家高新技術企業、專精特新企業、質量管理體系等榮譽認證。

公司具有核心研發和專業技術團隊,致力於成為全國動物科研服務領跑品牌,實現“願天下沒有難治的疾病”美好願景。

Founded in 2015, Shenzhen TopBiotech Co., Ltd. is an innovative CRO enterprise focusing on animal research and serving pre-clinical research and evaluation. The company takes animal models as the core, and carries out one-stop services such as cell, pathology, protein, molecule, biochemistry and behavior, enabling life science and biomedical research.

TOPBIOTECH has research and development bases and laboratory animal centers in Nanshan, Guangming, Pingshan and Guangzhou, providing pre-clinical CRO services such as medical device evaluation, large and small animal model development, drug screening and evaluation, and animal breeding. It has successively obtained the honorary certification of national high-tech enterprises, specialized and new enterprises, quality management system and so on.

The company has a core R & D and professional technical team, and is committed to becoming the leading brand of animal research services in the country, realizing the beautiful vision of "wishing there is no refractory disease in the world".

技術平臺與產品

TECHNOLOGY PLATFORMS AND PRODUCTS



深圳坪山生物医药产业加速器园区




坪山生物医药产业加速器园区位于坪山高新区国家生物产业基地内，园区将打造集生物医药产业研发、孵化、生产和多功能配套于一体，城市功能与产业要素相结合的综合型生物医药产业园。园区定位为全国领先的综合型生物医药产业示范区、深圳市生物医药发展核心增长极、产城融合的现代“生物科技新城”。

12 研发楼

标准层面积: 1512.55-2265.19m²

楼层	层高	荷载
1F	5.5/7.5m	0.8t/m²
2F	7.6/9.1m	0.45t/m²
3F	4.3m	0.45t/m²
4-5F	5.1m	0.35t/m²
6F	5.1m	0.5t/m²
7F	4.5m	0.5t/m²
8-12F	4.5m	0.8t/m²



5/9 生物医药加速器生产厂房

标准层面积: 1632.06-3349.62m²

楼层	层高	荷载
1F	6.9m	1.2t/m²
2-12F	4m	0.8t/m²



6 实验动物房

标准层面积: 2231.87-2870.11m²

楼层	层高	荷载
1F	6.9m	1.2t/m²
2-7F	5.7m	0.8t/m²



- 聚焦神经系统疾病领域人工智能及数字诊疗
- 超过11年创新及积累, 公司拥有**全球唯一**该领域完整**诊疗闭环技术体系**
- 国家高新技术企业、专精特新企业、科技型企业
- 所有产品获得**中国NMPA、美国FDA及欧洲CE Medical**医疗注册证
- 全面推动中国帕金森病领域新理念发展**深度承载中国帕金森病专科建设及国家帕金森病临床质控**
同时相关**技术纳入《中国帕金森病治疗指南》**



睿评 MATRIX Pro

下一代神经系统疾病智能评估平台

面向神经系统疾病

面向**运动功能及运动症状量化评估、量表智能评分、疾病分类分析及早期概率计算**

X Perception

融合感知

机器视觉感知&可穿戴感知&语音感知

Smart UPDRS

灵动慧评

全球唯一完整智能评分

Movement Insights

动见

60+个量化特征、30+种直观图表

Mobility Q

运动量点

240+量化指标



睿餐 BRAVO

智能防抖勺

轻松吃放, 找回自信

实时感知
震颤状态主动稳定
进食辅助

睿行 SKYWALK

冻结步态辅助系统

说走就走, 解放双脚



自动识别

主动干预

恢复行走



生物器材网

www.bio-equip.com

生物仪器、试剂、耗材和技术服务的专业信息平台



扫一扫关注微信号



服务领域

生命科学, 医学研究, 生物制药, 生物工程, 现代农业, 食品安全, 环境监测, 公安司法等



产品范围

仪器设备、试剂、耗材、实验动物、细胞株、生物技术服务



访客来源

大学、研究所、医院、制药厂、疾控中心、检验检疫、环保、食品检测、公安、仪器生产制造、销售、代理、经销商等机构和企业

为生命科学服务，为优质厂商服务

35000⁺
厂商用户

120 万⁺
产品信息

20 万⁺
在线询价

全球首個

血尿同測移植液體活檢技術

雙重保險

技術驗證+臨床驗證

核心發明專利

23項核心專利為診斷護航

適用人群



肌酐波動患者，鑒別排斥因素是否存在；或肌酐不升高但抗體或尿蛋白陽性或藥物濃度查直偏低



BK病毒攜帶，需早期診斷；或BKVN患者處於調藥期，肌酐波動



PRA陽性，但供體HLA基因分型不明；或術後3-6個月懷疑有亞臨床排斥患者



病原菌感染和排斥混合的患者，需同時明確致病菌及排斥風險



電話：186 2619 7911

官網：www.allograftdx.com

更多檢測項目， 護航移植全程



遺傳性腎髒病 全外顯子檢測

- Alport 綜合征 (遺傳性腎炎) 基因檢測
- 薄基底膜腎小球病基因檢測
- 高草酸尿症基因檢測
- 移植相關 TMA (TA-TMA) 基因檢測
- 激素抵抗性腎病綜合征基因檢測

移植相關 抗體檢測

- PRA 抗體檢測
- MICA 抗體檢測
- Nephritin 抗體檢測
- 抗磷脂酶A2受體抗體檢測 (PLA2R)
- HLA-DSA 檢測
- 抗GBM抗體檢測
- C5b-9 抗體檢測

HLA 基因分型檢測

- 無創HLA分型檢測
- HLA分型-NGS
- HLA分型-SBT





项目清单 Project List

项目分类 Project Classification	项目清单 Project List		
乳膏/软膏/凝胶类 Cream/Ointment/Gel	1. 利多卡因乳膏(已获批) 1. Lidocaine and Prilocaine Cream	14. 卢立康唑乳膏 14. Luliconazole Cream	27. 莫匹罗星软膏 27. Mupirocin Ointment
	2. 阿达帕林凝胶(已注册申报) 2. Adapalene Gel	15. 曲安奈德益康唑乳膏 15. Triamcinolone Acetonide and Econazole Nitrate Cream	28. 克立硼罗软膏 28. Crisaborole Ointment
	3. 夫西地酸乳膏(已注册申报) 3. Fusidic Acid Cream	16. 布洛芬乳膏 16. Ibuprofen Cream	29. 双唑泰乳膏 29. Metronidazole, Chlorhexidine and Chlorbutolol Acetate Cream
	4. 过氧化苯甲酰凝胶(已注册申报) 4. Benzoyl Peroxide Gel	17. 阿昔洛韦氯化可的松乳膏 17. Acyclovir and Hydrocortisone Cream	30. 卡泊三醇软膏 30. Calcipotriol Ointment
	5. 阿达帕林过氧化苯甲酰凝胶(已注册申报) 5. Adapalene and Benzoyl Peroxide Gel	18. 氢醌乳膏 18. Hydroquinone Cream	31. 复方多粘菌素B软膏 31. Compound Polymyxin B Ointment
	6. 盐酸阿莫罗芬乳膏 6. Amorolfine Hydrochloride Cream	19. 糠酸莫米松乳膏 19. Mometasone Furoate Cream	32. 盐酸丁卡因凝胶 32. Tetracaine Hydrochloride Gel
	7. 咪康唑硝酸酯乳膏 7. Miconazole Nitrate Cream	20. 丙酸氟替卡松乳膏 20. Fluticasone Propionate Cream	33. 壬二酸凝胶 33. Azelaic Acid Gel
	8. 利多卡因丁卡因乳膏 8. Lidocaine and Tetracaine Cream	21. 磷卢司可替尼乳膏 21. Busulfinitib Phosphate Cream	34. 酮洛芬凝胶 34. Ketoprofen Gel
	9. 克林霉素乳膏 9. Clascoterone Cream	22. 复方他米松糠酸乳膏 22. Compound Betamethasone Dipropionate and Cantharol Cream	35. 雌二醇凝胶 35. Estradiol Gel
	10. 伊维菌素乳膏 10. Ivermectin Cream	23. 曲咪新乳膏 23. Triamcinolone Acetonide and Nicotinic Nicotinamide Lotion Cream	36. 黄体酮阴道缓释凝胶 36. Progesterone Sustained-release Vaginal Gel
	11. 维A酸乳膏(氟芬松/维A酸/维他命A乳膏) 11. Fluorouracil acetonide, Hydroquinone and Retinoin Cream	24. 多磺酸粘多糖乳膏 24. Mucopolysaccharide Polysulfate Cream	37. 盐酸利多卡因凝胶 37. Lidocaine Hydrochloride Gel
	12. 尿素乳膏 12. Urea Cream	25. 氟维司酮乳膏 25. Fulvestrant Cream	38. 硝酸夫那唑和克霉唑阴道乳膏 38. Nifuratel and Nystatin Vaginal Cream
	13. 盐酸特比萘芬乳膏 13. Terbinafine Hydrochloride Cream	26. 卡泊三醇倍他米松乳膏 26. Carboptriol Betamethasone Ointment	39. 双氯芬酸二乙胺乳剂 39. Diclofenac Diethylamine Emulgel
贴剂 Patches	1. 利多卡因凝胶贴膏 1. Lidocaine Cataplasms	4. 双氯芬酸贴剂 4. Diclofenac Epilamine Patch	7. 奥昔布宁透皮贴剂 7. Oxybutynin Transdermal System
	2. 双氯芬酸钠贴剂 2. Diclofenac sodium patch	5. 洛索洛芬钠凝胶贴膏 5. Loxoprofen Sodium Cataplasms	8. 妥洛特罗贴剂 8. Tulobuterol Patches
	3. 氟比洛芬凝胶贴膏 3. Flurbiprofen Cataplasms	6. 洛索洛芬钠贴剂 6. Loxoprofen Sodium Patches	9. 雌二醇贴片 9. Estradiol Patch
其他 other	1. 非那雄胺喷雾剂 1. Finasteride Spray	5. 盐酸特比萘芬溶液剂 5. Terbinafine Hydrochloride Pigment;	9. 艾氟康唑外用溶液 9. Eflconazole Topical Solution
	2. 盐酸阿莫罗芬溶液 2. Amorolfine Hydrochloride Liniment	6. 咪康唑硝酸酯喷雾剂 6. Econazole Nitrate Spray	10. 利多卡因喷雾剂 10. Lidocaine Spray
	3. 联苯苄唑溶液 3. Bifonazole Solution	7. 酮甲咪唑乳膏 7. Simeticone Emulsion	11. 盐酸氯氮卓外用散剂 11. Azimilofoline Acid Hydrochloride for Topical Powder
	4. 盐酸特比萘芬喷雾剂 4. Terbinafine Hydrochloride Spray	8. 利多卡因/普鲁卡因喷雾剂 8. Lidocaine Prilocaine Cataplasma spray solution	12. 美沙拉嗪栓 12. Mesalazine Suppositories

Company Snapshot



Leadership

Renowned Scientific Founder
Seasonal Management Team



Platform

Highly Efficient AAV Cassette
BBB-penetrant AAV Capsid Discovery



Pipeline

Rare and Common Diseases
Leading AAV GTx for Hemophilia A



Manufacture

FDA-compliant In-house GMP Facility
Flexible and Scalable

Assets in Development

Liver-targeting



GS1191

Hemophilia A

Pivotal trial
in 2025 Q1

GS1168

Phenylketonuria

IND filing in 2025

GS1196

Hereditary Angioedema

PCC in 2025

CNS Diseases



Asset 1

Parkinson's disease

Asset 2

Alzheimer's disease

Asset 3

Huntington's Disease

Metabolic
Disorders



Asset 1

Asset 2

Asset 3

為中華之屹立

人民喜樂康健

概况 Overview

苏州生物医药产业园于2007年6月开园，是苏州工业园区为发展生物医药产业而建立的专业科技创新载体。历经17年的发展，已建成载体350万平方米，汇聚620余家各类生物医药创新企业，形成了创新药物、高端医疗器械与体外诊断、生物技术三大重点产业集群。随着“国家生物药技术创新中心”的建立，未来苏州生物医药产业园将紧密跟踪细胞与基因治疗、核酸药物、AI制药、医疗机器人、创新IVD诊断、心脑血管植入医疗器械等医药前沿技术，以全新的载体物理空间、全新的公共服务平台、全新的产业生态环境继续为苏州工业园区生物医药产业的发展、为人类的健康生活做出新贡献。

● 企业融资
超1000亿元

● 上市企业
24家

● 生物医药产业综合竞争力
位列**全国第一**

● 集聚生物医药企业
超620家

● 专业人才总量
超4万人

生物医药及高端医疗器械集群入选国家工信部
先进制造业集群



生物药品制品制造创新型产业集群获批国家级
创新型产业集群

人才资源 High-Level Talents



产业集群 Industrial Cluster



新药成果转化 Transformation Of New Drug Achievements



累计**45**款药物上市
其中**8**款为1类新药
创新药**15**款进入国家医保

器械成果转化 "绿色通道" 企业 Instrument Achievement Conversion "Green Channel" enterprises



注册证 Registration Certificate





早獭生物
MARMOT BIO



VIEWGENE
惟佑基因



动物相关实验

大小鼠、兔子、猫模型构造

常规给药、眼内给药、

眼科检查、血液检测、常规检测

动物代饲养

免疫健全小鼠、免疫缺陷小鼠

大鼠、兔子、扩繁

实验室租赁

生物安全实验室二级

配置生物安全柜、大小鼠笼架

细胞与病毒

293T转染后蛋白表达WB检测

转染后蛋白表达免疫荧光检测

转染后RT-QPCR mRNA水平

表达分析，病毒的包装纯化

AAV基因组滴度检测分析

病毒对视网膜的感染能力检测



猫冠状病毒模型

猫细小病毒模型

猫疱疹病毒模型

小鼠人源化模型

肿瘤动物模型

代谢疾病模型

生殖类疾病模型

神经类模型

小鼠眼科模型

苏州早獭生物科技有限公司

联系人：李女士

联系电话：+86-15840245131/+853-68915310

联系地址：苏州工业园区生物医药产业园

一期A2楼208单元





企业简介

苏州雅深智慧科技有限公司成立于2021年6月，是一家数据驱动型人工智能新药研发初创公司，致力于通过前沿的技术加速新药的发现和开发。我们的使命是利用高质量的药物研发数据和最先进的AI算法和计算模型，提供高效、精准的药物设计方案，助力制药企业和科研机构更快地发现具有潜力的候选药物。我们以创新为核心，旨在成为全球药物研发领域的领导者。



产品介绍

雅深智慧已经建立了一站式的药物研发平台，包括两大核心产品：以数据为主的PharmaNexus平台和以计算为主的AMD平台，涵盖了早期药物研发的全链条。通过以高质量数据指导算法开发，同时打通了各个数据库与计算工具的通道，颠覆了传统制药行业模式，更好地帮助科研团队和药物研发企业实现创新型药物研发。

雅深智慧WEB平台



数据 触手可及

雅深智慧从全球文献和专利中深度挖掘数据，利用大预言模型和我们独有的算法正确地实时地提取了药物、靶点、疾病、突变等实体和关系，形成了知识图谱，获取药物知识的全景图，帮助研究人员揭示隐藏的关系和洞察潜在的机制，在靶点发现和适应症的选择上做更好的决策。尤其是在GPCR、激酶等细分领域，利用蛋白结构和活性数据在计算平台进行计算、比对、溯源、分析等工作，帮助快速发现具有靶点选择性的药物分子。

模式 全面解析

雅深智慧对药物与靶点结合模式识别做了深入的研究，利用先进的人工智能和机器学习技术，从蛋白质-小分子复合物晶体结构中挖掘其作用关系，识别其药效团模式，帮助研究人员筛选出与靶点有良好结合模式的候选药物分子。同时也通过构效关系分析工具和ADMET分子对工具解析药物结构中的基团贡献，在优化分子结构、提高候选化合物的成药性上有至关重要的作用。

计算 得心应手

雅深智慧提供了包括靶点口袋发现、分子生成&优化、分子对接、自由能微扰、分子动力学模拟等计算工具，同时利用机器学习、强化学习等先进算法，结合传统的量子化学计算，实现了高效实用的药物设计。同时将计算平台与雅深智慧的高质量数据库联用，实现了从靶点挖掘预测到临床前化合物评估的一系列工作，降低了使用门槛，提高了结果的准确度，显著降低研发成本和时间。

数据整合挖掘



高效精准计算



人工智能引领



功能持续开发



Athena Pharma Intelligence
苏州雅深智慧科技有限公司



+86-0512-66967885



BD@atelligence-ai.com



中国江苏省苏州市苏州工业园区星湖街218号

ROMEGA

挪威魚籽油

NATURE'S FINEST BEST Omega-3 AVAILABLE

富含磷脂DHA 穿越生物屏障

 挪威原裝進口



ROMEGA神經營養素

ROMEGA孕婦DHA

ROMEGA視覺營養素

ROMEGA®

專注人類腦眼健康的醫學營養品牌



純淨海域 優質原料

源於北冰洋純淨海域
甄選銀海黃金-鯊魚籽



專利技術 卓越品質

物理溫和專利提取技術
雙重國際權威檢測認證



天然成分 高效吸收

富含天然磷脂Omega-3
主動穿越生物屏障



關鍵營養 直達大腦

滿足孕產婦、成人、兒童青少年
等全年齡段人群的营养需求



ROMEGA官方公眾號

歐洲上市醫藥企業Arctic BioScience (股票代碼: ABS) 榮譽出品



特勒姆瑟營養科技(香港)有限公司
TROMSO NUTRITION TECHNOLOGIES (H.K.) LIMITED

百年老牌

天喜堂天喜丸®



改善女性体质
舒缓周期性不适
100%香港制造
天然草本成份安全有效



天喜堂 藥廠有限公司

Tin Hee Tong Medicine Factory Limited

香港柴湾新业街 6 号安力工业大厦

联系人: 骆小姐

电话: +852 6114 4128

Email: alice@tinheetong.com



打造健康全产业链

Create a healthy whole industry chain

引领健康新方向

Lead the new direction of health



威海食德源生物科技有限责任公司

Weihai Shi de Yuan Biotechnology Co

Add: 山东省威海市荣成市滕家工业园

Tengjia industrial park, Rongcheng, Weihai

Tel: 0631-7680988

先思达生物是一家以糖组学为核心基础，集体外诊断试剂与仪器的研发、生产、销售为一体的生物医药企业。专注于肿瘤诊断及生理健康两大领域，拥有自主知识产权的 GlyFace® 糖组检测技术平台和 GlySeer® 糖组数据分析平台，产品管线涉及肿瘤、神经退行性疾病及生理状态评估等。

洁太司® 肝癌辅助诊断

国械注准20243400663
国家创新医疗器械产品

对人体血清中的糖链进行检测，通过分析得到相应数值，评估肝癌，辅助临床诊断。



高灵敏度和高特异度

临床试验结果表明，与临床诊断 / 病理诊断结果比较，洁太司® 灵敏度达 **89%**，特异度达 **95%**。

用于肝癌早期诊断

洁太司® 对肝癌的检测不受肿瘤分期的限制，对于早期肝癌同样具有较好的灵敏度，可达 **88%**。

用于 AFP 阴性患者

与肝癌血清标志物 AFP 相比较，在 cutoff 20 ng/mL 的情况下，**84%** 的 AFP 漏检样本的洁太司® 检测结果为阳性。

用于影像不典型患者

在缺乏典型影像学特征的适用人群中，洁太司® 灵敏度达 **88%**，特异度达 **95%**。

洁太司® 临床优势

甘达健® 肝脏健康评估

苏械注准20232400366

采用全新糖组学检测分析技术，通过检测血清糖链实现肝脏健康评估。



风险早知



居家便捷



全面评估



权威认证

先思达(南京)生物科技有限公司
地址: 江苏省南京市江北新区浦滨路211号基因大厦A栋23层
南京康鑫达医学检验实验室有限公司
地址: 南京市江北新区中丹生态生命科学产业园一期B栋10层
江苏先思达生物科技有限公司
地址: 江苏省泰州市中国医药城三期厂房G26幢6层

官网: www.sysdiagno.com
咨询电话: 025-58219850





公司简介

广州华腾生物医药科技有限公司是一家致力于为全国科研院校、医院、制药企业、医疗器械企业提供专业的实验动物模型研发、生产和生物医药研发外包服务于一体的国家高新技术企业。目前已建立六个科研/产业服务基地，广州总部（黄埔区5000m²）、深圳分公司（光明区1300m²）、重庆分公司（1500m²）、香港分公司、佛山大型实验动物模型研发生产实验基地（50亩），江苏丹阳基地（25亩），是粤港澳大湾区专注于大型实验动物和动物模型研发和生产规模最大的基地之一。

Guangzhou Huateng Biopharmaceutical Technology Co., Ltd. is a national high-tech enterprise dedicated to providing professional R & D and production of experimental animal models, biomedical R & D outsourcing services for scientific research institutions, hospitals, pharmaceutical enterprises, and medical device enterprises nationwide. Six research/industrial service bases have been established for now, including the Guangzhou headquarters (5000m² in Huangpu District), Shenzhen branch (1300m² in Guangming District), Chongqing branch (1500m²), Hong Kong branch, Foshan large-scale experimental animal model research and production experimental base (50 acres), and Jiangsu Danyang base (25 acres). It is one of the largest bases in the Guangdong Hong Kong Macao Greater Bay Area that focuses on large-scale experimental animal and animal model research and production.

2000+

超过2000个研发项目

over 2000 projects

20+

20项以上产品成功申报

over 20 products successfully declared

1500+

服务超过1500个客户

over 1500 clients

1

粤港澳大湾区1小时服务圈

1 hour service circle

in the Guangdong Hong Kong Macao Greater Bay Area

01

医疗器械评价

Evaluation of medical devices

02

动物疾病模型构建

Construction of animal disease

03

临床前研发服务

Pre-clinical R&D Service

05

药效/药代

Pharmacodynamics

04

实验动物

生产及销售

Production of experiment

06

临床手术培训

Clinical surgical training

合作伙伴



广州翔康医学研究有限责任公司在广州开发区打造了5000㎡以CDO+CRO+CMO一体化服务为核心的医械共生圈，专注于为医疗器械(含IVD)企业提供从概念设计到产品上市的全方位、全产业链技术服务，极大地降低了项目产品审批的风险，加速医疗器械产业的产学研医融合。

Guangzhou Xiangkang Medical Research Co., Ltd. has created a 50000 medical equipment symbiosis circle with CDO+CRO+CMO integrated service as the core in the Guangzhou Development Zone, focusing on providing medical device (including IVD) enterprises with all-round, whole-industry chain technical services from conceptual design to product listing, and greatly reducing the risk of project product approval. It accelerates the integration of industry, academia, research and medicine in the medical device industry.




翔康公众号

广州地址：广州市黄埔区萝山大街29号联东U谷8楼11楼-12楼（总部）
联系方式：18923094140（技术顾问）
电子邮箱：ht@htscience.com

深圳地址：深圳市光明区凤凰街道凤凰社区招商局智慧园C4栋8楼（深圳分公司）
联系方式：15920412726

HKAD ROOM 503, 5/F HANG SENG CASTLE PEAK ROAD BUILDING 339
CASTLE PEAK ROAD CHEUNG SHA WAN HONG KONG
TEL:13570271260
Email: fangshunli@htscience.com

Founded in August 2021, Starna Therapeutics commits to developing innovative mRNA drugs that address unmet clinical needs, using extrahepatic delivery technology for tissue- and cell-specific RNA drug delivery. The company has several platforms, including lipid synthesis and LNP development, linear and circular RNA, end-to-end pilot-scale production.




Tissue Specific LNP

Starna's deep lipid chemistry knowledge has created a vast library of unique lipids, enabling the evaluation of numerous LNP formulations. Using advanced HTS, we've developed tissue-specific LNPs for targeted delivery to organs like the lungs, spleen, liver, muscles, enhancing treatment precision

Antibody LNP conjugates

By attaching antibodies to LNPs, we create cell-selective LNPs that target specific cell types for precise in vivo cell therapy. The in vivo CAR-T platform has shown efficacy and safety both in mice and NHP.



We are a Pioneer in Genome Editing 2.0

A comprehensive tool set to remedy genetic diseases and more

Technology

Full Suite of Novel In Vivo Gene Editing Tools

- **Engineered Protein Delivery Vehicles (ePDVs)** for safe and efficient extrahepatic delivery
- **CasX and Lead Editors** for long fragment genome editing
- **EDITED-Seq** for high sensitivity off-target detection

Pipeline

First-In-Class and Best-In-Class Assets

- Lead program: FIC transient, allele-specific editing for eye disease
- Second program: FIC long fragment editing for CNS disease
- BIC liver and cardiovascular programs open for licensing

People & Funding

Experienced Founders Backed by Private and Public Investors

- Founders from leading research institutes and pharma
- Raised USD45M+ to date from strong private and public investors



We are Developing a 2nd Generation Integrated Platform

In vivo insertion, deletion and correction in any targets



~100 Priority PCT Applications Filed

1 Wide Tissue Tropism

- Extrahepatic: Engineered protein delivery vehicles (ePDVs)
- Liver: Lipid nanoparticles (LNPs)
- Proprietary screening workflow

2 Versatile Editing Capability

- Metagenomics based nuclease discovery
- RNA chemistry
- Lead editor

3 Minimize Off-Target Risk

- Highly sensitive off-target detection
- Based on real-scenario editing event in cell

中肽生化有限公司

多肽/寡核苷酸CRDMO合作伙伴

多肽和寡核苷酸治疗药物的一站式CRDMO平台

多肽药物CRDMO平台

From Discovery to Commercial
Both GMP and Non-GMP

寡核苷酸药物CDMO平台

From Discovery to Commercial
Both GMP and Non-GMP

中肽是提供全方位服务的专注于多肽的CRDMO，在多肽药物开发和生产方面拥有垂直整合能力。鉴于多肽的复杂性及高度技术性，多肽的开发及制造具有耗时及资本密集的特点，公司的CDMO服务非常适合寻求外包解决方案以满足其开发及生产需求的多肽类药厂及生物技术公司。

覆盖整个多肽类药物周期的端至端服务



+86 571 86737011



sales@chinesepeptide.com



www.chinesepeptide.com



福州新投生物科技产业园 联系方式：杨女士 186 0213 5553

福州

园区背景

在福州新区管理委员会与福州市长乐区人民政府的大力支持下，由福州新区集团携手贝瑞基因（股票代码：000710）合资成立福州新投生物科技产业园建设发展有限公司，共同打造福州新投生物科技产业园。

发展目标

旨在打造建设一个专注于生物制药、高端医疗器械生产和生物医疗服务等产业聚集的生物医药产业园。

入驻优势

- 1、渠道与客户资源：在生育健康、遗传病、肿瘤、以及科技服务等领域拥有稳定的渠道和客户资源，是园区企业业务发展的“高速公路”；
- 2、共享仪器平台：引进illumina、PacBio、10x Genomics等知名的测序服务平台，可为入驻企业提供便捷的测序服务；
- 3、产品注册与生产：拥有完善的医疗器械产品孵化流程，从“产品研发-工艺验证-技术转移-试制生产-注册检验-临床试验-注册申报”等各环节有着深厚的经验，可助力客户依据注册人制度快速获得上市许可；
- 4、产业政策支持：入驻企业可享受“一园一策”的产业政策，为入驻企业提供人才、国投、研发等政策奖励，助力企业快速发展；
- 5、配套产业基金：由福州新区集团领投，成立初期规模数亿元的产业基金，支持生物医药企业落地园区。



共享测序服务平台



仪器共享平台



共享办公区



生物信息中心



Australian owned and
operated
capability CRO
Local Directorship
Project Management
and Full Project Support



The Australian CRO With A Personalized Approach To Your Project



Who are we?

Alithia Life Sciences is an Australian owned full capability, boutique, clinical research organization (CRO) launched to support and assist pharmaceutical, biotechnology, device companies and institutional research groups undertaking their project in the Australian region and beyond.

What we do?

- Overall management of projects and clinical strategy on behalf of local and international Sponsors from concept to start up and through to close out.
- Biotech executive management and director support provision (local directorship).
- Access to an extensive network of project enabling KOLs and vendors including laboratories and R&D tax experts and Investigational Product depots.
- Clinical research suite: project and site management, site feasibility and selection, selection and management of vendors, monitoring support, trusted data management and biostatistical solutions, local and global medical monitor capabilities.

Contact: A/Prof Tina Soulis

Founder and Director

tina.soulis@alithialifesciences.com

+61 (0) 429 300 705



SCAN ME



ASX: OPL

TrialKey.ai leverages real-world data to simulate and optimise clinical trial designs with unparalleled accuracy. Whether for drugs, medical devices, alternative therapies, rare or novel conditions, TrialKey enhances success probabilities across all phases, providing comprehensive global capabilities for optimal trial design. The platform's scalable model caters to both small companies running a handful of trials annually and major companies running thousands of trials each year.



OUR SERVICES

Create Optimal Trial Designs


Our platform provides precise recommendations for various trial elements, including study type, sponsor, start and end dates, number of arms and groups, primary and secondary purposes, intervention models, masking types, allocations, enrollment numbers, inclusion/exclusion criteria, hard trial status, number and location of sites, and outcome measures.

Optimise Existing Trials

TrialKey refines and enhances existing trial designs for better outcomes. Our platform applies the same rigorous AI-driven analysis to optimise and compare with past and current trials. By comparing your trial with competitors and identifying areas for improvement, TrialKey reduces the need for costly amendments and maximises success rates.

Predict Outcomes

TrialKey offers unparalleled predictive power with over 90% accuracy in forecasting trial success. Our AI models analyse vast amounts of data to deliver reliable success probabilities and competitor insights, enabling informed decision-making and strategic planning for clinical research and development.



USERS



- Clinical Research Organisations
- Hospitals and Universities
- Pharmaceutical Companies
- Biotechnology Companies
- Biotechnology Investors

REPORT INCLUSIONS

- **Trial Overview & Success Rate:** Study Design, Success Probability, Competitor Analysis
- **Study Design Optimisation:** Endpoints, Criteria, Study Arms, Duration
- **Study Impacts:** Patient Enrolment, Geographic Distribution, Patient Touchpoints, Sponsor Track Record, Technology Use, Feature Contribution
- **Competitor & Market Analysis:** Successes & Failures, Competitor Benchmarks, Real-World Data, Market Trends
- **Visualisation & Reporting:** Graphs & Charts, Probability Graphs, Feature Impact, Competitor Comparison, Executive Summary
- **Investor Packs:** Probability of success backed by RWD, Patient Recruitment Risk, Protocol Risk, Regulatory/Endpoint Risk, Technology Risk, Patient Recruitment and Retention, Site Engagement, Competitor Analysis, Market Analysis, Data Conduct/Collection



Market-leading +92% accuracy in predicting the probability of success of any clinical trial



Our platform is trained using data from over 350,000 clinical trials and 1000+ variables



Each trial is simulated over 10,000 times using our advanced AI model to ensure robust and reliable predictions and recommendations

BOOK DEMO



support@trialkey.ai
Socials @trialkeyai

OUR SERVICES

Full consultancy services covering medicines, medical technology, cell and gene therapies, and other cutting-edge products across major international markets including Asia/Pacific, North and Latin America, EU/UK and more.

1. STRATEGY AND PROJECT MANAGEMENT

At Adjutor, we help you design a focused plan of how to achieve your commercial product vision.

2. DEVELOPMENT AND CLINICAL

We are specialists in managing drug and medical technology development requirements, including lab, non-clinical, clinical trial sponsorship and CRO services.

3. REGULATORY AFFAIRS AND MARKET ACCESS

We are experts in product registration/lifecycle management and market access, able to efficiently and effectively guide you to being market-ready.

4. QUALITY AND TRAINING

Whether your existing quality system needs a refresh or you're just embarking on your first quality journey, we can help with documentation, training and auditing.

5. SPONSORSHIP AND COMMERCIALISATION

Now that your product has been developed and approved, we can help you access markets in a wide variety of countries and ensure effective commercialisation and product launch strategies, as well as introducing you to potential distributors and logistics providers.

The Adjutor **ADVANTAGE**

is how we demonstrate, every day, that we are a great partner for your business. We're engaged, and motivated, to help you at each stage of your journey to market and beyond.

- **RESPONSIVE** From your first interaction with us, to project completion.
- **AGILE** Like you, we adapt quickly to changing circumstances and priorities.
- **FLEXIBLE** Customised and modular services, not one size fits all.
- **EXPERT** Depth and breadth of lived industry experience, across the world.
- **COLLABORATIVE** Not just IQ but EQ. Our consultants easily integrate into your existing team.
- **RELIABLE** Effective and efficient high-quality support, matching your sense of urgency.

Helping put the
pieces together.



Wirtschaftsmission
Medizintechnik & Life Sciences
Hong Kong and Taiwan

CONNECT WITH AUSTRIAN COMPANIES IN THE MEDICAL TECHNOLOGY SECTOR

COME & MEET US AT THE
ADVANTAGE AUSTRIA
STAND!

ADVANTAGE AUSTRIA - Austrian Trade Commission

13/F Diamond Exchange Bldg.

8-10 Duddell Street, Central

Hong Kong

Contact Person:

Ms Monica NG & YinChi LIU


T +852 2522 2388

E hongkong@advantageaustria.org

W www.advantageaustria.org/cn



 **ADVANTAGE
AUSTRIA** 





Advancing medicine,
improving lives.



Your Nucleus Network Advantage

"Our expertise, your choice"

The world's only
multi-country,
multi-site

1

clinical trial specialists
in Australia and the USA,
we have the regulatory and clinical
expertise to assist clients in determining
the most appropriate clinical trial strategy.

2

Located across
Countries
Australia and the USA,

we are uniquely positioned to offer our clients
flexibility in their trial location, including multi-
site trials with a single provider.



3

Each of our
Sites

in Melbourne, Brisbane and
Minneapolis,

are strategically co-located within leading
hospitals or medical research precincts.

Our proven capabilities

1,000+

Clinical Pharmacology
trials conducted

200+

Phase 1 clinical trial beds

200+

Independent sponsor audits including
FDA & EMA regulatory inspections

50 FIH

studies completed annually
across Australia and USA

20

years' experience
conducting Phase 1 clinical trials

210,000+

qualified participant database

Market Leader in Phase 1 Clinical Trials in Australia & USA



Our Multi-Country Advantage

Melbourne - Brisbane - Minneapolis

Nucleus Network is unmatched in our capabilities, experience and ability to offer specialized facilities for clinical pharmacology study execution and protocol optimization.

Working in two of the world's most attractive markets for first-in-human Phase 1 trials, our multi-country delivery also supports customers across all clinical development strategies.

Our Australian Advantage

- ▶ Speed - first-in-human in less than 5 weeks
- ▶ Cost - R&D tax incentives

Our USA Advantage

- ▶ Leader in adaptive FIH studies
- ▶ Rapid 6-week start-up for NDA enabling clinical pharmacology studies



Melbourne Clinic - 100+ beds



Brisbane Clinic - 65+ beds



Minneapolis Clinic - 50+ beds

Broad Therapeutic Expertise

- Cardiology
- Dermatology
- Gastroenterology
- Immunology
- Infectious Diseases
- Metabolism & Endocrinology
- Nephrology
- Neurology
- Ophthalmology
- Radiology
- Respiratory
- Women's Health

Study Specializations

- First-in-human (healthy & patients)
- DDI, TQT, FE, BA
- Renal & Hepatic impairment
- Ethnobridging
- Biosimilar
- Vaccine

Elleon Biotech

TOGETHER LET US BETTER PREPARE FOR THE NEXT PANDEMIC WITH

PhenoDot

THE NEXT GENERATION IMMUNOASSAY

IDENTIFY, QUANTIFY, & ISOLATE

cells in a single step

SIMULTANEOUS SURFACE & SECRETION
marker detection.

Marker -ve
cell



Marker +ve
cell

Chromagen cell tagging

In development the next generation of immunoassay boasting the phenotyping strengths of both FACs and ELISpot in a single assay. Develop visible dots at the cell site by positive identification of cell surface and secretion markers. Maintain viability and isolate cells with single cell resolution. Applications in development

IMMUNITY TESTING

CLONING

ANTIBODY GENERATION

MOA

DIAGNOSTICS

IMMUNOTHERAPY

Come visit us at

BIOHK2024

香港國際生物科技論壇暨展覽

Find out more at

www.elleonbiotech.com



樂嘉文—您可靠的醫藥生物技術合作夥伴

屹立製藥行業五十載，樂嘉文為您提供專業和高端的製藥與研發設備解決方案，涵蓋領域包括：化藥、生物藥、細胞與基因治療用藥、中藥、營養藥、醫療器械、特殊給藥系統、診斷試劑、日化用品、功能糖果等，集結製藥行業頂尖設備製造商和耗材供應商組成的平臺，從工程與工藝設計、研發與生產設備、耗材推薦與供應、項目管理與執行、設備安裝與調試、校驗與驗證，售後維護與備件供應、人員培訓、到升級改造均能為客戶提供最佳的工業解決方案。

工程規劃 | 工業設備 | 技術服務

360° 客製化工業解決方案

展位號

3E-C01

歡迎您前來諮詢



樂嘉文製藥科技有限公司
www.rieckermann.com
852-23759911

Rieckermann
Machinery & Industrial Solutions

Daan Gene Co., Ltd.

- China's leading **molecular diagnosis** company
- WHO, World Bank Group, Global Fund, UNICEF, China CDC strategy partner
- The **1st** company in China to obtain **CE List A** approval for **HBV/HCV** PCR kit
- The 1st company to obtain China NMPA approval for Monkeypox PCR kit

Molecular

Immunoassay

Pathology



廣州生物醫藥與健康產業投資有限公司

Guangzhou Biopharma and Health Industry Investment Co., Ltd.

企業簡介

COMPANY PROFILE

廣州生物醫藥與健康產業投資有限公司是廣州金融控股集團有限公司全資子公司。公司參控股10家生命健康類企業，培育出達安基因(股票代碼002030)、萬孚生物(股票代碼300482)、廣州金城等行業標杆企業。2022年設立“廣州廣金生命健康產業投資基金”支持創新醫療服務、檢驗診斷、醫療器械、創新藥等產業發展。

公司以“科技賦能，金融服務，培育粵港澳大灣區生命健康產業集群”為使命，充分利用“產業投資+創新平台”的運營模式和獨有優勢，全力打造全國最具競爭力的生物醫藥與健康產業投資和服務的平臺型公司，助力廣州建設全球生物醫藥創新與產業發展高地。

公司前身為廣州生物工程中心，成立於1990年，是廣州市科技局直屬事業單位，2019年由事業單位轉企改制後成為廣州金融控股集團有限公司全資子公司。2024年公司正式更名為廣州生物醫藥與健康產業投資有限公司，同年，成立廣州健康產投私募基金管理有限公司，專注於生物醫藥與健康領域投資與服務。

參控股企業

SHAREHOLDING ENTERPRISES



業務板塊

BUSINESS SEGMENTS

產業投資

● 基金投資

建設完善的生物醫藥與健康產業創新孵化投資服務平臺，打造覆蓋生物醫藥與健康企業全生命週期的科技投資體系。

設立生物醫藥與健康產業投資基金，引導社會資本扶持創新醫療服務、檢驗診斷、醫療器械、創新藥等關鍵領域。依託廣州金控基金和萬聯天澤，募集社會資本，發起相關創業投資基金，發揮政府引導基金和社會資本作用，培育市場化創業投資。

2024年5月，成立廣州健康產投私募基金管理有限公司，立足廣州，輻射灣區，以“子基金+直投基金”為運作模式，吸引全球優秀的醫藥與健康領域早期專案到廣州落地生根、開花結果，打造廣州生物醫藥領域專注於“投早、投小、投創新”的專業高效天使投資生態體系。

廣州廣金生命健康產業投資基金已投企業



● 孵化直投

● 科技金融

產業服務

建設“科研服務+臨床前服務+臨床服務+成果轉化+產業化+市場應用+產業媒體”一站式生物醫藥與健康產業鏈服務體系。

● 平臺建設

廣州市創新藥物臨床試驗服務中心

粵港澳大灣區生命健康產業技術轉化中心

廣州研究型醫院聯盟一盟會單位

廣州市生物醫藥領軍企業高質量發展培育工程

● 醫工轉化



● 創新賦能



國際生物醫藥大會



2023 國際研究機構發展醫藥研究產業交易會



地址：廣州國際生物島螺旋大道51號廣洲生命科學創新中心A塔3209-3218

電話：020-87579599

郵箱：center@guangzhoubio.com

官網：www.gzbio.net



廣州健康產投



廣州生物醫藥公共服務平臺

手机胃镜 掌握“胃”来

思德慧医手机胶囊胃镜



无痛



无创



无麻醉

无主机低成本组建胃镜室

开创胶囊胃镜无设备检查新纪元,受检者吞服胶囊,通过操作系统指导,变换体位动作,完成胃部全景扫描,全程享受安全、便捷的检查体验。



GICE-G-1000

一次性使用胶囊式胃内窥镜

小巧易吞服,轻松通过消化道,
150°超大视场角,高清呈现胃内全景



GICE-APP-100

APP软件

APP全流程智能指导
简单易操作,检查完成一键上传



GICE-R-100

便携记录仪

无需大型磁控设备,舒适无感便携记录仪,
无需穿戴马甲,全程无线操作



GICE-AISF-100

图像分析软件

支持云服务器部署,打破时空限制
专业医生团队可提供远程阅片服务

依据《医疗器械临床试验质量管理规范》开展的多中心、开放、配对设计的临床研究结果显示:
思德慧医手机胶囊胃镜在检查时



胃部
覆盖率达 **99.8%**



准确性
高达 **96.8%**

4006401683

网址:www.sidecce.com

地址:广州市黄埔区萝岗大道51号2301单元



思德慧医官方微信公众号



广州信筑医疗技术有限公司

Guangzhou SINCHOO Medical Technology Co., Ltd.



提兰蓝拉仪



电动手术固定架系统



光子嫩肤仪

广州信筑医疗技术有限公司是一家以激光医疗为核心业务的高新技术企业。公司聚焦激光医疗事业，专注于微创医疗和医疗美容两个业务板块。通过深入挖掘激光技术在精准微创介入手术及高效安全医疗美容治疗过程的用户需求和临床价值，创新研究开发激光治疗、监测、诊断技术相关的医疗产品及其辅助功能器械。通过多年的潜心研究和技术攻关，公司现已掌握多种激光医疗核心关键技术，正在开发一系列激光医疗产品，未来将为用户提供更加先进的激光诊疗技术解决方案，更好的服务于精准医疗事业。

守护大众健康， 筑造美好生活



SEPTEMBER 九月11-14
HONG KONG CONVENTION AND EXHIBITION CENTRE
香港會議展覽中心

BIOHK2024

香港國際生物科技論壇暨展覽

HKBO
Hong Kong Biotechnology Organization
香港生物科技協會

FOLLOW BIOHK ON SOCIAL MEDIA



 **Facebook**



 **LinkedIn**



WeChat:
BIOHK2024



WeChat:
HKBIO

Address 地址:
Unit 15-18, 16/F
South Wing Delta House
No. 3 On Yiu Street, Shatin
N.T. Hong Kong
香港新界沙田石門安耀街3號
匯達大廈1615-18室

Email 電郵: editorial@hkbio.org.hk
Telephone 電話: (+852) 2799 7688